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Meinem Vater in liebevoller Erinnerung. 
 
 
 
 
„Es gibt zwei menschliche Hauptsünden, aus welchen sich alle andern ableiten: Ungeduld 
und Lässigkeit. Wegen der Ungeduld sind sie aus dem Paradiese vertrieben worden, wegen 
der Lässigkeit kehren sie nicht zurück.  
Vielleicht aber gibt es nur eine Hauptsünde: die Ungeduld. Wegen der Ungeduld sind sie 
vertrieben worden, wegen der Ungeduld kehren sie nicht zurück.“ 
                                                                                                                                 Franz Kafka 
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1. Summary 
ATP-dependent chromatin remodelers are enzymes which use the energy from ATP 
hydrolysis to alter the chromatin structure. Thus, they play a key role in the 
transcriptional control of many important cellular processes such as proliferation, 
senescence and differentiation. 
The first part of this study focused on CHD5, a novel chromatin remodeling enzyme. To 
gain further insight into its expression profile and biological function, polyclonal 
peptide antisera were, together with a commercially available antiserum, successfully 
established for use in western blot, immunoprecipitation and immunofluorescence 
staining.  
ATP-dependent chromatin remodelers are expressed by very different patterns 
ranging from ubiquitous expression to an expression restricted to specific cell 
populations. So far, CHD5 expression was thought to be restricted to neural-related 
tissues. Here, it was shown for the first time that CHD5 expression is not restricted to 
neural tissues but additionally expressed in rodent testes. Furthermore, several cell 
lines were tested for CHD5 expression on transcript and protein level. CHD5 expression 
was not detected in any of the tested neuroblastoma and glioblastoma cell lines. In 
neuroblastoma cell lines this was expected due to the suggested function as tumor 
suppressor. Furthermore, a primary astrocyte culture was established. No CHD5 could 
be detected in protein lysates from astrocytes but was found in those from murine 
neural stem cells. This suggests that CHD5 expression in brain is restricted to neural 
stem cells and probably also to neurons.  
In the second part of this thesis, the impact of the chromatin remodelers CHD4 and 
BRG1 on a TNFα-induced inflammatory response was investigated. BRG1 and CHD4 
expression was disrupted by a siRNA-mediated knockdown in HEK293 cells. After 
stimulations with TNFα for one to four hours, gene induction of typical inflammatory 
NF-κB target genes was determined by RT-qPCR. BRG1 and CHD4 were both required 
for the efficient induction of all tested target genes exclusively after one hour but not 
after four hours of TNFα treatment. Expression of the housekeeping gene ß-actin was 
unaffected. Surprisingly, although CHD4 is mainly known to be involved in 
transcriptional repression, a requirement for CHD4 in active transcription during this 
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inflammatory response was revealed. To gain further insight into the mechanism of 
involvement, co-immunoprecipitations of the NF-κB subunit p65 with BRG1 and CHD4, 
respectively, were performed upon TNFα stimulation. No robust interactions between 
these proteins could be observed. Furthermore, ChIP experiments with the NF-κB 
subunit p50, histone H3 and CHD4 were carried out on the model target gene CXCL2. 
p50 was recruited to the promoter of CXCL2 rapidly after TNFα was added. Histone H3 
binding to the promoter and the open reading frame of the gene strongly decreased 
within the first hour of TNFα stimulation, indicating that chromatin remodeling took 
place during the early period of gene induction. Recruitment of CHD4 was non-
conclusive. Thus, the mechanism of how BRG1 and CHD4 act during TNFα response 
needs to be investigated further.  
In summary, a major influence of the chromatin remodelers BRG1 and CHD4 on the 
TNFα-induced gene activation during its early phase in HEK293 cells was 
demonstrated. 
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1. Zusammenfassung 
ATP-abhängige Chromatin Remodeler sind eine Gruppe von Enzymen, welche die 
Energie aus der ATP-Hydrolyse nutzen, um die Chromatinstruktur zu verändern. Damit 
spielen sie eine bedeutende Rolle für die Transkriptionskontrolle wichtiger zellulärer 
Prozesse, wie beispielsweise Proliferation, Seneszenz und Differenzierung.   
Der erste Teil dieser Arbeit konzentriert sich auf CHD5, ein neu identifiziertes Mitglied 
der ATP-abhängigen Chromatin Remodeler. Um wichtige biologische Funktionen dieses 
Proteins studieren zu können, wurden polyklonale Peptid-Antiseren,  zusammen mit 
einem später kommerziell erhältlichen Antikörper, für den Gebrauch in Western Blot, 
Immunpräzipitation und Immunfluoreszenzfärbungen etabliert.  
ATP-abhängige Chromatin Remodeler zeigen vollkommen unterschiedliche 
Expressionsmuster. Diese reichen von einer ubiquitären Präsenz bis hin zu einer auf 
spezielle Zellpopulationen beschränkten Expression. Bislang ging man davon aus, dass 
CHD5 nur in neuronalen Geweben exprimiert wird. In dieser Arbeit konnte erstmalig 
gezeigt werden, dass dies nicht zutrifft, da das CHD5 Protein in Hoden-Lysaten von 
Nagetieren detektiert werden konnte.  
Weiterhin wurden RNA- und Proteinextrakte diverser Zelllinien auf ihre CHD5-
Expression hin untersucht. Keine der untersuchten Neuroblastom- und Glioblastom-
Zelllinien zeigte eine  signifikante CHD5-Expression. Zumindest in den Neuroblastom-
Zelllinien steht dies in Einklang mit der vermuteten Rolle als Tumorsuppressor in dieser 
Tumorentität. Außerdem konnte eine primäre Astrozytenkultur etabliert werden. 
Proteinlysate dieser Kultur waren negativ in Bezug auf eine CHD5-Expression, jedoch 
konnte das Protein in Extrakten muriner neuronaler Stammzellen nachgewiesen 
werden.  Daraus ergibt sich die Schlussfolgerung, dass eine CHD5-Expression im Hirn 
auf bestimmte Zellpopulationen beschränkt ist, nämlich auf neuronale Stammzellen 
und vermutlich zusätzlich auf Neurone, jedoch nicht in Astrozyten exprimiert wird. 
Im zweiten Teil dieser Arbeit wurde der Einfluss der Chromatin Remodeler BRG1 und 
CHD4 auf die TNFα-vermittelte Induktion von NF-κB Targetgenen untersucht. Die 
Expression von BRG1 bzw. CHD4 wurde mit Hilfe von spezifischen siRNAs in HEK293 
Zellen herunter reguliert. Anschließend wurden die Zellen für ein bis vier Stunden mit 
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TNFα stimuliert. Die Induktion von typischen NF-κB Targetgenen wurde mit Hilfe einer 
RT-qPCR untersucht. Dabei ergab sich, dass beide Proteine für die Induktion aller 
untersuchter Targetgene nach einer Stunde benötigt werden. Die Expression der 
Targetgene nach vier Stunden war nicht beeinträchtigt, ebenso unverändert war die 
des Haushaltsgens ß-Actin. Dies war überraschend, denn CHD4 ist hauptsächlich als 
Repressor bekannt. Hier konnte jedoch ein Stellenwert innerhalb der aktiven 
Transkription gezeigt werden.  
Um einen Einblick zu erhalten, in welcher Form CHD4 und BRG1 an der untersuchten 
Targetgen-Induktion beteiligt sind, wurden Ko-Immunpräzipitationen der NF-κB 
Untereinheit RelA mit CHD4 bzw. BRG1 nach einer Inkubation mit TNFα durchgeführt. 
Es konnten keine robusten Interaktionen der Proteine gezeigt werden. Weiterhin 
wurden ChIP-Experimente mit der NF-κB Untereinheit p50, Histon H3 und CHD4 am 
Beispiel des Targetgens CXCL2 nach einer TNFα-Induktion durchgeführt. Nach einer 
kurzen Inkubationszeit mit TNFα wurde p50 zum CXCL2-Promoter rekrutiert. Die 
Dichte von Histone H3 im Bereich des Promoters und, weniger ausgeprägt, auch des 
Open-Reading-Frame sank ebenfalls innerhalb der ersten Stunde. Dies symbolisiert 
eine stattgehabte Aktion von Chromatin Remodelern. Eine Rekrutierung von CHD4 
blieb jedoch unklar aufgrund technischer Details. Daher bleibt der Mechanismus der 
beobachteten Effekte während dieser Transkriptionsaktivierung unbekannt. 
Zusammengefasst wurde eine wichtige aktivierende Funktion der beiden Chromatin 
Remodeler BRG1 und CHD4 während der frühen Phase der TNFα-Antwort gezeigt.  
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2. Introduction 
 
2.1. General introduction 
Nearly every higher eukaryotic cell contains within its DNA the complete genomic 
information of the whole organism. This condition has two major implications: firstly, 
the total length of a single cell’s chromosomal DNA would extend to over two meters. 
Thus, the DNA has to be compacted to fit into the small nucleus. This compaction is 
achieved by wrapping the acidic DNA around basic proteins, the histones. Such a 
polymer of DNA and histones together with some non-histone proteins is called 
chromatin. Secondly, only a small part of a cell’s whole genome needs to be actively 
transcribed at the same time. That enables different cells to take over independent 
functions in the formation of a higher organism. These two implications in conjunction 
additionally require a cell to have a fine-tuned dynamic chromatin structure which can 
regulate access to the transcription machinery depending on the cells current 
metabolic activity and overall function.
1
  
In summary, the dynamics of higher-order chromatin structures serve as one key 
regulatory element of transcriptional control. 
Although so many intriguing questions are still unsolved in the field of chromatin 
research, the importance in pathology and also in the treatment of various diseases is 
increasing, resulting even in the approval of drugs modifying epigenetic mechanisms. 
As one example, 5-azacytidine, a drug modifying the DNA methylation pattern, was 
approved for the treatment of Myelodysplastic syndrome in Europe in 2009.  
2.2 Chromatin structure 
The term chromatin, as defined by the complex of DNA and associated proteins, was 
coined by the German cell biologist Walther Fleming at around 1880. He found a 
strongly basophile stainable sub-cellular structure which he called chromatin after the 
ancient Greek word for color (χρῶμα, chroma). He wrote “the word chromatin may 
stand until its chemical nature is known, and meanwhile stands for that substance in 
                                                           
1
 Allis DC, Jenuwein T, Reinberg D; Overview and Concepts; in: Allis CD, Jenuwein T, Reinberg D; Epigenetics, 
Cold Spring Harbor Laboratory Press, New York (2007). 
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the cell nucleus which is readily stained.”
2
 After these words it took over 90 years until 
a more thorough understanding of the chromatin structure was achieved
3
 by the 
ground-breaking work of Woodcock,
4
 the Olins
5
 and Kornberg
6
. Finally, Luger et al
7
 
could resolve a detailed structure of the chromatin key subunit, the nucleosome, by   
X-ray crystallography in 1997.  
The repeating key subunit of chromatin is the nucleosome and provides the first level 
of higher-order packaging of chromosomal DNA by histones. It consists of 147 base 
pairs of DNA wrapped around a histone octamer in 1.65 superhelical turns resulting in 
a 5 – 10 fold compaction of DNA. The histone octamer includes dimers of the core 
histones H2A, H2B, H3 and H4. All core histones have a similar basic structure with a 
globular domain for histone-DNA as well as histone-histone interactions within the 
nucleosome and the protruding N-terminal and C-terminal tails. These tails as well as 
the globular domains are rich in the basic amino-acids lysine and arginine. Within the 
tails, the basic amino-acids provide a site for common post-translational regulatory 
modifications such as methylation and acetylation.
8
  
Between the nucleosomes, linker DNA of variable length is interposed, producing the 
characteristic appearance of ‘beads on a string’ (10 - nm fibre). This string of 
nucleosomes is further compacted into a 30 - nm fibre fixed by the linker histone H1, 
resulting in an approximately fifty fold compaction of chromatin. The 30 - nm fibre is 
additionally capable of condensing into secondary and tertiary chromatin structures. 
The mechanisms contributing to these higher order structures are yet unknown.  
The mitotic or meiotic metaphase chromosome displays a highly condensed structure 
with a 10 000 fold compaction. Remarkably, the condensation of the Barr body is even 
higher.
 9
 
For an overview of different levels of chromatin compaction see Fig. 2.1. 
                                                           
2
 Cited after Olins DE, Olins AL; Chromatin history: Our view from the bridge. Nat Rev Mol Cell Biol (2003).  
3
 Olins DE, Olins AL; Chromatin history: Our view from the bridge. Nat Rev Mol Cell Biol (2003).  
4
 Woodcock CL et al, Structural repeating units in chromatin. I. Evidence for their general occurrence. Exp Cell 
Res (1976). 
5
 Olins AL and Olins DE, Spheroid chromatin units (v bodies). Science (1974). 
6
 Kornberg RD, Chromatin structure: a repeating unit of histones and DNA. Science (1974). 
7
 Luger K et al, Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature (1997). 
8
 Horn PJ and Peterson CL, Molecular biology. Chromatin higher order folding: wrapping up transcription. 
Science (2002). 
Luger K and Hansen JC, Nucleosome and chromatin fiber dynamics. Curr Opin Struct Biol (2005). 
9
 Felsenfeld G and Groudine M, Controlling the double helix. Nature (2003). 
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Fig. 2.1: Multiple levels of chromatin folding
(from: Felsenfeld G, Groudine M, Controlling the double helix. Nature 2003 )
 
According to its nuclear staining pattern, chromatin is further classified into 
euchromatin as an ‘active’ form and heterochromatin as a more compacted and 
‘inactive’ form. Euchromatin is usually gene-rich, although it is not necessarily always 
transcriptionally active. Conversely, heterochromatin remains packaged in interphase 
and consists mostly of non-coding and repetitive DNA. Specific markers of 
heterochromatin include a general histone hypoacetylation, the presence of histone 
H3K9 methylation and cytosine hypermethylation in DNA. This leads to a recruitment 
of heterochromatin-associated proteins (such as HP1) in order to further stabilize the 
chromatin compaction.
10
 
Moreover, constitutive heterochromatin is distinguished from facultative 
heterochromatin. Constitutive heterochromatin is commonly found around 
centromeres and telomeres. It displays the same condensed packaging in nearly all 
somatic cell types of an organism under physiological conditions. In contrast, 
facultative heterochromatin is only compacted in some cell types where the 
inactivation is dependent on developmental decisions.
11
 
                                                           
10
 Elgin SC, Grewal SI, Heterochromatin: silence is golden. Curr Biol (2003). 
11
 Elgin SC, Grewal SI, Heterochromatin: silence is golden. Curr Biol (2003). 
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2.3 Chromatin modifying enzymes, histone modifications and DNA methylation 
Regulating the degree of chromatin compaction is one major regulatory element in 
transcription, DNA repair and replication. Strong compaction of chromatin impairs the 
accessibility of DNA towards DNA binding factors that are involved in the above 
mentioned processes. Thus, an extra machinery to dynamically alter the local 
chromatin state is essential.  
Basically, three major groups of enzymes are responsible for structural changes of 
chromatin: histone modifying enzymes, DNA methyltransferases and ATP-dependent 
chromatin remodelers. All three groups are crucial for a dynamic interplay between 
each other. They are described in the following part. Because this thesis focuses on 
ATP-dependent chromatin remodelers, these are discussed more broadly in a separate 
chapter (see 2.4.). 
2.3.1 Histone modifications 
The usually regular distribution of nucleosomes along the 10 - nm fibre can be changed 
by covalently modified histone tails.  
Vincent Allfrey was the first to discover the influence of histone acetylation and 
methylation on transcriptional activity in 1964.
12
 
Histones can be modified by attachment of small chemical groups (e.g. acetyl- and 
methyl-groups) or larger peptides (e.g. SUMO).    
The effects of the histone modifications on the chromatin structure are divided into 
cis- and trans-effects. Cis-effects generate alterations in the physical properties of the 
covalently modified histone tails. As the prime example, histone acetylation neutralizes 
positive charges of the basic histone tails, bringing about localized stretching of the 
chromatin fibre, thus allowing a better access of the transcription machinery to the 
DNA.
13
 Trans-effects can be described as the recognition of histone modifications by 
specific protein domains and the subsequent recruitment of protein complexes for 
further remodeling of the chromatin structure. As example, methylated lysine residues 
of histone tails might be recognized by protein domains of the Royal family (including 
chromo, tudor and MBT domains), acetylated lysine-residues by bromodomains and 
                                                           
12
 Allfrey VG et al, Acetylation and Methylation of histones and their possible role in the regulation of RNA 
synthesis. Proc Natl Acad Sci USA (1964). 
13
 Allis DC, Jenuwein T, Reinberg D; Overview and Concepts; in: Allis CD, Jenuwein T, Reinberg D; Epigenetics, 
Cold Spring Harbor Laboratory Press, New York (2007). 
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phosphorylations by 14-3-3 domains.
14
 Although a specific modification is often said to 
be linked to a more repressive or more activating outcome, most likely many 
modifications can in principle contribute to both, activation and repression, depending 
on the context and the position of the nucleosome along the DNA.
15
  
In conclusion, histone modifications are via their cis-effects as well as via trans-effects 
an important part of the control over the chromatin accessibility. Their occurrence can 
be transient, stable or even propagated from one cell generation to the next.  
For some of the histone modifying enzymes pharmacological inhibitors are already in 
clinical use like the HDAC inhibitor vorinostat for the treatment of cutaneous T-cell 
lymphomas. It is noteworthy that, only seven years after the discovery of the histone 
demethylase LSD1
16
 specific inhibitors are already under investigation. This 
demonstrates both that the field is rapidly developing and of great clinical relevance. 
 
2.3.2 DNA methylation 
In DNA methylation the fifth carbon position of cytosine is covalently modified. That 
methylation is associated with gene silencing and is involved in important 
developmental processes such as genomic imprinting and X chromosome inactivation. 
It occurs to various degrees in all higher eukaryotes with the exception of yeast. In 
mammals, CpG dinucleotides are modified, but different patterns occur in N. crassa 
and plants.  
 
CpG dinucleotides are not equally distributed across the genome. Rather, there are 
CpG islands and CpG-poor regions. 
17
 
A CpG island is defined as a genomic region longer than 500 base pairs, C+G content 
greater than 55 % and an “observed CpG/expected CpG” ratio of more than 0.65.
18
 
                                                           
14
 Kouzarides T, Chromatin modifications and their function. Cell (2007). 
Allis DC, Jenuwein T, Reinberg D; Overview and Concepts; in: Allis CD, Jenuwein T, Reinberg D; Epigenetics, 
Cold Spring Harbor Laboratory Press, New York (2007).  
Bannister AJ et al, Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. 
Nature (2001). 
Nakayama J et al, Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. 
Science (2001).  
15
 Kouzarides T, Chromatin modifications and their function. Cell (2007). 
16
 Shi Y et al, Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004). 
17
 Miranda TB, Jones PA. DNA methylation: the nuts and bolts of repression. J Cell Physiol (2007).  
Allis DC, Jenuwein T, Reinberg D; Overview and Concepts; in: Allis CD, Jenuwein T, Reinberg D; Epigenetics, 
Cold Spring Harbor Laboratory Press, New York (2007). 
2 .  I n t r o d u c t i o n  |  1 0  
 
About 40 % of genes contain CpG islands. They are mostly located in the 5’ region of a 
gene, usually within the promoter, the 5’ untranslated region and first exon. In normal 
cells a CpG island is most likely hypomethylated. The CpG poor regions are usually 
methylated. During the development of cancer CpG islands can become 
hypermethylated resulting in the silencing of tumor suppressor genes. Furthermore, 
loss of methylation at CpG poor regions can lead to genomic instability.
19
 
Hypermethylated CpG islands and histone tail modifications together are often 
described as ‘epigenetic marks’.  
In mammals, DNA methyltransferases (DNMTs) are categorized into three major 
families (DNMT1-3).
20
 Basically, DNA methylation is divided into de novo and 
maintenance methylation. In early embryogenesis, developmental processes and 
carcinogenesis the methyltransferases DNMT3a and DNMT3b establish de novo 
methylation patterns.
21
 For maintenance of methylation patterns, especially during 
replication, DNMT1 is thought to be the main factor. 
DNMTs catalyse the methyl transfer using S – adenosyl - methionine as the methyl 
donor.
22
 
The biological role of DNMT2 is less well defined in comparison to DNMT1 and DNMT3. 
Recent evidence suggests that it works as a RNA methyltransferase specifically 
methylating tRNA
Asp
.
23
  
DNA methylation contributes in many ways to gene silencing. One possibility is that 
the binding of transcription factors is directly disturbed by the presence of the methyl 
group in the major groove of the DNA. As an example, Prendergast et al
24
 showed that 
CpG methylation of the Myc recognition site inhibits its binding. Another mechanism is 
the recruitment of Methyl-CpG-binding proteins like MeCP1
25
 and the methyl-CpG-
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binding domain (MBD) family.
26
  These proteins are known to associate with different 
co-repressor complexes like the NuRD complex. This constitutes a link between DNA 
methylation and ATP-dependent chromatin remodeling as discussed in greater detail 
in the next chapter.  
2.4 ATP-dependent chromatin remodelers 
2.4.1 ATP-dependent chromatin remodelers – overview and mode of action 
ATP-dependent chromatin remodelers utilize the energy from ATP hydrolysis to alter 
the chromatin structure in a non-covalent manner, e.g. to remove or exchange 
histones, slide nucleosomes along DNA and disrupt DNA - nucleosome contacts (see 
Fig. 2.2 for an overview). 
 
Fig. 2.2: Alterations of chromatin structure by chromatin remodeling enzymes
Chromatin remodelers can assist in chromatin assembly by moving already deposited histone octamers, thus
generating space for additional deposition. Other modes of action include repositioning, ejection and
unwrapping of nucleosomes as well as histone dimer exchange or dimer ejection.
(modified after: Clapier CR and Cairns BR, The biology of chromatin remodeling complexes. Annu Rev Biochem. 2009)
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The exact mechanism how the hydrolysis of ATP is linked to nucleosome sliding is still a 
matter of investigation. One hypothesis was the ‘twist-diffusion-model’. It assumed 
that Brownian energy fluctuations are enough to rotate the DNA helix at one edge of a 
nucleosome leading to a replacement of current DNA-histone interactions by 
neighboring DNA base pairs. By spreading of that twist around the histone octamer 
surface, the translational and rotational position of the nucleosome would change. 
Several findings argue against this model.
27
 
An alternative, more favoured model is the ‘loop-recapture-model’. It postulates that 
energy from ATP hydrolysis leads to the separation of a DNA segment from the histone 
octamer at the entrance or exit of the nucleosome forming a small DNA loop. The 
propagation of this loop around the nucleosome would change the translational 
position of the nucleosome. The detached DNA of the loop could then interact with 
transcription factors.
 28
 
All nucleosome remodeling ATPases belong to the SNF2-like family of ATPases 
characterized by their similarity of their ATPase/helicase domain to the yeast 
Snf(sucrose non-fermenting)2p domain. The Snf2-like family members can be further 
divided into several subfamilies according to the presence of additional protein 
domains.
 29
  
Eukaryotes have four main families of chromatin remodelers namely SNF2H/ISWI, 
INO80/SWR1, SWI/SNF and CHD/Mi-2.
30
  
Most of the ATP-dependent chromatin remodelers are part of large multi-protein 
complexes.  
2.4.2 The SNF2H/ISWI family 
The ATPase ISWI (=imitation switch) was first identified in Drosophila melanogaster.
31
 
At the C-terminus of the ISWI protein two characteristic domains reside, the SANT 
(switching-defective protein 3, adaptor 2, nuclear receptor co-repressor, transcription 
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factor IIIB) domain for binding of unmodified histone tails and the SLIDE (SANT-like 
ISWI) domain for interactions with nucleosomal DNA.
32
 
In Drosophila, three ISWI-containing complexes are known, dNURF (nucleosome 
remodeling factor), dCHRAC (chromatin accessibility complex) and dACF (ATP-utilizing 
chromatin assembly and remodeling factor). All three are capable of inducing 
nucleosome sliding to the next DNA segments in vitro, thereby possibly facilitating 
DNA access to interacting factors in vivo.
33
 
Mammals possess two ISWI homologues, SNF2L within the NURF and CERF complexes, 
and SNF2H in CHRAF, NoRC, ACF and others.
34
 
In mouse brain, ovaries and testes, SNF2H was found to be predominantly expressed in 
proliferating cell populations during development whereas SNF2L was mainly 
expressed in terminally differentiated cells after birth and in adult animals, suggesting 
that the different ISWI homologues own distinct functions during development.
35
 
Interestingly, the RNA levels of SMARCA5 (SNF2H) were found to be upregulated in 
CD34
+
 hematopoietic progenitor cells of AML patients. After complete hematologic 
remission SMARCA5 levels decreased, suggesting a major role in hematopoietic 
differentiation.
36
 
Moreover, protein complexes containing ISWI have been implicated in a huge number 
of other biological functions such as DNA replication, heterochromatin formation and 
transcriptional repression. 
37
 
2.4.3 The INO80 family 
INO80 (inositol requiring 80) was first identified in a genetic screen for mutants 
interfering with the inositol biosynthesis in yeast.
38
 Subsequently, orthologues in 
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higher metazoan like the human INO80
39
 and hSRCAP (SNF2-related CREB-activator 
protein)
 40
 were identified. The INO80 and SWR1 family shares the property that their 
conserved ATPase domain is split by a long insert.
41
  
A broad variety of functions have been described for INO80/SWR1 complexes so far. 
The SWR1 complex is able to exchange histone H2A with H2A variants like H2AZ within 
one nucleosome.
42
 Furthermore, a major role for INO80 complexes in DNA repair has 
been suggested. For example, the INO80 null mutant is hypersensitive to DNA-
damaging agents
43
 and γ-H2AX is required for recruitment of INO80 to sites of double-
strand breaks
44
 where it was shown to regulate the DNA accessibility around these 
double-strand breaks.
45
  
2.4.4 The CHD/Mi-2 family 
The CHD (chromodomain, helicase, DNA binding domain) family of remodelers has as 
its most characteristic feature two tandemly arranged chromodomains at the              
N-terminus in addition to the ATPase domain.  
The term ‘chromodomain’ was first used by Paro and Hogness
46
 describing a region of 
similarity in Drosophila Polycomb and HP1 protein. They assumed a function in 
chromatin regulation, so ‘chromo’ stands for chromatin organization modifier. The 
prototype chromodomain consists of around 50 amino acids and is folded in three-
stranded antiparallel ß-sheets and an α-helix running across the sheet.
47
 By direct 
interaction with RNA, DNA and methylated histone tails chromodomains are involved 
in chromatin regulation.
48
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In yeast, only one CHD protein, namely CHD1, was identified.
49
 Drosophila has four 
CHD proteins and nine family members (CHD1-9) are known in mammals which are 
further divided into three subfamilies according to the presence of additional domains 
besides the ATPase domain.   
Subfamily I: CHD1 and CHD2  
Subfamily I includes CHD1 and CHD2 from higher eukaryotes. They contain a                
C-terminal DNA - binding domain that is known to interact with AT-rich DNA motifs.
50
  
CHD1 is thought to play an important role in the maintenance of an open, active 
chromatin state.
51
 Drosophila CHD1 localizes to the interbands and puffs of polytene 
chromosomes at transcriptionally active sites. Chromodomains of human CHD1 were 
shown to selectively bind to H3K4me3
52
 which is associated with the 5’ end of actively 
transcribed genes indicating that the mammalian CHD1 is targeted to open, active 
chromatin. This view is furthermore supported by the findings that CHD1 
downregulation leads to an accumulation of heterochromatin and that its presence is 
required for maintenance of mouse ES cell pluripotency. 
53
 
A homozygous CHD2 mutant mouse model showed embryonic and perinatal 
lethality.
54
 In CHD2 heterozygous mutant mice an increased number of 
megakaryocytes and a defective differentiation of hematopoietic stem cells into the 
erythroid lineage were found. In addition, mice were prone to develop T-cell 
lymphomas and had defects in the DNA damage-induced γ-H2AX response.
55
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Subfamily II: The NuRD complex and CHD5 
Subfamily II includes CHD3 (Mi-2α) and CHD4 (Mi-2ß).  They are characterized by        
N-terminal paired PHD (plant homeo domain) zinc-finger-like domains absent in 
subfamily I.
 56
  In addition, CHD5 can be placed into this family because of its large 
similarity to CHD4 and the presence of two PHD domains (see chapter 2.5.2 for details) 
but this classification is controversially discussed. Some authors place CHD5 into the 
third subfamily because of a strikingly unique region of fifty residues at the C-terminus 
that is significantly diverging from CHD3/4.
 57
 
PHD fingers are commonly found in a variety of nuclear proteins. They span around 50 
to 80 residues and have a characteristic Cys4-His-Cys3 motif.
58
 They are proposed to 
function as ‘histone code readers’ but the exact function in most CHD proteins is 
unknown so far.
59
 
The PHD zinc fingers of Mi2ß are required to bind HDAC-1 within the NuRD complex.
60
 
Furthermore, the first PHD finger of CHD4 was found to interact with the N-terminus 
of H3.
61
 The second PHD finger of CHD4 was shown to bind to the N-terminus of H3 
facilitated by methylation or acetylation of Lys9 (H3K9me and H3K9ac, respectively) 
and this binding was inhibited by methylation of Lys4 (H3K4me).
 62
 Recently, it was 
demonstrated that this concomitant interaction of the tandem PHD domains of CHD4 
with two histone H3 tails is required for the repressive role of CHD4.
63
 
Since my thesis focuses mainly on the chromatin remodelers Mi2ß/NuRD complex and 
CHD5 I will describe these proteins in greater detail.  
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CHD3 (Mi2α) and CHD4 (Mi2ß) were first described as autoantigens in 
dermatomyositis.
64
 Patients with this autoimmune disease are prone to develop 
cancers.
65
  
The Mi2 protein exists in many species including Drosophila, Caenorhabditis elegans 
and Xenopus laevis but is absent in yeast. It has ATP-dependent chromatin remodeling 
activity. ATPase activity of Drosophila Mi2 is stimulated by nucleosomes but not by 
free DNA or core histones.
66
 In contrast, ATPase activity of human Mi2ß was shown to 
increase in presence of DNA as well as nucleosomes.
67
 
Human CHD3 and CHD4 are the core subunits of the hNuRD (Nucleosome Remodeling 
and Deacetylase) complex. This complex is considered a classical repressor complex 
and uniquely links three fundamental activities in regulation of chromatin structure, 
namely chromatin remodeling, recognition of methylated CpG dinucleotides and 
histone deacetylation. The chromatin remodeling activity is performed by CHD3 and 
CHD4, the histone deacetylation by HDAC-1 and/or HDAC-2. Other non-enzymatic 
components of this complex include metastasis - associated proteins (MTA) 1/2/3, 
methyl CpG binding domain (MBD) proteins 2/3, p66α/ß and histone-
binding/retinoblastoma-binding proteins (RBBP7/RbAp46 and RBBP4/RbAp48). 
68
 
Recently, the histone demethylase LSD1 was described to be associated with the 
human NuRD complex.
69
 But whether LSD1 associates with NuRD ubiquitously and 
permanently is still a matter of debate. 
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Drosophila Mi2 resides in a NuRD-like complex containing the histone deacetylase 
dRPD3, dp66, dp55 (as homologue to RbAp46/48) and dMBD2/3.
70
 Recently, a second 
dMi2 containing complex, dMec (Drosophila MEP-1 containing complex), was purified 
that does not rely on histone deacetylation to effect transcriptional repression.
71
 
The composition of human NuRD complex can vary dependent on the context and 
function.  
The integral catalytic deacetylase subunits of NuRD are HDAC-1 and/or HDAC-2.
72
        
In addition to NuRD, HDAC-1/2 were found in different co-repressor complexes such as 
CoREST
73
 and mSin3.
74
  In this context, it is still far from clear whether different      
HDAC-1/2 containing complexes can repress synergistically their targets or whether 
the different complexes are specifically targeted to different regions of the genome.
75
 
Besides the two catalytic subunits, NuRD includes some important proteins mainly 
regulating interactions. The two methyl CpG-binding domain proteins MBD2 and 
MBD3 are alternative subunits.
76
 But only MBD2 is able to interact with methylated 
DNA,
77
 MBD3 seems to have lost this ability during vertebrate evolution.
78
  
MBD2 was recently found to preferentially bind to methylated transcriptional start 
sites. 
79
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MBD3 was linked to the establishment of altered epigenetic marks in acute 
promyelocytic leukemia (APL). The key mediator of APL, the t(15;17) fusion protein 
PML-RARα, recruited Mi2/NuRD to target genes like the important tumor suppressor 
RARß2. Upon RNAi-mediated depletion of MBD3, leukemia cells displayed a more 
matured morphology.
80
 However, it is unclear whether that effect of MBD3 depletion 
is due to a destabilization of NuRD complex or to a so far unknown property of MBD3. 
The family of metastasis-associated proteins (MTA) was found based on the discovery 
of MTA1 in a model for metastatic growth.
81
 Several other members of this family, 
including different isoforms, have been identified so far. NuRD seems to be able to 
constitute specialized complexes with the different MTA proteins since many different 
functional roles are reported for MTA1, 2 and 3 up to now. 
MTA1 is upregulated in several cancers. In gastric and colorectal cancers an 
overexpression correlated with an advanced stage.
82
 In breast cancer cells MTA1 is a 
potent co-repressor of estrogen-receptor element (ERE)-driven transcription, thus it 
blocks the ability of estradiol to stimulate ER-mediated transcription.
83
 This finding 
provides a partial explanation for the clinical data in which the highest expression of 
MTA1 in untreated node-negative breast cancer was associated with increased relapse 
risk. Furthermore, Tamoxifen and/or anthracyclene-based chemotherapies eliminated 
all MTA1 associations with clinical outcome.
84
 
Whether the described MTA1 effects on carcinogenesis are due to an increase of 
MTA1-containing NuRD, or whether it acts as a monomer or even in a different 
complex is far from clear.  
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In a MTA2 knock-out mouse abnormal T-cell activation upon stimulation and lupus-like 
autoimmune disease were observed.
85
 
MTA3 is also linked to carcinogenesis. The absence of MTA3 or estrogen receptor 
resulted in aberrant expression of the transcriptional repressor Snail, a master 
regulator of epithelial to mesenchymal transition (EMT). Aberrant Snail expression 
reduced the expression of the cell adhesion molecule E-cadherin, an event associated 
with changes in epithelial architecture and invasive growth.
86
 Interestingly, transient 
overexpression of MTA1 leads to dramatic decrease in MTA2 and MTA3 on protein 
level but not on transcript level.
87
 
The additional subunits RbAp48 (RBBP7) and RbAP48 (RBBP4) were originally identified 
based on their interactions with Retinoblastoma protein.
88
 They are also able to 
interact with histone H4 to mediate further recruitment of proteins to chromatin.
89
 
The subunits p66α/ß are both able to interact with MBD2 as well as MBD3. 
90
 Both 
proteins interact with the tails of all core histones in vitro.
91
 
As already mentioned, the NuRD complex is thought to be a classical repressor 
complex as it uniquely combines histone deacetylation with chromatin remodeling. 
One mechanistic model for this repression is that the binding of methylated DNA by 
MBD2 recruits other NuRD components. Of these, HDAC-1/2 are then responsible for 
deacetylation of histones and CHD3/4 use their ATPase-dependent remodeling 
property to further compact the chromatin.
92
 An alternative model suggests that 
CHD3/4 remodel nucleosomes to facilitate access of HDAC-1/2 to histone tails.
93
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An alternative recruitment by co-repressors is also possible: Mi2α is able to interact 
with co-repressor KAP-1, thereby recruiting the NuRD complex to target genes of 
KRAB- (Krüppel-associated-box) zinc-finger proteins.
94
  
Another possibility to recruit NuRD is the interaction with DNA-binding proteins, for 
example the DNA-binding protein Ikaros recruits Mi2/NuRD to regions of 
heterochromatin upon T-cell activation.
95
 
Within this repressive role, the NuRD complex can also function as a barrier to 
complexes known as transcriptional activators like SWI/SNF family members. Such 
antagonistic roles were shown for Mi2ß and SWI/SNF remodeling complexes during 
the activation of inflammatory genes in response to LPS stimulation. BRG1 was 
required for activation and Mi2ß for limitation of this response.
96
 Similar opposing 
effects were observed for Mi2/NuRD and SWI/SNF in reprogramming of genes by EBF 
(early B-cell factor) and Pax5 during B-cell differentiation.
97
  
CHD5 is a new member of the CHD family. A more detailed introduction to CHD5 is 
given in chapter 2.5.2 in the context of Neuroblastoma. 
Subfamily III: CHD6-9 
Subfamily III contains CHD6-9. This family is the most variable of all three because they 
are characterized by different additional domains in the C-terminal area, including 
paired BRK (Brahma and Kismet) domains, a SANT-like domain, CR (conserved region) 
domains and DNA-binding domains.
98
 These DNA-binding domains are similar to those 
in subfamily I although a DNA binding activity has only been shown for CHD9 so far.
99
  
CHD6 is ubiquitously expressed in mouse tissues and it co-localizes with RNA 
polymerase II engaged in transcription pre-initiation and elongation.
100
 The location of 
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CHD6 on human chromosome 20q12 is a locus commonly deleted in human ataxias. 
Interestingly, in a mouse model with deletion of CHD6 exon 12 (located within the 
ATPase domain) impaired motor coordination was observed.
101
 
CHD7 encodes a protein mutated or deleted in most patients with CHARGE syndrome. 
CHARGE is an acronym for coloboma of the eye, heart defects, atresia of nasal 
choanae, retardation of growth and/or development, genital and/or urinary 
abnormalities, ear abnormalities and deafness. 
102
 
CHD7 is highly expressed in ES cells but its expression becomes restricted to tissue 
specific progenitor populations during development. It is noteworthy that, these 
progenitors give rise to specific cell types in different organs that are affected in 
CHARGE syndrome, including neural crest derivatives, ear, eye, heart and kidney.
103
 
CHD7 binds several PBAF specific subunits in human neural crest-like cells
104
  but forms 
different complexes in other cell types and developmental stages.
105
 
CHD8 was identified to be a negative regulator of the Wnt-/β-catenin pathway that 
binds directly to β-catenin. Thus, it suppresses its transactivation activity.
106
 Recently, 
CHD8 was found to be involved in regulation of HOX2A gene expression.
107
 
The last family member, CHD9, was shown to take part in osteogenic cell 
differentiation.
108
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2.4.5 The SWI/SNF family 
Initially, the family of SWI/SNF chromatin remodelers was discovered in two genetic 
screens in yeast.
 109
 The first screen revealed genes involved in mating-type switching 
(switch (SWI) mutants)
110
 and the second identified genes required for SUC2 
expression in sucrose metabolism (sucrose non-fermenting (SNF) mutants).
111
  
The central catalytic subunits of SWI/SNF complexes in mammals are hBRG1 (Brm-
related gene 1; also known as SMARCA4) and hBRM (human Brahma; or SMARCA2); 
but presumably no individual SWI/SNF complex contains both. Additionally, nine to 
twelve subunits which are referred to as BRG1/Brm-related factors (BAFs) constitute 
such a complex. Core subunits are BAF155, BAF170 and SNF5 (also known as INI1 or 
BAF47). Among the accessory subunits are BAF180 and BAF250. Depending on their 
presence, the BRG1-containing complexes are further divided into BRG1/BAF 
(containing BAF250) and BRG1/PBAF (with BAF180)
 112
 but several other BRG1-
containing complexes like WINAC
113
 or NUMAC
114
 were identified. 
BRG1 and Brm share approximately 75 % amino acid identity. However, they seem to 
take over some different functions, as a homozygous Brm knockout mouse was 
viable
115
 whereas homozygous BRG1 deficiency resulted in embryonic lethality.
116
  
Underscoring these differences, distinctive expression patterns were observed in adult 
tissues: BRG1 was predominantly expressed in cell types constantly undergoing 
proliferation or self-renewal and Brm mainly seen in brain, liver, fibromuscular stroma, 
and endothelial cell types.
117
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Both proteins were shown to have chromatin remodeling activity by themselves and 
this activity was further stimulated by presence of the core subunits in vitro.
118
 
A hallmark of BRG1 and Brm is the conserved C-terminal bromodomain known to be a 
typical recognition module for acetylated lysine residues of histones. The yeast 
BRG1/Brm homologue Swi2/Snf2 requires that domain for a stable association with 
chromatin in vitro. 
119
  
Although SWI/SNF complexes are considered as characteristic transcriptional 
activators, some evidence suggests that they can also function as repressors. For 
example, in embryonic stem cells BRG1 was shown to be required for repression of 
genes involved in differentiation while activating genes for maintenance of 
pluripotency.
120
 
Emerging evidence has shown that various SWI/SNF subunits are involved in the 
development of cancer. BRG1 or Brm interfere with a couple of key regulatory proteins 
like p53,
121
BRCA1,
122
 Rb
123
 and the ß-catenin/Wnt pathway.
124
 Furthermore, 
reintroduction of BRG1 into cells lacking its expression was sufficient to reverse their 
transformed phenotype and induce growth arrest as well as a senescent phenotype.
125
 
The most prominent example for the relevance of SWI/SNF complexes in cancer is the 
core subunit SNF5 that turned out to be a bona fide tumor suppressor in malign 
rhabdoid tumors.
126
  
BRG1 was shown to be mutated or deleted in many cell lines and primary samples 
from non-small cell lung cancer (NSCLC). 
127
 Loss of BRG1/Brm occurred in around 10 % 
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of NSCLC and was, independent of the stage, significantly associated with a worse 
patient survival in comparison with BRG1/Brm expressing tumors.
128
 In a lung-specific 
conditional knockout of BRG1 using an ethyl carbamate lung carcinogenesis mouse 
model, the heterozygous inactivation of BRG1 resulted in an increased number and 
size of tumors whereas the homozygous loss was associated with increased apoptosis 
in lung tissue without tumor formation.
129
 However, BRG1 resides on the short arm of 
chromosome 19, only around 10 Mb from LKB1, another candidate tumor suppressor 
in NSCLC.
130
 Since loss of both proteins in cancer is mostly due to larger deletions, a 
concomitant loss of both seems likely. Unfortunately, in none of the publications with 
clinical data a multivariate analysis was performed showing that the prognostic 
significance of either protein is independent of the other. In conclusion, although the 
role of BRG1 in NSCLC is suggestive I would take these data with great caution.  
2.5 Neuroblastoma and CHD5 
2.5.1 Neuroblastoma 
The neuroblastoma is the most common extracranial solid tumor during childhood. It 
arises from the sympaticoadrenal lineage of the neural crest. Therefore it can occur 
everywhere in the sympathetic nervous system; even though it is usually located 
paraspinally in the abdomen or the chest.
131
   
A clinical hallmark is the amazing variability of this cancer, differing from spontaneous 
regression without any therapy to extended disease upon aggressive multimodal 
treatment.
132
 Based on the tumor’s ability to secrete catecholamines, a 
Neuroblastoma screening for raised urine catecholamines at the age of one year was 
performed in two independent population-based controlled trials in Germany and 
North America in the 1990s. Both trials resulted in an increased incidence (more 
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children suffering from this disease detected by screening) without any change in 
mortality caused by neuroblastomas. 
133
 
Typical features of neoplasia such as mutations of TP53 and Ras as well as deletions of 
the INK4a locus are rarely reported in primary neuroblastomas, indicating that there 
might be different events which influence major tumor promoting pathways like 
aberrant cell cycle control and apoptosis. 
134
 
Since the neuroblastoma is genetically one of the best characterized tumors, there are 
several clinical features and molecular markers allowing a prediction of the clinical 
course although there remain cases in which the established prediction factors show 
limited clinical utility:
135
 
A major prognostic factor is the age. In general, infants have a much better prognosis 
than children older than one year.
136
 In addition, the expression of the NGF receptor 
TrkA is highly correlated with favourable outcome.
137
  
Roughly 20 % of primary tumors have an amplification of N-Myc which is associated 
with a poor outcome, advanced stage of the disease (according to the International 
Neuroblastoma Staging System, INSS) and treatment failure. Furthermore, the 
biological impact of this amplification is indicated by the fact that also patients with 
otherwise favourable disease have a poor prognosis.
138
 25 - 35 % of neuroblastomas 
show an allelic loss of the short arm of chromosome 1, of which the smallest region of 
deletion could be mapped to 1p36. This LOH occurs commonly in patients with an 
advanced stage of the disease and seems to predict the disease progression and not 
the overall survival, although this has been controversially discussed. Most tumors 
with amplified N-Myc additionally own a LOH 1p, but not every tumor with LOH 1p has 
an amplified N-Myc. This deletion is characterized by whole chromosome gains lacking 
rearrangements suggesting that this deletion might precede the amplification.
139
 
Furthermore, a microcell-mediated chromosome transfer of 1p into neuroblastoma 
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cells suppresses transformation and tumorigenity.
140
 All these data suggest that there 
might reside one or more potent tumor suppressors on 1p36, but despite intensive 
investigations a defined 1p tumor suppressor could not be identified so far. Recently 
Chromodomain Helicase DNA binding domain 5 (CHD5) was proposed as a candidate 
tumor suppressor gene. CHD5 was absent in neuroblastoma cell lines and a large 
percentage of primary tumors.
141
 In a group of 99 neuroblastoma patients, CHD5 
expression correlated with the event-free survival independently from a deletion of 
the short arm of chromosome 1 (1p) but correlated with amplified N-Myc and age.
142
  
The prognostic impact of CHD5 is further supported by a recent publication of Garcia 
et al
143
, demonstrating low or absent CHD5 expression in high-risk neuroblastoma and 
intense nuclear CHD5 staining in low-risk tumors. These findings suggest a possible 
clinical utility to distinguish between low-risk stage 4s and high-risk stage 4 tumors in 
infants. According to the International Neuroblastoma Staging System (INSS), stage 4 
neuroblastomas include metastasized tumors, usually with an unfavourable prognosis. 
In contrast, Stage 4S denotes a specific metastatic stage of neuroblastomas in children 
younger than one year with small primary tumors and metastases in liver, skin, or 
bone marrow that spontaneously regress in most cases.
144
 To distinguish between 
stage 4 and stage 4S is important for a treatment decision (ranging from aggressive 
multimodal treatment to watch-and-wait strategy) but can be difficult. Thus, a 
molecular marker that improves the differentiation between these two stages would 
be of great clinical advantage. 
In addition, high CHD5 expression was found to be associated with an increased event-
free and overall survival independently of INSS stage, patient age and amplification of 
MYC-N. In addition, a reactivation of CHD5 expression was related to a complete or 
very good response towards cytotoxic induction therapy in high-risk neuroblastoma.
145
 
[A complete response is defined by the absence of tumor in CT or MRI scan; a 
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classification as very good partial response includes tumors with > 90 % reduction in 
3D tumor volume reconstructed by CT/MRI].
146
 
2.5.2 Chromodomain Helicase DNA-binding domain 5 (CHD5) 
The human CHD5 gene consists of 42 exons coding for a 223 kDa protein. Predicted 
from its protein sequence it contains two zinc-fingers of the PHD class, two 
chromodomains and a Helicase/ATPase domain (see Fig 2.3).
147
  
 
NH3 COOH
2 PHD zink fingers 2 chromodomains Helicase/ATPase domain
 
 
Thompson et al
148
 described a CpG island within the CHD5 gene starting 630 base pairs 
5’ to the transcriptional start site, containing the complete exon one and the first 680 
base pairs of intron one. The presence of a CpG island suggests a possible 
transcriptional regulation by methylation.  
CHD5 is a vertebrate-specific gene. Sequence homology between vertebrate CHD5 
proteins is very high as shown in table 2.1. Notably, not all vertebrates have a CHD5-
like protein encoded in their genome according to their predicted transcripts or to a 
blast search for a CHD5-specific region of its C-terminal part. Interestingly, the NCBI
149
 
database suggests only very few orthologues. In contrast, many predicted orthologues 
are listed in the Ensembl
150
 database. However, both databases provide only a 
prediction of CHD5-like protein sequences. It has not yet tested whether the predicted 
CHD5-like proteins really exist and if they are expressed in the different species.   
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Fig. 2.3: Predicted structural motifs of CHD5 
(modified after Thompson PM et al, Oncogene 2003) 
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A 
species % protein identity species % protein identity 
gorilla 99 horse 94 
marcaque 99 cow 93 
orangutan 99 marmoset 92 
chimpanzee 98 mouse 92 
pig 97 guinea pig 91 
dog  96 tasmanian devil 89 
elephant 96 chicken 87 
gibbon 96 kangaroo rat 87 
panda 96 turkey 87 
dolphin 95 anole lizard 82 
rat 95 cat 82 
bushbaby  94     
 
B 
species % protein identity 
chimpanzee 96 
horse 96 
rat 95 
dog 95 
cow 95 
mouse 94 
 
Table 2.1: Conservation of CHD5 between vertebrates expressed as % protein 
identity after alignment of predicted CHD5 protein sequences according to Ensembl (A) 
and NCBI database (B) with ClustalW. 
 
Fig. 2.4: Phylogenetic tree of CHD5 in selected species
The phylogenetic tree was constructed with the “one-click“ method (www.phylogeny.fr.).
Sequences from NCBI were used.
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In addition, hCHD5 shows an identity of 70 % with hCHD3 and 75.5 % with hCHD4.
151
  
In comparison to CHD4 which is ubiquitiously expressed in all tissues, CHD5 expression 
seems to be restricted to neural-derived tissues like brain and adrenal gland. CHD5 
mRNA could not be detected in liver, placenta, spleen, bone marrow, thyroid, 
stomach, pancreas, small intestine, colon and prostate.
152
    
Recently, CHD5 was identified as a tumor suppressor controlling proliferation, 
senescence and apoptosis. Bagchi et al
153
 used chromosome engineering to generate 
different mouse models with gain and loss of a region on mouse chromosome 4 that 
corresponds to human 1p36.  
A gain resulted in perinatal lethality caused by developmental abnormalities within the 
nervous system; MEFs harvested during late gestation showed reduced proliferation, 
increased apoptosis and senescence.  
Loss of this region was tolerated during embryogenesis; in the corresponding MEFs an 
enhanced proliferation, facilitation of Ras-induced transformation and spontaneous 
immortalization were found. Furthermore, mice with a heterozygous deficiency of the 
(human) 1p36 locus were prone to develop several non-neural tumors (lymphoma, 
squamous cell carcinoma and hibernoma).   
Within this region, expression of the candidate tumor suppressor genes was 
sequentially disrupted by specific shRNAs. Of these, CHD5 was identified to cause the 
observed phenotype. Further experiments revealed that CHD5 positively regulate p53 
presumably via p14/p19
ARF
.
154
 The exact molecular mechanisms for these effects could 
not be defined. 
The high sequence homology between CHD4 and CHD5 suggests that CHD5 might be 
also a part of a multi-protein complex like NuRD. Recently, Potts RC et al
155
 identified 
CHD5 in a NuRD-like complex in brain containing MTA3, p66ß, MBD3, RbAp46 and 
HDAC-2. Furthermore, shRNA-mediated CHD5 depletion in primary rat neurons altered 
neuronal expression of genes implicated in aging, Alzheimer’s disease and neuronal 
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function. Besides that, CHD5 was found to bind to its target genes, thus suggesting a 
direct regulation.  
2.6 Malignant Glioma and 1p deletions 
2.6.1 Malignant Glioma 
Malignant gliomas are a spectrum of tumors displaying various glial cell differentiation 
and malignancy grades. The major histopathological entities include 
oligodendroglioma, ependymoma and astrocytoma, but they also exist as a continuous 
spectrum.
156
 The glioblastoma is the most aggressive form of an astrocytoma and the 
most common primary brain tumor in adults although it is a relatively rare event with 
an annual incidence of about 2/100 000 in Europe.
157
 The prognosis is almost always 
fatal with a median survival of 4.7 months after diagnosis despite an overall 
improvement of multimodal cancer therapy.
158
 Histopathologic hallmarks of 
glioblastomas are diffuse infiltration, large necroses and brisk glomeroid microvascular 
proliferation.  
Although malignant gliomas (including glioblastomas) present many cancer typical 
features in their biology like oncogene and tumor suppressor alterations, they exhibit 
an otherwise unique biology: Most solid tumors expand first into areas of soft tissue 
where their growth is not physically limited, e.g. colon cancer into the gut lumen. The 
expansion of brain tumors necessitates active tissue destruction nearly right from the 
start because only a small part of the brain is occupied by the ventricular system as a 
possible space for tumor expansion without tissue destruction. Indeed, apoptotic cell 
death in tumor surrounding neurons can be observed.
159
 A second unique finding is 
the mode of tumor cell spread. Glioma cells usually do not form metastases by passive 
circulation in the blood flow and the development of metastases itself is an extremely 
rare phenomenon. Infiltration of the brain takes place by active migration of tumor 
cells through the extracellular spaces in the brain.
160
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Besides these observations epigenetic alterations might contribute extensively to 
glioblastoma formation as suggested by mainly two findings:  
Hypermethylation of the DNA repair gene O
6
 Methylguanine DNA transferase (MGMT) 
promoter seems to be associated with a substantially better response to the alkylating 
agent temozolomide.
161
 Data from preclinical experiments (e.g. Papi A et al
162
, 
Svechnikova I et al
163
) and case reports (e.g. Witt O et al
164
) suggest HDAC inhibition as 
a promising part of future glioblastoma therapy but clinical trials are discouraging so 
far.
165
  
2.6.2 Loss of the short arm of chromosome 1 in malignant glioma 
Loss of 1p occurs in primary and secondary glioblastomas with the same frequency   
(~15 %).
166
 The combined loss of 1p and 19q is a distinctive genetic feature of 
oligodendrogliomas and associated with a better response to chemotherapy and 
prolonged survival.
167
  
Two different types of 1p deletions are reported in general: Firstly, the complete loss 
of chromosome 1p associated with loss of 19q in oligodendroglial phenotypes. 
Secondly, the partial loss of usually 1p36 is mainly found in astrocytic gliomas. In 
oligodendrogliomas and low-grade astrocytomas LOH 1p /19q and p53 mutations are 
rarely detected in the same tumor indicating that these alterations lead to distinct 
molecular subtypes
168
 or that the same molecular effect is achieved by these 
alternating events. 
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A recent study by Wernersbach Pinto et al
169
 could not detect a different outcome of 
glioblastoma patients regarding their 1p status whereas Ichimura et al
170
 found a 
significantly longer survival in patients with total 1p deletions.  
A tumor suppressor mapped on chromosome 1p36 is not yet identified, but data from 
Ichimura et al
171
 found CHD5 mostly included in the deleted area of 1p36 suggesting a 
possible function as a tumor suppressor. This is supported by the findings of Bagchi et 
al
172
 showing absent expression of CHD5 in glioma samples in comparison to normal 
brain.  
2.7 Inflammation and cancer  
Chronic inflammatory and infectious conditions can trigger a variety of cancers. Thus, 
as prime examples the relation between Helicobacter pylori infection and gastric 
cancer
173
 and gastric MALT lymphoma
174
, respectively, chronic inflammatory bowel 
disease and colon cancer
175
 as well as cervical cancer and human papilloma virus (HPV) 
infection
176
 are omnipresent. The characteristics of cancer-related inflammation 
include the infiltration of the tumor and its environment with inflammatory cells and 
the presence of tumor-promoting chemokines and cytokines like TNFα and IL1ß. On 
the sub-cellular level, inflammation often operates on the same signalling pathways as 
oncogenic processes (like ras or myc). One of the key mediators of these is NF-κB.
 177
 
2.8 NF-κB, a key regulator of inflammation 
The NF-κB family of transcription factors includes a number of structurally-related 
proteins that constitute homodimers and heterodimers. In mammals, it contains 
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 Reviewed in: Rathbone M and Rathbone B, Helicobacter pylori and gastric cancer. Recent Results Cancer 
Res (2011). 
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p50/p105, p52/p100, p65 (RelA), c-Rel and RelB. All these proteins share a N-terminal 
Rel homology (RH) domain that organizes DNA-binding, dimerization and IκB-binding. 
At their C-terminus RelA, RelB and c-Rel have transcriptional activation domains. In 
contrast, p105 and p100 possess inhibitory domains. p50 and p52 are the shortened 
and active forms of p105 and p100, respectively. The most abundant heterodimer is 
formed by p50/p65. When inactive, the heterodimer is kept in the cytoplasm by direct 
binding of the IκB (inhibitor of κB) protein. Upon stimulation by various signals NF-κB is 
released from its inhibitor and translocated into the nucleus.
178
 As a transcription 
factor, the heterodimer binds specifically to its consensus site, the κB-site. This DNA-
binding site spans 9 – 11 base pairs and is highly degenerated. It is usually represented 
as G-5 G-4 G-3 R-2 N-1 N0 Y+1 Y+2 C+3 C+4 where R represents purine, N any nucleotide, Y 
pyrimidine and the subscribed number gives the relation to the assumed centre of the 
structure.
179
 
Aberrant regulation of NF-κB plays an important role in many cancer entities. It can 
affect all six major hallmarks of cancer, namely cell proliferation, suppression of 
apoptosis, angiogenesis, acquisition of limitless replication, metastasis and 
inflammation.
180
 However, the NF-κB network displays a confusing complexity: 
Depending on the context, it was also shown to promote apoptosis
181
 and even a 
tumor suppressor-like role was suggested. 
182
 
2.9 Tumor necrosis factor alpha (TNFα) 
Since I use the TNFα and TLR-9 pathway to study the impact of ATP-dependent 
chromatin remodelers on gene activation, I briefly describe these molecules and their 
pathways.  
The history of tumor necrosis factor began with an amazing observation of the New 
Yorker surgeon William Coley. At the end of the 19
th
 century, he started to treat 
sarcoma patients with filtrated bacterial cultures, the so-called ‘Coley’s mixed toxins’, 
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 Reviewed in: Rayet B and Gélinas C, Aberrant rel/nfkb genes and activity in human cancer. Oncogene 
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 Natoli G et al, Interactions of NF-kappaB with chromatin: the art of being at the right place at the right 
time. Nat Immunol (2005). 
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 Baud V and Karin M, Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug 
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 Ryan KM et al, Role of NF-kappaB in p53-mediated programmed cell death. Nature (2000). 
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 Keller U et al, Myc suppression of Nfkb2  accelerates lymphomagenesis. BMC Cancer (2010). 
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and achieved a hemorrhagic necrosis of this otherwise devastating disease. Although 
his work was controversial and poorly reproducible, the role of TNFα in cancer and 
inflammation as a currently major research topic was initiated by Coley’s 
experiments.
183
 
Despite the tumor-destructive role of TNFα, today used only for some rare indications, 
it has a paradoxical tumor-promoting activity. These pro-tumor actions are not fully 
understood but they are most likely related to its pro-inflammatory properties within 
the cancer microenvironment. 
184
 
Two human TNFα receptors are known: TNFR1 and TNFR2. TNFR1 is ubiquitously 
expressed and belongs to the death receptor family that possess the ability to induce 
apoptotic cell death. TNFR1 is activated by soluble TNFα. Binding of TNFα to TNFR1 
leads to an activation of the NF-κB, MAPK pathway and AP-1 (see Fig. 2.5). The TNFR2 
expression is restricted to hematopoietic cells and does not harbour a death domain 
like TNFR1. Its pathway has been less well studied.
185
  
Both TNF receptors seem to participate in tumor promotion by TNFα. Within tumors, 
TNFR1 in mainly found on tumor and stroma cells whereas TNFR2 mainly resides on 
tumor-infiltrating immune cells. Mice deficient in TNFR1 exhibit an attenuated 
development of cancer in mouse models for cancer.
186
 Interestingly, TNFR2 is highly 
expressed on CD4
+
 FoxP3
+
 regulatory T cells. Its activation contributes to activation, 
proliferative expansion and survival of Treg.
187
 Several subsets of regulatory T cells 
were found to inhibit the antitumor immunity, thus, promoting tumor growth and 
metastasis.
188
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2.10 Toll-like receptor 9 (TLR-9) 
The mammalian family of Toll-like receptors (TLRs) is named after the Drosophila 
melanogaster gene Toll. That receptor is involved in Drosophila development and plays 
an important role in the defence against infections in the adult fly.
189
 
In mammals, TLRs belong to the group of pathogen-associated molecular pattern 
(PAMP) recognition receptors that are important for cells of the innate immunity 
system to sense microbial structures. They recognize conserved molecules like 
lipopolysaccharide from Gram-negative bacteria (TLR-4), flagellin (TLR-5) or ssRNA 
(TLR-7). TLR-9 is located in the endosomal compartment and recognizes unmethylated 
CpG motifs that are a hallmark of bacterial DNA. Its activation results in an activation 
of the NF-κB pathway.
190
 
TLR9 agonists are currently under investigation for cancer treatment. One of these     
so-called immune modulatory oligo nucleotides (IMOs) stimulating TLR-9 signalling, 
                                                           
189
 Reviewed in: Chtarbanova S and Imler JL, Microbial sensing by Toll receptors: a historical perspective. 
Arterioscler Thromb Vasc Biol (2011). 
190
 Kawai T and Akira S, The role of pattern-recognition receptors in innate immunity: update on Toll-like 
receptors. Nat Immunol (2010). 
Fig. 2.5: Activation of NF-κB downstream of TNFR resulting in pro- and anti-
inflammatory functions (modified after Ben-Neriah Y and Karin M, Nat Immunol. 2011)
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IMO-2055, was demonstrated to possess anticancer activity in a mouse model. This 
anticancer activity was even amplified when it was used in combination with 
chemotherapeutic agents but the mechanism of action remains unclear.
191
 
2.11 Objectives 
The two main research objectives of this thesis focus both on ATP-dependent 
chromatin remodelers but are otherwise independent projects. 
1. Analysis of expression pattern and function of the ATP-dependent chromatin 
remodeler CHD5. 
2. Impact of different ATP-dependent chromatin remodelers on NF-κB induced 
transcriptional activation. 
 
1.) Recently, the novel chromatin remodeler CHD5 has been identified (see chapter 
2.5.2). So far, little is known about its distribution, function and biochemical 
characteristics. Therefore, we decided to generate polyclonal antisera against CHD5 for 
further studies on this protein. One main goal of this thesis is the characterization of 
these and commercially available antisera.  
CHD proteins are in general expressed by very different patterns, for example, CHD4 
and CHD6 are ubiquitously expressed whereas the expression of CHD7 becomes 
restricted to progenitor cells during development (see chapter 2.4.4). To gain insight 
into the expression pattern of CHD5, a detailed analysis is carried out. At the beginning 
of this thesis, CHD5 was thought to be restricted to neural-related tissues
192
 but 
further evidence was required. Thereby, particular attention is paid to its expression in 
glioblastoma cell lines because CHD5 resides on 1p36, a locus commonly deleted in 
glioblastomas (see 2.6.2). This suggests a possible role as tumor suppressor in this 
cancer entity. 
Furthermore, CHD5 has been implicated in senescence, cell cycle control and 
apoptosis.
193
 In order to study its function, a suitable cell system is explored and some 
key experiments on its biological role are carried out. 
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2.) Upon NF-κB activation by various stimuli, chromatin structure has to be opened up 
in order to allow the transcriptional machinery to get full access to the DNA. One 
major group of enzymes involved in these changes is the family of ATP-dependent 
chromatin remodelers. To study the impact of two typical family members, CHD4 and 
BRG1, on NF-κB induced transcriptional regulation, two pathways leading to NF-κB 
activation are chosen as models. The TNFα pathway is chosen to study the direct 
impact of chromatin remodelers on a subset of NF-κB target genes in HEK293 cells; the 
Toll-like receptor 9 (TLR-9) pathway is used in a NF-κB reporter cell system to get 
information about the influence of CHD4 and BRG1 on overall NF-κB activity. 
Recently published data suggest an opposing role for BRG1 and CHD4 in macrophages 
upon LPS stimulation whereas BRG1 was required for activation of NF-κB induced 
transcription and CHD4 for the termination of it.
194
 Whether CHD4 and BRG1 are also 
involved in TNFα and TLR-9-induced NF-κB activity and whether an opposing role of 
CHD4 and BRG1 represents an universal model in immunologic pathways needs to be 
determined. 
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3. Material and methods 
3.1 Material 
Unless otherwise stated, all common chemicals were ordered from Applichem, Biomol, 
Calbiochem, Fluka, Roth, SERVA and Sigma-Aldrich. Tubes, pipettes and any plastic 
ware were purchased from Greiner Bio-One, Sarstedt and Eppendorf. Enzymes were 
purchased from Fermentas, New England Biolabs, Roche and Promega. 
3.1.1 Standard solutions 
Stock solutions and buffers were prepared according to standard protocols. The most 
common solutions are listed below: 
Phosphate Buffered Saline (PBS) 
140 mM NaCl 
2.7 mM KCl 
8.1 mM Na2HPO4 
1.5 mM KH2PO4 
- pH adjusted to 7.4 with HCl 
 
TAE buffer 
40 mM Tris-Acetat 
1mM EDTA 
 
LB medium 
1 % (w/v) tryptone 
0.5 % (w/v) yeast extract 
177 mM NaCl 
- pH 7.0 
 
LB agar plates 
1.5 % agar 
LB medium 
 
SDS-PAGE running buffer  
192 mM glycine 
25 mM Tris 
0, 1 % (w/v) SDS 
 
5x SDS loading buffer 
250 mM Tris-HCl pH 6.8 
10 % (w/v) SDS 
50 % (w/v) glycerol 
0.5 % (w/v) bromphenolblue      
500 mM DTT 
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3.2 Mammalian tissue culture 
Material Source 
DMEM (with high glucose and  L-glutamine) PAA 
RPMI 1640 + GlutaMax Invitrogen 
IMDM + GlutaMax Invitrogen 
Dulbecco's PBS without Ca
2+
 and Mg
2+
 (1x) PAA 
Trypsine (1x, 10x) PAA 
Sodium-pyruvate (100mM) PAA 
ß-mercaptoethanol  Invitrogen 
Penicilline/Streptomycin PAA 
DMSO Roth 
Fetal Bovine Serum Sigma-Aldrich 
Horse Serum Sigma-Aldrich 
Poly-L-Lysin, 0.01 % Sigma-Aldrich 
OPTI-MEM + GlutaMax Invitrogen 
Oligofectamine Reagent Invitrogen 
Nanofect Reagent Quiagen 
HBSS (1x, without Ca
2+
 and Mg
2+
) PAA 
Dnase I Sigma-Aldrich 
Polyethylenimin (PEI) Sigma-Aldrich 
Puromycin PAA 
NGF (2.5 S) from murine submaxillary glands Sigma-Aldrich 
recombinant hTNFa ImmunoTools 
PTO 1668 Gift from A. Kaufmann 
Diester 1668 Gift from A. Kaufmann 
5-Azacytidine (50x) Sigma-Aldrich 
cell culture flasks, dishes, pipettes Greiner 
 
3.2.1 General cell line maintenance 
All used cell lines, their growth medium and their source are listed below. Cells were 
cultured in tissue culture flasks in a humidified incubator at 37°C with 5 % CO2. Tissue 
culture work was done under sterile conditions. Fresh medium was added at least 
twice per week regarding the half life-time of the used antibiotics. When cells have 
reached a confluence of 80-90 % they were trypsinized and splitted in a ratio between 
1:2 to 1:10 depending on their growth behaviour and further use.  
The cell number was determined using an improved Neubauer chamber. A 
Mycoplasma test was performed several times. 
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cell line description source culture medium 
Gl261 glioblastoma, murine 
A. Pagenstecher,  
Dept. of Neuropathology, 
University Hospital Marburg 
DMEM, 10 % FBS,                                              
1 % PS 
A172 glioblastoma, human 
Chris van Bree,                                      
Academic Medical Center,  
Amsterdam 
DMEM, 10 % FBS,                              
1 % PS 
U373 glioblastoma, human 
Chris van Bree,                                      
Academic Medical Center, 
 Amsterdam 
DMEM, 10 % FBS,                                              
1 % PS 
U87 glioblastoma, human 
Chris van Bree,                                      
Academic Medical Center,  
Amsterdam 
DMEM, 10 % FBS,                                              
1 % PS 
T98G glioblastoma, human 
Chris van Bree,                                      
Academic Medical Center, 
 Amsterdam 
IMDM, 10 % FBS,                                              
1 % PS 
U251 glioblastoma, human 
Chris van Bree,                                      
Academic Medical Center,  
Amsterdam 
DMEM, 10 % FBS,                                       
1 % PS 
SH-EP neuroblastoma, human Tobias Otto, IMT Marburg 
RPMI, 10 % FBS,                          
1 % PS 
SH-SY-5Y neuroblastoma, human Tobias Otto, IMT Marburg 
RPMI, 10 % FBS,                          
1 % PS 
SMS-KCN neuroblastoma, human Tobias Otto, IMT Marburg 
RPMI, 10 % FBS,                          
1 % PS 
IMR-32 neuroblastoma, human Tobias Otto, IMT Marburg 
RPMI, 10 % FBS,                          
1 % PS 
Ht22 
hippocampal neurons, 
murine 
C. Culmsee, Dept. of 
Pharmacy,  
University of Marburg 
DMEM, 10 % FBS,                          
1mM sodium 
-pyruvate,                
2mM stable  
L-glutamate,                                  
1 % PS 
Pc12 pheochromocytoma, rat 
M. Schäfer,  
Dept. of Anatomy,             
University of Marburg 
RPMI, 10 % HS, 
 5 % FBS,                                                  
1 % PS 
Hela 
cervical carcinoma, 
human 
G. Suske, IMT Marburg 
DMEM, 10 % FBS,                                              
1 % PS 
HEK293T human embryonic 
kidney 
U.M. Bauer, IMT Marburg 
DMEM, 10 % FBS,                                              
1 % PS 
SAOS-2 osteosarcoma, human M. Eilers, Würzburg 
DMEM, 10 % FBS,                                              
1 % PS 
HEK293-TLR9 
-NF-κB-
reporter 
HEK293, stably 
expressing 
mTLR9 and  NF-κB 
reporter 
Andreas Kaufmann, 
Institute for Immunology, 
University of Marburg 
DMEM, 10 % FBS,                                              
1 % PS  
50 µM ß-mercapto-
ethanol 
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3.2.2 Mycoplasma Test 
Primers were synthesized by MWG: 
Name  Sequence  
Myco3 5’-actcctacgggaggcagcagta-3’ 
Myco 5 5’-tgcaccatctgtcactctgttaacctc-3’ 
 
Mycoplasma is a small bacterium without a cellular wall. Its infection of cultured cells 
can disturb cell culture maintenance, growth behaviour and tranfectability leading to 
uncontrolled biased results. Infected cells are not detectable by light microscopy 
certainly; thus a regular exclusion of mycoplasma infection has to be performed. 
Therefore, 100 µl of the cell culture supernatant was cooked at 95 ° C for 5 minutes in 
an Eppendorf tube, followed by a brief centrifugation at 13 000 rpm in a Hereus 
Biofuge pico. The supernatant was transferred to a new tube and DNA precipitation 
was achieved by addition of 10 µl 10 mM TRIS/HCl, pH 8.8. After a centrifugation at   
13 000 rpm the supernatant was transferred to a new tube and stored at 4°C. 1 µl was 
used as template in the PCR (25 µl total PCR volume).  In a positive mycoplasma test a 
band at around 500 base pairs can be observed on agarose gel.  
PCR program:  
94° C for 3 min. 
94° C 30 sec. 
55° C 30 sec.           38 cycles 
72° C 30 sec. 
72° C 5 min. 
3.2.3 Kryoconservation 
Medium I: 
60 % DMEM/RPMI 
40 % FBS 
Medium II: 
80 % DMEM/RPMI 
20 % DMSO 
 
Confluent cells from a 10 cm dish were washed with PBS and trypsinized with 3 ml 
trypsine-EDTA. After addition of 10 ml DMEM with 10 % FBS this mixture was 
transferred to a 15 ml tube and centrifuged at 1000 rpm for 5 minutes. The 
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supernatant was removed and the remaining cell pellet re-suspended in 500 µl 
Medium I followed by addition of 500 µl Medium II and transfer to a kryovial which 
was stored in 7 ml isopropanol at -80°C.  
3.2.4 Thawing cells 
Cells were thawed at room temperature and immediately seeded. After re-attachment 
of the cells to the culture flask bottom, the medium was removed to stop DMSO 
induced growth arrest, cells washed twice with PBS and fresh medium was added.  
3.2.5 Primary astrocyte culture: Coating cell culture flasks with Poly-L-Lysin 
To improve the attachment of the primary cells to the surface of the tissue culture 
flask the flasks were coated with Poly-L-Lysin. Therefore, the flasks were incubated 
with 2-5 ml of Poly-L-Lysin (MW > 300 000) overnight at 4° C. Afterwards the Poly-L-
Lysin was removed and the flasks were washed twice with ice-cold PBS. Prepared 
flasks were kept at 4° C until use. 
3.2.6 Primary astrocyte culture: Preparation and maintenance  
Dnase I solution: 
Dnase I 0.05 % (w/v) 
0.25 % glucose (w/v) 
10 mM HEPES 
DMEM (+2 mM L-Glutamine) 
10 % Horse Serum (HS) 
1 % Penicillin/Streptomycin (PS) 
 
In order to keep primary astrocytes into culture, 3 day old pups from C57BL/6 mice 
were decapitated; their forebrain cortices were harvested and freed of meninges and 
blood vessels. The extracted forebrains were washed with ice-cold Hank’s balanced 
salt solution (HBSS) and incubated for 15 minutes at room-temperature in 1 % (w/v) 
trypsine solution. 7 ml HBSS were added and centrifuged for 8 minutes at 600 g at 4° C. 
The sediment was incubated for several minutes on ice in Dnase I solution and 
centrifuged again. The sediment was re-suspended in DMEM with 10 % HS and 1 % 
Penicillin/Streptomycin and cultured in Poly-L-Lysin coated 25 cm
2
 flasks (one brain per 
flask). 6 hours later, non-viable and floating cells were removed, attached cells were 
washed with PBS and fresh medium was added. Afterwards, the medium was 
refreshed daily. The cells were kept until they reached confluence. Then, they were 
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thoroughly expanded. In the general maintenance of these cells there is no major 
difference to the used cancer cell lines regarding splitting procedures, freezing and 
thawing.
195
  
It was assumed that any neurons and oligodendrocytes naturally present in the culture 
after the dissection of the brain are killed by the neurotoxicity of glutamate in the 
culture medium. A small percentage of microglial cells cannot be excluded but reduced 
by a gentle washing step with trypsine before splitting. Astrocyte presence in the 
culture was supported by their typical morphology.
196
 The astrocyte culture was kept 
over several passages.  
Fig. 3.1: Primary astrocytes in culture
Microscopic view of primary astrocytes in culture. A: after 5 DIV, B: after 8 DIV.
Pictures were taken with the IMT-2 light microscope (Olympus) with 100 fold
magnification showing the typical astrocyte cell morphology.
A B
 
3.2.7 Transient DNA-transfection of human cell lines 
Plasmid Source 
pcDNA3.1/V5-His-TOPO/LacZ Invitrogen 
pcDNA3.1/V5-His-TOPO-hCHD5 Judith Bergs 
pCMV-hRb(379-928) A. Brehm 
pcDNA3.1-hp53 Th. Stiewe, IMT Marburg 
pcDNA3-hMi2beta-Flag Bauer group, IMT Marburg 
Cells were transfected with Nanofect, according to the manufacturer’s instructions.  
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 Protocol modified after N. Weiler, Inaugural-Dissertation, Medizinischen Fakultät der Rheinischen 
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 Nagasawa K et al, Astrocyte cultures exhibit P2X7 receptor channel opening in the absence of 
exogenous ligands. Glia, (2009).  
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3.2.8 Tranfection of HEK293 cells with siRNA 
siRNA sequence source 
siBRG1/Brm gcuggagaagcagcagaag Huuskonen J et al (2005)
197
 
siCHD3 cguaugagcugaucaccau Dharmacon, D-023015-01 
siCHD4.1 ccaaggaccugaaugauga Dharmacon, D-009774-01 
siCHD4.2 caaaggugcugcugaugua Dharmacon, D-009774-02 
siNon-targeting#2 uaaggcuaugaagagauac Dharmacon, pre-designed 
 
On the day before transfection cells were seeded at a low densitiy. 4-6 hours prior to 
transfection cells were washed and the medium was exchanged to antibiotic-free 
medium. siRNAs and Oligofectamine were separately solved in OPTI-MEM (used 
amounts according to the dish size, see following table) and incubated for 5 minutes at 
room-temperature. Both mixtures were gently mixed and incubated for 20 minutes at 
room-temperature. In the meantime cells were washed and medium without serum 
and antibiotics was added. The siRNA-Oligofectamine-solution was added to the cells 
dropwise. 4 hours after transfection the doubled amount of the beforehand added 
medium with 20 % FBS was provided to the cells.  
 
dish siRNA OPTI-MEM Oligofectamine OPTI-MEM medium on cells
6-well-plate 10 µl 175 µl 3 µl 15 µl 800 µl
6 cm dish 20 µl 350 µl 7 µl 30 µl 1600 µl
 
3.2.9 Flat cell assay 
PEI stock solution:  
450 µl 10 % PEI in 50 ml H2O, pH 7.0 
 
A mixture of DNA with PEI leads to a DNA/PEI complex formation resulting in the 
formation of compact colloids which are taken up by the cell via endocytosis
198
. 
For PEI transfection 1x10
7 
cells were seeded into a 25 cm
2
 flask the day before 
transfection. For transfection 214 µl PBS and 6 µg DNA were mixted (3 µg vector 
coding for LacZ + 2 µg Rb, 3 µg CHD5 + 2 µg LacZ, 3 µg CHD5 + 2 µg Rb, each +1 µg 
pBABE) and a solution of 214 µl PBS with 9.8 µl PEI was added, briefly vortexed and 
incubated for 15 minutes at room-temperature. The cells were washed twice with PBS, 
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 Huuskonen J et al, Activation of ATP-binding cassette transporter A1 transcription by chromatin 
remodeling complex. Arterioscler Thromb Vasc Biol. (2005).  
198
 Godbey WT et al, Improved packing of poly(ethylenimine)/DNA complexes increases transfection 
efficiency, Gene Ther. (1999).  
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4 ml of DMEM with 2 % FBS were supplied and the DNA solution was added dropwise. 
4 hours after transfection cells were washed again and 4 ml of DMEM with 10 % 
medium added.  
48 hours post-transfection cells were trypsinized and 100 000 cells seeded on a 10 cm 
dish. 24 hours later puromycin was added at a concentration of 2µg/ml. Puromycin 
was refreshed after 48 hours. On day 4 of selection, cells were washed twice with ice-
cold PBS, fixed with Methanol (-20°C) for 10 min, again washed with PBS and stained 
with crystal violett for 4 hours (2% crystal violett, 20 % Methanol) at 4°C on a shaker. 
Cells were washed with PBS. Around 200 cells (10 views) were counted under a light 
microscope (100 fold magnification). The experiment was done in triplicates and 
percentage of flat cells was calculated.  
 
3.2.10 Treatment of cells with 5-Azacytidine 
Cells were incubated with their normal growth medium including 1 or 10 µM                
5-Azacytidine for 3 days. RNA and protein was extracted. 
 
3.2.11 Differentiation of Pc12 cells with NGF (2.5 S) from murine submaxillary glands  
Pc12 cells were seeded on Poly-L-Lysin coated 6 cm dishes in DMEM with 10 % HS, 5 % 
FBS and 1 % penicilline/streptomycin. 24 hrs later cells were washed twice with PBS 
and 3 ml of fresh medium (DMEM + 1 % FBS) with mNGF at a concentration of 10 
ng/ml were added. Cells were kept over 7 days, medium and NGF were refreshed 
every second day.  
 
3.2.12 NF-κB activation by stimulation with TLR-9 agonists and TNFα 
For stimulation of HEK293 cells with TNFα at a concentration of 20 ng/ml TNFα was 
supplied in DMEM medium with 0.1 % FBS and cells were kept for 1-18 hrs under 
normal growth conditions.  
For stimulation of TLR-9 cells were incubated in DMEM with 10 % FBS and 1 µM 1668 
PTO/Diester for 2-18 hours under normal growth conditions.  
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3.3 Bioinformatics 
DNA and protein sequences were taken from NCBI
199
 and Ensembl.
200
 Alignments were 
performed with ClustalW.
201
   
Primers were designed by hand under calculation of melting temperature and 
exclusion of disturbing secondary structures by Oligo Analyser 3.0
202
, with Roche 
Universal Probe Library Assay Design
203
 and Primer3.
204
  
Prediction of transcription factor binding was performed with the UCSC genome 
browser.
205
  
Phylogenetic trees were generated using the “one-click”-method.
206
 
3.4 Molecular biology 
Standard procedures in molecular biology, including preparation of competent 
bacteria, transformation of chemically-competent bacteria with DNA, amplification of 
plasmid DNA in bacteria, purification, concentration determination, restriction enzyme 
digestion, analysis of DNA on agarose gels and amplification of DNA by polymerase 
chain reaction (PCR) were performed according to standard protocols. 
In addition, plasmid DNA was prepared using plasmid purification kits (Qiagen).  
3.4.1 Quantification of mRNA by RT-qPCR (real-time PCR) 
The quantitative reverse transcription polymerase chain reaction is the currently most 
sensitive method for detection and quantification of mRNA. Compared to Northern 
blot and RNAse protection assay it allows a detection of smaller RNA amounts.  As RNA 
cannot serve as template in PCR, the first step of a RT-PCR is the reverse transcription 
of the RNA into cDNA followed by the PCR itself. All currently available chemistries for 
real-time PCR allow the detection of the PCR products by generation of a fluorescent 
signal. One of them is SYBR Green, a fluorogenic dye. It exhibits little fluorescence in 
                                                           
199
 www.ncbi.nlm.nih.gov 
200
 www.ebi.ac.uk 
201
 http://vit-embnet.unil.ch/software/ClustalW.html 
Chenna R et al, Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 
(2003).  
202
 Integrated DNA Technologies: www.eu.idtdna.com.  
203
 www.roche-applied-science.com 
204
 www.fokker.wi.mit.edu/primer3/input.htm 
205
 http://genome.ucsc.edu 
206
 www.phylogeny.fr; Dereeper A et al, Phylogeny.fr: robust phylogenetic analysis for the non-
specialist. Nucleic Acids Res. (2008).  
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solution and emits a strong signal upon binding to the minor groove of double-
stranded DNA. This fluorescent signal is measured after each PCR elongation step and 
increases when the PCR product accumulates.
207
 
For relative quantification the target RT-PCR product is normalized to an internal 
control which is usually an abundantly expressed gene, called “housekeeping gene”. 
This internal standard should be unaffected by the experimental procedure and 
expressed constantly.  
As SYBR Green binds to any double-stranded DNA, also to primer dimers and 
unspecific products, leading to an overestimation of the target concentration, there is 
a strong need to exclude such disturbances by a precise melting curve analysis and a 
gel electrophoresis of the resulting PCR products. A melting curve is created at the end 
of the PCR by a slow increase of the temperature above the melting temperature of 
the amplicon while measuring the fluorescence which is then plotted as a function of 
the temperature. A specific product should result in a single peak at the amplicon’s 
melting temperature.
208
 
3.4.2 RNA isolation 
Material Source 
peqGOLD Total RNA Kit, Safety Line PeqLab 
Injection water B.Braun 
Trizol Invitrogen 
Chloroform-Isoamylalcohol, 49:1 Fluka 
 
RNA from human cell lines was extracted using PeqGold total RNA kit according to the 
manufacturer’s instructions which allows a purification of RNA with a size of greater 
than 200 bases. 
The RNA was finally eluted with RNase-free water; the concentration was measured by 
ND-1000 Nanodrop from PeqLab.  
RNA from tissue, rat or mouse cell lines was extracted by Trizol (Invitrogen) using the 
manufacturer’s protocol. RNA with an OD 260/280 between 1.8 and 2.18 was 
estimated to have a sufficient pureness. The RNA was stored at -80°C.   
                                                           
207
 Pfaffl MW et al, Real-time RT-PCR: Neue Ansätze zur exakten mRNA Quantifizierung. BIOspektrum 
(2004). 
208
 Bustin SA, Absolute quantification of mRNA using real-time reverse transcription polymerase chain 
reaction assays. J Mol Endocrinol. (2000).  
Bustin SA, Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J 
Biomol Tech.( 2004).  
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3.4.3 cDNA synthesis 
Material Source 
M-MLV Reverse Transcriptase Invitrogen 
dNTPs Fermentas 
oligo (dT) MWG 
random primers Invitrogen 
Aqua ad iniectabilia Braun B.Braun 
Ribolock Fermentas 
 
1-1.5 µg of total RNA, 1 μl oligo(dT) (500 μg/ml) and 1 μl 10 mM dNTP Mix (10 mM 
each dATP, dGTP, dCTP and dTTP at pH 7.0) were pipetted in an Eppendorf tube and 
filled up to 12 µl with RNAse-free distilled water. To open the secondary structure of 
the RNA this mixture was heated up at 70° C for 5 minutes and chilled on ice for 1 
minute. The contents of the tube were collected by a brief centrifugation, then 4 μl 5X 
First Strand Buffer, 2 μl 0.1 M DTT and 1 μl RNAse-Inhibitor (RNAsin) were added and 
pre-warmed at 37°C for 2 minutes. After addition of 1 μl (200 units) M-MLV RT the 
mixture was incubated at 37°C for one hour. The enzyme activity was inactivated by 
heating for 15 minutes at 70°C. The cDNA pool was diluted (1:10) and stored at -20°C.  
When cDNA synthesis was performed with random primers, 150 ng of these primers 
were used alternatively to oligo (dT) primers.  
When RNA was isolated with Trizol, 2.0 µg as starting material for cDNA synthesis were 
used.  
 
3.4.4 SYBR Green real-time PCR 
Material Source 
Absolute QPCR SYBR Green Mix Thermo Scientific 
Thermo-Fast® 96 (0.2ml non-skirted 96-well PCR plates) Thermo Scientific 
Adhesive PCR Film Thermo Scientific 
Aqua ad iniectabilia Braun B. Braun 
Stratagene Mx3000P Agilent Technologies 
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All listed primers were synthesized by MWG: 
 
Name Sequence Description  Source 
qCHD5-f 5'-agctggagctgtaccaca-3' Human CHD5    
qCHD5-r 5'-tcttgtcaaagctatggttcagga-3'     
CHD5/2-F 5'-cctctgggaaaatctacgaca-3' Human CHD5,     
CHD5/2-R 5'-taccgtgggtcattctgga-3' 
located closed to 
3‘-end 
 
  
hRPS14-fwd 5'-ggcagaccgagatgaatcctca-3' Human RPS14  Eilers group 
hRPS14-rev 5'-caggtccaggggtcttggtcc-3'     
CHD5-Maus-F 5'-aatgctgtcctgcacaagg-3' Mouse CHD5    
CHD5-Maus-R 5'-tgctttcatgtcactcagca-3'     
ß-actin-f 5'-gatctggcaccacaccttct-3' Mouse ß-actin   Bagchi et al
209
 
ß-actin-r 5'-ggggtgttgaaggtctcaaa-3'     
rRPS14-F 5'-tcatcagccttggacctca-3' Rat RPS14    
rRPS14-R 5'-ttactcggcaaatggtttcc-3'     
rCHD5-F 5'ctaccacttgcactgcctca-3' Rat CHD5    
rCHD5-R 5'-cccttcagtgggggacat-3'     
BRG1-F 5'-ccttcctcatcatcgtgcctc-3' Human BRG1  Huuskonen J et al,  
BRG1-R 5'-cggtgaccttcgtccacaatc-3'    2005
210
 
hBrm-F 5'-agaaaggctcacctgtgaaga-3' Human Brm    
hBrm-R 5'-ccaaattgccgtcttcgat-3'     
CHD4-F 5'-tctgtccccgttgtacgtg-3' Human CHD4    
CHD4-R 5'-ttgggatcagcatctggag-3'     
CHD3-F 5'-ggggcaagactgagaagga-3' Human CHD3    
CHD3-R 5'-catcggcaaaggtttcagag-3'     
IL8-RT-F 5'-actgagagtgattgagagtggac-3' Human IL-8    
IL8-RT-R 5'-aaccctctgcacccagttttc-3'     
CXCL2-F 5'-catcgaaaagatgctgaaaaatg-3' Human CXCL2  Bauer group, IMT 
CXCL2-R 5'-ttcaggaacagccaccaata-3'   
 
CCL2-F 5'-agtctctgccgcccttct-3' Human CCL2  Bauer group, IMT 
CCL2-R 5'- gtgactggggcattgattg-3'   
 
TNFa-F 5'- gtgactggggcattgattg-3' Human TNFa  Bauer group, IMT 
TNFa-R 5'-gccagagggctgattagaga-3'   
 
IRF1-F 5'-gagctgggccattcacac-3' Human IRF-1  Bauer group, IMT 
IRF1-R 5'- ttggccttccacgtcttg-3'   
 
IkB-F 5'cttgggtgctgatgtcaatg-3' Human IkB  Bauer group, IMT 
IkB-R 5'- acaccaggtcaggattttgc-3'   
 
CXCL10-F 5'-gaaagcagttagcaaggaaaggt-3' Human CXCL10  Bauer group, IMT 
CXCL10-R 5'-gacatatactccatgtagggaagtga-3'   
 
 
The primers for the gene of interest and the housekeeping gene should have a similar 
primer efficacy to avoid accumulating errors. Therefore, a dilution series for qCHD5 
                                                           
209
Bagchi A et al, CHD5 is a Tumorsuppressor at Human 1p36. Cell (2007). 
210
Huuskonen J et al, Activation of ATP-binding cassette transporter A1 transcription by chromatin 
remodeling complex. Arterioscler Thromb Vasc Biol (2005). 
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and RPS14 (human) in the range from 1:5 to 1:1000 followed by the calculation of the 
primer efficacy was performed.  
 
For QPCR, a reaction volume of 25 µl per well was used consisting of 6 µl cDNA and    
19 µl PCR master mix (8 µl water, 0.5 µl of each primer at a concentration of 70 nM,   
12 µl Sybr Green).  
QPCR program: 
step temperature time  cycles 
enzyme activation 95° 15' 1x 
denaturation 95° 15''   
annealing 60° 30'' 40x 
elongation 72° 30''   
 
Each experiment was done thrice in technical duplicates or triplicates. 
Relative gene expression was determined using the 2
- Δ ΔCt 
method.
211
  
The mean threshold cycle (Ct) of duplicates or triplicates was computed for each 
sample. The sample mean Ct for the housekeeping gene (ribosomal protein RPS14 in 
human system and rat samples, ß-actin for mouse) was subtracted from the sample 
mean Ct of the respective gene of interest (ΔCt). The mean ΔCt of the control (e.g. 
untreated sample, not-expressing sample) was selected as a calibrator and subtracted 
from the mean ΔCt of each experimental sample (ΔΔCt). The several fold change in 
gene expression (normalized to the housekeeping gene and relative to the control 
sample) was expressed as 2
- Δ ΔCt 
. 
 
Product specificity was tested by generation of a melting curve after QPCR and an 
agarose gel electrophoresis (2%) on resulting QPCR products.  
Result reliability for the CHD5 expression analysis was tested by a second CHD5-
specific primer pair (CHD5/2) and the comparison of oligo (dT)-generated cDNAs with 
random-primers generated cDNA as a qPCR template.  
 
 
 
                                                           
211
 Pfaffl MW, A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids 
Res. (2001).  
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3.4.5 RT-PCR 
All PCR reagents were purchased from Fermentas. 
Primers used in RT-PCR: 
Name Sequence 
mouse-iso 1-f 5’-cgtggaaggcatgatgt-3’ 
mouse-iso1-r 5’-ctttgttatcgcctggc-3’ 
mouse-iso2-f 5’-gtggaaggcgataacaaag-3’ 
mouse-iso 2-r 5’-aggtactcgttcatgttct-3’ 
 
PCR mix (30 µl): 
MgCl2: 3 µl 
10x PCR buffer (-Mg Cl2, +KCl): 3 µl 
10 mM dNTPs: 2 µl 
4 µM forward primers: 1 µl 
4 µM reverse primers: 1 µl 
Taq polymerase: 0.3 µl 
H2O: 15.7 µl 
cDNA (1:10 dilution): 4 µl 
  
PCR program: 
step temperature time  cycles 
enzyme activation 95° 5' 1x 
denaturation 95° 30''   
annealing 55° 30'' 35x 
elongation 72° 30''   
 
PCR products were separated on a 1.5 % agarose gel, DNA was stained with ethidium-
bromide and visualization was achieved with the intas imager 2009 gel documentation 
system.  
3.5 Analysis of Proteins 
3.5.1 Preparation of whole cell extract (WCE) 
Lysis Buffer:  
50 mM Tris pH 8.0 
300 mM NaCl 
10 mM MgCl2 
0.4 % NP-40 
protease inhibitors (Leupeptin/Pepstatin/Aprotinin 1 µg/ml, PMSF (1 mM)) 
DTT (1mM) 
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Preparation from adherent growing cell lines: 
Cells were washed once with ice-cold PBS. An appropriate amount of Lysis Buffer was 
added. After harvesting the cells with a cell-scraper, the lysate was transferred to a 
pre-cooled tube, incubated for 15 min on ice followed by additional 10 minutes in an 
ultrasound bath and finally centrifuged at 13 000 rpm and 4°C for 15 min in a table-top 
centrifuge. The supernatant was transferred to fresh tubes, frozen in liquid nitrogen 
and stored at  -80°C. The protein concentration was determined by Bradford assay.  
Preparation from suspension cells: 
Cells were centrifuged at 1000 rpm for 3 minutes at room-temperature in a Hereus 
Megafuge 1.0. Medium was removed and the cell pellet was washed once in ice-cold 
PBS and again centrifuged at 1000 rpm for 3 minutes. After removal of PBS, the cell 
pellet was re-suspended in an appropriate amount of lysis buffer followed by the 
above described procedure.  
3.5.2 Preparation of whole cell extract (WCE) from mouse/rat tissue 
The tissue of interest was dissected and washed several times in ice-cold 0.9 % 
sodium-chloride solution to remove as much blood as possible. A part of the tissue was 
cut into small pieces, subsequently transferred into a Lysis Buffer filled and pre-cooled 
Eppendorf tube and incubated for 20-30 minutes on a rotation-wheel at 4° C, followed 
by the described procedure.  
3.5.3 Preparation of nuclear extract (NE) 
Buffer A: 
10 mM Hepes/KOH pH 7.9 
1.5 mM MgCl2 
10 mM KCl 
- proteinase inhibitors and DTT were added freshly 
 
Buffer B: 
20 mM Hepes/KOH pH 7.6 
1.5 mM MgCl2 
420 mM NaCl 
0.2 mM EDTA 
25 % glycerol 
- proteinase inhibitors and DTT were added freshly 
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Cells were washed twice with ice-cold PBS. An appropriate amount of Buffer A (low 
salt buffer) was added. Cells were harvested with a cell scraper and transferred to an 
Eppendorf tube. After incubation on ice for 10 minutes, the lysate was briefly vortexed 
and centrifuged at 13 000 rpm for 10 seconds. The supernatant was kept representing 
the cytoplasmic fraction. The pellet was re-suspended in Buffer B (high salt buffer), 
incubated for 20 minutes on ice and centrifuged at 13 000 rpm for 10 minutes at 4°C. 
The supernatant was transferred to a fresh tube representing the nuclear fraction.    
3.5.4 Determination of the protein concentration by Bradford Assay 
Protein concentration was determined using the colorimetric assay as described by 
Bradford.
212
 The Bradford reagent contains the dye ‘Coomassie Brillant Blue’ which 
changes its maximal absorption from 465 nm to 595 nm in presence of proteins. It is 
thought to be the most sensitive protein quantification based on a dye.
213
  
3.5.5 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Denaturising SDS-PAGE
214
 allows a separation of proteins according to their molecular 
weight irrespective of their electrical charge. 
215
 
Material Source 
Gel-Cassettes, 1.0 mm Invitrogen 
Novex Mini-Cell gel chamber Invitrogen 
PageRuler Prestained Protein Ladder Fermentas  
Rotiphorese® Gel 30 Roth 
TEMED Roth 
 
SDS-polyacrylamide gel electrophoresis was performed using the Invitrogen “Novex 
Mini-Cell” system and pre-assembled gel cassettes. Running and stacking gels were 
poured according to standard protocols. Before electrophoresis, protein samples were 
mixed with 5x SDS-PAGE sample buffer and denatured by heating up to 95°C for 5 min. 
Proteins were separated at 24 mA (constant)/gel until the dye front had run out of the 
gel. The molecular weight of proteins was estimated by loading 5 µl of PageRuler pre-
stained protein marker next to the protein samples. Following electrophoresis, 
proteins were stained with PageBlue or subjected to Western blotting. 
                                                           
212
 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein 
utilizing the principle of protein-dye binding. Anal Biochem. (1976).  
213
 Lottspeich F, Engels JW (eds.), Bioanalytik, München (2006)
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214
 Laemmli UK, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. 
Nature.  (1970).  
215
 Lottspeich F, Engels JW (eds.), Bioanalytik, München (2006)
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3.5.6 Coomassie Blue/PageBlue staining of protein gels 
Material Source 
PageBlue Protein Staining Solution Fermentas 
Whatman paper, 1mm Roth 
 
Proteins on a SDS-PAGE gel can be visualized by Coomassie staining. Here, PageBlue 
staining was used alternatively. Therefore, the gel was washed with ddH2O three times 
for 10 minutes on a shaker. The staining solution was added and incubated on a shaker 
overnight at room-temperature. Afterwards, the gel was again washed in ddH2O three 
times. For documentation the gel was placed on a Whatman paper and dried for 2 
hours at 60°C in a Biorad gel dryer, Model 583.  
 
3.5.7 Western Blotting 
Material Source 
Mini Trans-Blot Cell BioRad 
Immobilon Western Kit Millipore 
Hyperfilm ECL GE-Healthcare 
Roti PVDF Roth 
 
Transfer buffer: 
25 mM Tris  
192 mM glycine 
0.005 % SDS  
20% methanol (v/v)  
 
Proteins were separated by SDS-PAGE as described followed by transfer to PVDF 
membranes using the BioRad Mini Trans-Blot Cell, a wet blot system. The PVDF 
membrane was activated in Methanol for 15 seconds and placed onto the gel and 
sandwiched by Whatman paper and sponges in a gel holder. The proteins were then 
transferred onto the membrane for 1 hour (proteins < 100 kDA) or 2 hours (>100kDa) 
at 400 mA (constantly). The transfer reaction was cooled by surrounding the gel 
chamber with ice and the addition of an ice block into the transfer chamber. To reduce 
the non-specific background, the PVDF membranes were incubated for 1-2 hr in 
blocking solution (PBS + 0.1% Tween-20 + 5-10 % dried milk) after transfer. The 
membranes were then incubated overnight on a horizontal shaker at 4°C with an 
appropriate dilution of the primary antibody (see following table).  
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Antibody Dilution Specificity Species Source 
α-CHD5-K 1:1000 CHD5, Aa 661-676 rabbit, polyclonal 
Ina Wanandi, 
Jakarta 
α-CHD5-S 1:200 CHD5, Aa 46-61 rabbit, polyclonal 
Ina Wanandi, 
Jakarta 
α-CHD5-R 1:2000 CHD5, Aa 1386-1405 rabbit, polyclonal 
Ina Wanandi, 
Jakarta 
α-CHD5-K,S                    
(pre-immune 
serum) 
1:1000  pre-immune serum rabbit 
Ina Wanandi, 
Jakarta 
α-CHD5         
 (M-182) 
1:200-
1:400 
CHD5 from human, mouse 
and rat origin 
rabbit, polyclonal 
sc-68389, 
Santa Cruz 
α-Mi2 (H-242) 1:300 Mi2 rabbit, polyclonal 
sc-11378, 
Santa Cruz 
α-BRG1 (H-88) 1:1000 BRG1 rabbit, polyclonal sc-10768 
α-p53 (DO-1) 1:1000 p53 
mouse, 
monoclonal 
sc-126 
α-p53 (FL-293) 1:300 p53 rabbit, polyclonal 
sc-6243, 
Santa Cruz 
α-Flag 1:4000 Flag-Tag 
mouse, 
monoclonal 
Sigma 
α-p65 (F-6) 1:300 RelA rabbit, polyclonal 
sc-109, 
 Santa Cruz 
α-ß-Tubulin 1:15 000 ß-Tubulin 
mouse, 
monoclonal 
MAB 3408, 
Chemikon 
α-mouse ECL IgG 1:30 000 
HRP-coupled secondary 
antibogy against mouse 
IgG/IgM 
sheep, polyclonal Amersham 
α-rabbit ECL IgG 1:30 000 
HRP-coupled secondary 
antibogy against rabbit 
IgG/IgM 
donkey, polyclonal Amersham 
 
PVDF membranes were washed five to six times in PBS + 0.1 % Tween-20 for 8-10 min 
and incubated for 50 minutes at room temperature with horseradish-peroxidase-
coupled secondary antibodies. After five additional washes (7 min each, in PBS + 0.1 % 
Tween-20) antigen-antibody complexes were detected using the Immobilon
TM 
Western 
Kit and autoradiography according to the manufacturer´s instructions. 
 
3.5.8 Stripping of Western blot membranes 
Stripping Buffer: 
100 mM ß-mercaptoethanol 
2% SDS 
62.5 mM Tris-HCl pH 6.8 
ddH2O 
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To re-use a PVDF membrane, a disruption of the antigen-antibody binding is necessary. 
Thus, the membrane was incubated with 50 ml stripping buffer in a water bath at 50°C 
for 30 minutes and washed in PBS + 0.1 % Tween-20 twice for 10 minutes, followed by 
normal western blot procedure starting with the blocking step.  
 
3.5.9 Immunoprecipitation 
Material Source 
ProteinG beads  GE Health Care 
ProteinA beads GE Health Care 
Low-binding  Eppendorf tubes (1.5 ml)  Biozym 
 
Flag IP Buffer: 
25 mM Hepes pH 7.6 
12.5mM MgCl2 
0.1 mM EDTA pH 8.0 
10 % glycerol 
0.1 % NP-40 
150 mM NaCl 
+ proteinase inhibitors and DTT 
 
400-2000 µg of protein were diluted to a total volume of 600 µl with ice-cold PBS in a 
low-binding (siliconized) Eppendorf tube and incubated overnight on a rotation wheel 
at 4°C with an appropriate amount of antisera (for dilution see following table).  
Antibody dilution specificity species source 
α-CHD5-K 1:2-1:200 CHD5, Aa 661-676 
rabbit, 
polyclonal 
Ina Wanandi, Jakarta 
α-CHD5-S 1:2-1:200 CHD5, Aa 46-61 
rabbit, 
polyclonal 
Ina Wanandi, Jakarta 
α-CHD5-R 1:2-1:200 CHD5, Aa 1386-1405 
rabbit, 
polyclonal 
Ina Wanandi, Jakarta 
α-CHD5  
(M-182) 
1µg 
antibody/500µg 
protein 
CHD5 from human, 
mouse and rat origin 
rabbit,  
polyclonal 
sc-68389,  
Santa Cruz 
α-Mi2  
(H-242) 
1µg 
antibody/500µg 
protein 
Mi2 
rabbit,  
polyclonal 
sc-11378,  
Santa Cruz 
α-BRG1  
(H-88) 
1µg 
antibody/500µg 
protein 
BRG1 
rabbit,  
polyclonal 
sc-10768,  
Santa Cruz 
α-p53  
(DO-1) 
1µg 
antibody/500µg 
protein 
p53 
mouse,  
monoclonal 
sc-126,  
Santa Cruz 
α-p65 (F-6) 
1µg 
antibody/500µg 
protein 
RelA 
rabbit,  
polyclonal 
sc-109,  
Santa Cruz 
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Protein A or G beads were washed 3 x 5 minutes in 1 ml of ice-cold Flag-IP buffer on a 
rotation wheel, centrifuged at 2000 rpm for 2 minutes at 4°C and pre-blocked in 1:1     
1 % BSA/Flag-IP buffer overnight at 4 °C. The next day, 20 µl of this 1:1 slurry was 
pipetted to the protein-antisera-mixture and incubated on a rotation wheel at 4°C for 
60 minutes. Afterwards, the mixtures were centrifuged at 2000 rpm for 2 minutes at 
4°C and washed three times with 600 µl of ice-cold Flag-IP buffer. After the last 
washing step the supernatant was thoroughly removed and the beads were                
re-suspended in 40 µl of 2xSDS-loading buffer. This mixture was boiled at 92°C for 5 
minutes and centrifuged at 2000 rpm for 2 minutes at room-temperature. 20 µl of the 
supernatant were loaded onto a SDS-PAGE and subjected to western blotting. 
 
3.5.10 αFlag-Co-immunoprecipitation 
Material Source 
Anti-Flag M2 agarose from mouse Sigma-Aldrich 
 
Flag IP Buffer: 
25 mM Hepes pH 7.6 
12.5 mM MgCl2 
0.1 mM EDTA pH 8.0 
10 % glycerol 
0.1 % NP-40 
150 mM NaCl 
+ proteinase inhibitors and DTT 
 
αFlag M2 beads were equilibrated in Flag-IP buffer  and 20 µl of a 1:1 bead slurry were 
added to 500 µg whole cell extract. This extract including the 1:1 slurry was incubated 
in Flag-IP buffer for 3 hours to overnight at 4°C on a rotating wheel. Afterwards, the 
beads were washed three times with Flag-IP buffer. After washing, beads were            
re-suspended in 40 µl of 2xSDS-loading buffer. This mixture was boiled at 92°C for 5 
minutes and centrifuged at 2000 rpm for 2 minutes at room-temperature. 20 µl of the 
supernatant were loaded onto a SDS-PAGE and subjected to western blotting. 
 
3.5.11 Co-immunoprecipitation 
Protein G beads were equilibrated in Flag-IP buffer. 500 µg of nuclear extract were pre-
incubated with benzonase for 2 hrs at 4° C. Then the extracts were incubated with the 
respective antibody overnight at 4°C on a rotating wheel and after addition of 20 µl of 
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protein G beads for another hour. The beads were washed three times with Flag-IP 
Buffer, re-suspended in 2 x SDS-PAGE loading buffer and analyzed by Western Blot. 
 
3.5.12 Immunofluorescence staining (IF) 
Material Source 
Microscope Slides 76x26mm Thermo Scientific 
Cover Slides 18x18mm Roth 
10% formaldehyde (methanol-free), UltraPure EM grade Polysciences 
Bovine serum albumine (BSA) Sigma-Aldrich 
 
Glass slides were washed with Methanol and air-dried before the cells were cultivated 
on them at the bottom of a 6-well-plate. For immunofluorescence staining cells were 
washed twice with ice-cold PBS, fixed in 1-2 ml 3.7 % formaldehyde/PBS for 10 minutes 
and again washed in PBS twice. The cells were permeabilized by incubation in 1 ml 
PBS/0.1 % Triton-X-100 for 15 minutes. After removal of the permeabilizing reagent by 
two washes with ice-cold PBS, unspecific binding was blocked by incubation with 
PBS/3% BSA at room-temperature for 30 minutes. Incubation with the antibody 
against the protein of interest was performed on parafilm in 100 µl of PBS/3 % BSA 
with an appropriate dilution of the antibody (see following table) in a humid chamber 
overnight at 4° C.   
antibody dilution specificity species source 
α-CHD5 (M-182) 1:100 
CHD5 from human, mouse 
and rat origin 
rabbit, polyclonal 
sc-68389, 
Santa Cruz 
α-p50 (H-119) 1:100 NF-κB subunit p50 rabbit, polyclonal 
 Sc-7178, 
Santa Cruz 
α-p65 (F-6) 1:100 RelA rabbit, polyclonal 
sc-109,             
Santa Cruz 
Alexa Fluor 488 
goat    α-rabbit 
IgG (H+L) 
1:200 
rabbit IgG, heavy and light 
chain 
goat, polyclonal invitrogen 
 
The following day the glass slides were washed three times with PBS/0.1 % Triton-X-
100/3 % BSA and incubated with a suitable secondary antibody at 4° C for 1 hour. Glass 
slides were again washed in ice-cold PBS three times.  
Cellular nuclei were visualized by staining with 50 µl DAPI [1 µg/ml] for 1 minute. Glass 
slides were rinsed several times in PBS followed by washing in PBS three times for 5 
minutes in the dark. Finally the slides were mounted with adherent cells upside down 
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and sealed with nail polish.  Pictures were taken with the 020-519.010 fluoerescence 
microscope from Leica. Merging of pictures was performed with Photoshop.  
3.5.13 Concentration of antisera by Protein G affinitychromatography 
Material Source 
Poly-Prep® Chromatography Columns BioRad 
ProteinG beads  GE Health Care 
 
Binding Buffer: 20 mM sodiumdihydrogenphosphate, pH 7.0 at 4°C 
Elution Buffer: 0.1 M Glycin-HCl, pH 2.5 at 4° C 
Neutralization Buffer: 1 M Tris-HCl, pH 9.0 at 4° C 
To prepare the column, 3x 600 µl Protein G-Sepharose were washed in low-binding 
tubes with 1 ml of Binding Buffer for 5 minutes on a rotation wheel and centrifuged at 
2000 rpm for 2 minutes. The supernatant was removed and the washing repeated 
twice. After the last washing step Binding Buffer was added in a ratio of 1:1. This slurry 
was loaded onto the column. After settling of the beads the column was connected to 
a peristaltic pump and washed with 10 ml of Binding Buffer, followed by 10 ml Elution 
Buffer and again 10 ml Binding Buffer. 1.5 ml of Antiserum was diluted with 8 ml 
Binding Buffer and loaded onto the column endless running through the pump 
overnight (flow rate always 1 ml/min).  
Before the elution the column was washed with 30 ml of Binding Buffer. 4 ml of Elution 
Buffer were loaded onto the column and the flow through collected in eight fraction of 
400-500 µl subsequently mixed with 150 µl Neutralization Buffer. Finally the column 
was washed with 30 ml Binding Buffer, 10 ml Elution Buffer and again 10 ml Binding 
Buffer and stored in 20 % Ethanol at 4°C.  
To control the success of the procedure a sample of each step/fraction was taken and 
used for SDS Gel electrophoresis. The fractions of purified antiserum were stored at 
4°C.  
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3.5.14 Chromatin-Immunoprecipitation (ChIP) 
The protocol was modified after Upstate.  
SDS lysis buffer 
1% SDS 
10 mM EDTA 
50 mM Tris pH 8.0 
 
IP buffer 
0.01% SDS 
1.1% Triton-X-100 
1.2 mM EDTA 
16.7 mM Tris-HCl pH 8.0 
1 mM PMSF 
1 µg/ml aprotinin 
1 µg/ml pepstatin A 
 
Low salt wash buffer 
0.1% SDS 
2 mM EDTA ph 8.0 
20 mM Tris-HCl pH 8.0 
150 mM NaCl 
1% Triton-X-100 
 
High salt wash buffer 
0.1% SDS 
1% Triton-X-100 
2 mM EDTA pH 8.0 
20 mM Tris-HCl pH 8.0 
500 mM NaCl 
 
LiCl wash buffer 
0.25 M LiCl 
1% NP-40 
1% sodium-deoxycholate 
1mM EDTA pH 8.0 
10 mM Tris-Hcl pH 8.0 
 
TE buffer 
10 mM Tris-HCl pH 8.0 
1 mM EDTA pH 8.0 
 
Elution buffer 
1% SDS 
0.1% NaHCO3 
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Material Source 
PeqGOLD Cycle-Pure Kit PeqLab 
10% formaldehyde (methanol-free), UltraPure EM grade Polysciences 
 
All listed primers were synthesized by MWG: 
name  sequence  amplicon 
CXCL2_0.4kbds-F 5'-ggcattcgaagtcacaggat-3' 
region 0.4 kb downstream 
of CXCL2 
CXCL2_0.4kbds-R 5'-ttggctttggtgggttttag-3'   
CXCL2_Prom-F 5'-cgggagttacgcaagacagt-3' CXCL2 promotor 
CXCL2_Prom-R 5'-atcccgagttcggaagga-3'   
CXCL2-ChIP_prom2-F 5'-tcgccttccttccgaactc-3' CXCL2 promotor 
CXCL2-ChIP_prom2-R 5'-cgaaccccttttatgcatggt-3'   
CXCL2_ex1-F 5'-ctggagctccgggaattt-3' CXCL2 exon 1 
CXCL2_ex1-R 5'-accccttttatgcatggttg-3'   
CXCL2_ex2-F 5'-gcagggaattcacctcaaga-3' CXCL2 exon 2 
CXCL2_ex2-R 5'-agcgatgggcgagacttac-3'   
CXCL2_intr3-F 5'-agggttagctgcaggactga-3' CXCL2 intron 3 
CXCL2_intr3-R 5'-gggcactgggaatatcctct-3'   
CXCL2_ex4-F 5'-ggggaaactgcattcagaaa-3‘' CXCL2 exon 4 
CXCL2_ex4-R 5'-gaaaatgggtgccctgagta-3'   
ß-actin_prom-F 5'-gaggggagagggggtaaaa-3' ß-actin promotor, 
ß-actin_prom-R 5'- agccataaaaggcaactttcg-3' 
source: Gromak N et al, 
2006
216
 
 
3-4x10
6
 HEK293 cells were seeded in 10 cm dishes on the day before chromatin 
preparation. Cells were stimulated with TNFα at a concentration of 20 ng/ml for 40 
and 60 minutes or left untreated. 
Formaldehyde was added to a final concentration of 1 % (1 ml). After 10 minutes 
incubation at room-temperature 1.3 ml 2 M glycine was added. Cells were incubated 
for 5 minutes at room-temperature, dislodged from the plate with a cell scraper, 
transferred to a 50 ml tube and centrifuged at 1800 rpm in a Hereus Labufuge 400R at 
4°C for 10 min. The supernatant was removed, the pellet washed once in ice-cold PBS 
and again centrifuged at 1800 rpm at 4°C for 10 min. The cell pellet was then              
re-suspended in 210 µl/IP SDS lysis buffer and incubated on ice for 10 min, 
intermittently agitated. The lysate was transferred to a 15 ml tube and sonicated with 
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 Gromak N et al, Pause Sites Promote Transcriptional Termination of Mammalian RNA Polymerase II. 
Molecular and Cellular Biology (2006).  
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30 cycles (10 sec. on, 30 sec. off) to achieve a fragmentation of the DNA to 
approximately 500 bp. The lysate was transferred to a 1.5 ml tube and centrifuged at 
13 000 rpm at 4° C for 10 min in a Hereus BiofugeA and the supernatant was diluted 10 
fold in IP buffer. The solution was pre-cleared by addition of 80 µl 50 % pre-blocked 
Protein G beads/1% BSA/TE buffer per IP for 40 minutes on a rotation wheel in the 
cold room. To remove the beads, the solution was centrifuged at 1500 rpm for 10 min 
at 4° C in a Hereus Labufuge 400R.  40 µl of the pre-cleared solution was kept as input 
at 4° C. 2 ml were used for each IP and incubated with a suitable amount of antibodies 
on the rotation wheel overnight in the cold room. The next day 35 µl of 50 % Protein G 
beads which were pre-blocked with 1 % BSA overnight were added to the IP and 
incubated for 2h on a rotation wheel at 4° C. Beads were collected by a 5 min 
centrifugation at 6400 rpm in a Hereus Biofuge pico at room-temperature and the 
supernatant was removed. The beads were re-suspended in 1 ml of low salt wash 
buffer, transferred to a siliconized 1.5 ml tube and centrifuged at 3000 rpm for 5 min. 
at 4° C in a Hereus BiofugeA. The immunoprecipitates were then washed once with low 
salt wash buffer, once with high salt wash buffer, once with LiCl wash buffer and twice 
with TE buffer. After the last washing the supernatant was removed carefully and 
immunoprecipitated DNA-protein complexes were eluted by addition of 250 µl of 
elution buffer. After 15 min of incubation at room-temperature, beads were spun 
down and the supernatant was transferred to a fresh tube. The elution procedure was 
repeated once and eluates were combined.  
The input samples were diluted by addition of 460 µl elution buffer. 20 ml of 5 M NaCl 
were added to the eluates and inputs and incubated overnight at 65° C for                  
de-crosslinking of the immunoprecipitated DNA-protein complexes. The next day, 10 µl 
of 0.5 M EDTA, 20 µl of 1 M Tris-HCl, pH 6.8 and 2 µl of 10 mg/ml proteinase K were 
added to each sample, followed by an incubation of 1 h at 45° C.  
DNA was finally extracted with the PeqGOLD Cycle-Pure Kit, according to the 
manufacturer’s instructions, eluting the DNA to a final volume of 30 µl.  
For QPCR 6 µl of a 1:5 DNA dilution was used for input DNA and ChIP DNA. 
The % input and the standard deviation were calculated as followed: 
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∆Ct = CtInput – Ctsample 
% Input = 2 
ΔCt(sample)
 
S= ln(2) x % input √ (SInput
2
 + Ssample
2
) 
3.5.15 Luciferase-Reporter Assay 
Material Source 
Dual-Luciferase Reporter 1000 Assay System Promega 
AutoLumat LB953  EG&G Berthold 
 
HEK293 cells stably transfected with the murine TLR9 and a NF-κB reporter were used 
to measure the NF-κB activity after different stimuli using the Dual-Luciferase Reporter 
1000 Assay System from Promega according to the manufacturer’s instructions and the 
luminometer AutoLumat LB953 from EG&G Berthold. Experiments were performed in 
technical duplicats. 
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4. Results 
4.1.1 Establishment of polyclonal peptide antibodies directed against three 
different regions of CHD5 protein 
In order to detect and further biochemically characterize CHD5 protein, three 
polyclonal peptide antibodies were raised against different regions of human CHD5 
(see Fig. 4.1).  
These antisera were tested for their use in western blot, immunoprecipitation and 
immunofluorescence. Later during the study, a commercial CHD5 antibody (M-182) 
became available and was included in the characterization of our antisera for 
comparison. 
The peptide sequences (R-, K- and S-peptide) that were specific to human CHD5 (and 
not present in related CHD family members as determined by blast search
217
) were 
chosen for immunization of rabbits. Of these, only the R-peptide matches additionally 
the corresponding sequences of dog, horse, cow, mouse, rat and chimpanzee CHD5, 
suggesting that the corresponding antibody could possibly recognize CHD5 protein in 
all of these species (see Fig. 4.2).  
 
R-Peptide:
RPEGQSGRRQSRRQLKSDRD 
(Aa 1386-1405)
S-Peptide:
SLPKKKKPKKLKENKC (Aa 46-61)
K-Peptide: 
KKGKKLRDDKQEKPPD (Aa 661-676)
Fig. 4.1 Scheme of peptide positions within the CHD5 protein
= PHD zink finger           = chromodomain              = Helicase/ATPase domain
NH2 COOH
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 Internet source: http://blast.ncbi.nlm.nih.gov. 
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S-peptide:                              K-peptide:                         R-peptide:              
Fig. 4.2: Alignment of peptide sequences used for immunization
(www.ebi.ac.uk/Tools/clustalw2/index.html)
 
The three peptides were synthesized by Peptide Speciality Laboratories, Heidelberg, 
Germany, and coupled to KLH (Keyhole Limpet Hämocyanine). Immunization of three 
rabbits (one per peptide) was carried out by Ina Wanandi, Jakarta/Indonesia.  
 
The specificity of the antisera was tested by direct comparison of the pre-immune 
serum and the crude antiserum in western blot using purified recombinant Flag-tagged 
CHD5, protein extracts from HEK293 cells transiently transfected with pcDNA3.1/V5-
His-TOPO-hCHD5 (Flag-tagged CHD5) and protein extract from untransfected HEK293 
cells (negative control). In addition, mouse brain extract was analysed to determine 
whether the antisera were capable of detecting endogenous CHD5.   
 
Immune serum S strongly recognized a protein with an apparent molecular mass of 
greater than 170 kDa when baculovirus-expressed recombinant CHD5 protein was 
analyzed (Fig. 4.3, lane 5). This protein did not significantly react with the 
corresponding pre-immune serum (see Fig. 4.3, lane 1 in comparison to lane 5). 
Moreover, immune serum S detected a protein with the same electrophoretic mobility 
in extract from HEK293 cells expressing recombinant CHD5 protein (Fig. 4.3, lane 7) but 
not in extract from control HEK293 cells (lane 8).   
Again, the pre-immune serum failed to detect a corresponding protein in neither 
HEK293 extract (Fig. 4.3, lanes 3 and 4). The electrophoretic mobility of the protein 
recognized by serum S is in agreement with the theoretical molecular mass of CHD5 
(223 kDa). These results demonstrate that immune serum S is capable of reacting with 
recombinant CHD5 in Western blot.  
By contrast, serum S did not detect a protein with the same electrophoretic mobility in 
mouse brain extract (Fig. 4.3, lane 6). Given that the mouse brain extract contains 
CHD5 (see also Fig. 4.5 A, lane 2; Fig. 4.5 B, lane 2), this indicates that the crude serum 
S is not able to detect endogenous levels of CHD5 in Mus musculus. Predicted by 
4 .  R e s u l t s  |  6 7  
 
sequence alignment of CHD5 with S-peptide, immune serum S is specific for Homo 
sapiens and possibly Pan troglodytes (not tested; see Fig. 4.2).  
Fig. 4.3: Generation of a polyclonal antiserum against the N-terminal part of CHD5 (α-CHD5-S). 
The reactivity of the pre-immune serum and the unpurified immune serum was tested in western
blot using purified recombinant CHD5 (lanes 1 and 5), mouse brain protein extract (lanes 2 and
6), WCE from HEK293 cells transiently transfected with CHD5-Flag (lanes 3 and 7) and from
untransfected HEK293 cells as a negative control (lanes 4 and 8).
170 kDa
72 kDa
(223 kDa)
pre-immune serum S immune serum S
CHD5
1        2        3       4 5        6       7      8
 
Immune serum K detected a protein with an apparent molecular mass of more than 
170 kDa which is consistent with the estimated molecular mass of CHD5 when purified 
recombinant CHD5 was used in Western blot (see Fig. 4.4, lane 5). In agreement, 
antiserum K recognized a protein with the same electrophoretic mobility in extract of 
HEK293 cells transiently transfected with Flag-tagged CHD5 (Fig. 4.4, lane 7). The pre-
immune serum neither recognized a corresponding protein (see Fig. 4.4, lanes 1 and 3) 
nor was a corresponding band detected by serum K in HEK293 control extract (Fig. 4.4, 
lane 8). In summary, immune serum K is able to detect recombinant CHD5 in Western 
blot.  
Immune serum K does not react with CHD5 in mouse brain extract (see Fig. 4.4, lane 6) 
as expected because the peptide sequence mismatches the CHD5 sequence from Mus 
musculus. According to the peptide sequence immune serum K is regarded to be 
specific for Homo sapiens and possibly Pan troglodytes (not tested; see Fig. 4.2). No 
human tissue was available for a further assessment of endogenous CHD5.   
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pre-immune serum K immune serum K
Fig. 4.4: Generation of a polyclonal antiserum: α-CHD5-K. 
The reactivity of the pre-immune serum and the unpurified immune serum was tested in
western blot using purified recombinant CHD5 (lanes 1 and 5), mouse brain protein extract
(lanes 2 and 6), WCE from HEK293 cells transiently transfected with CHD5-Flag (lanes 3 and 7)
and from untransfected HEK293 cells as a negative control (lanes 4 and 8).
CHD5
(223 kDa)
170 kDa
72 kDa
1       2      3      4 5       6      7      8
 
When recombinant CHD5 was analyzed in Western blot probed with immune serum R, 
this antiserum recognized a protein with similar electrophoretic mobility as the protein 
detected by both other antisera (see Fig. 4.5 A, lanes 1 and 3 in comparison with Fig. 
4.3, 4.4). No corresponding band appeared in extract from untransfected HEK293 cells 
(negative control) (see Fig. 4.5 A, lane 4). No pre-immune serum was available from 
the rabbit immunized with R-peptide; therefore a comparison could not be carried out.  
Antiserum R does additionally detect a corresponding protein in mouse brain extract 
(Fig. 4.5 A, lane 2). This indicates that it is capable of detecting endogenous levels of 
CHD5 in extracts from Mus musculus.  
In conclusion R-peptide immune serum recognizes recombinant CHD5 and endogenous 
CHD5 from mouse brain in Western blot, whereas no corresponding signal is detected 
in extract from control HEK293 cells.  
 
In addition to recombinant CHD5, all three antisera also react with a number of other 
proteins, several of which are also recognized by the pre-immune sera or that are 
detected in both CHD5-expressing and non-expressing HEK293 cell extracts. Some of 
these Western blot signals are likely due to cross reactivity of the antibodies.  
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Fig. 4.5: Immune serum R (against the C-terminus of CHD5) and the CHD5 antibody M-182
A: Generation of a polyclonal antiserum against the C-terminal part of CHD5 (α-CHD5-R), 3rd bleed.
Antiserum reactivity was tested with purified recombinant CHD5 (lane 1), protein extract from
mouse brain (lane 2), WCE from transiently with CHD5-Flag transfected HEK293 cells (lane 3) and
WCE from untransfected HEK293 cells (lane 4) as a negative control.
B: Polyclonal CHD5 antibody (M-182, sc-68389), dilution 1:300.                                                     
Antiserum reactivity was tested with purified recombinant CHD5 (lane 1), protein extract from
mouse brain (lane 2), WCE from mouse glioblastoma cell line Gl261 (lane 3), WCE from transiently
with CHD5-Flag transfected HEK293 cells (lane 4) and WCE from untransfected HEK293 cells (lane
5) as a negative control. 
A      immune serum R B       α-CHD5 (M-182)
CHD5
170 kDa 170 kDa
CHD5
1       2        3      4 1     2      3     4     5
 
When the polyclonal CHD5 antibody M-182 became available, it was included in the 
analysis. M-182 recognized a protein above 170 kDa with the same electrophoretic 
mobility as that one recognized by our antisera using purified recombinant CHD5 and 
extract from HEK293 cells expressing recombinant CHD5 (Fig. 4.5 B, lanes 1 and 4). 
Besides, M-182 detected a strong band in mouse brain extract (Fig. 4.5 B, lane 2). No 
corresponding band appeared when extract from control HEK293 cells or from mouse 
glioblastoma cell line Gl261 (not CHD5 expressing) was loaded (Fig. 4.5 B, lanes 5 and 
3, respectively).   
To further confirm that the detected band above 170 kDa is CHD5, a Western blot 
using extract from HEK293 cells expressing recombinant Flag-tagged CHD5 was probed 
with α-Flag antibody in comparison with α–CHD5 (M-182). The α-Flag antibody stained 
a directly corresponding band to that one detected by α–CHD5 (see Fig. 4.6, compare 
lanes 1 and 7) indicating that both detected proteins are indeed identical. 
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α-Flag  α-CHD5
170 kDa
1      2       3      4      5      6     7    8
Fig. 4.6: α-Flag recognizes a protein with the same molecular weight as α-CHD5 (M-182)
To confirm the band (→) above 170 kDa detected by M-182 as CHD5, a Western blot with WCE from
HEK293 cells transiently transfected with CHD5-Flag (lanes 1 and 7) was probed with α-Flag antibody in
comparison to α-CHD5 (M-182). Both antibodies recognized a protein with the same electrophoretic
mobility.
Lanes 2-5, 8: WCE from cell line A172 (of no further interest). Lane 6: molecular weight marker.
 
CHD5 protein shows a high sequence homology to other members of the CHD protein 
family, especially to Mi2ß (see Introduction). Although the CHD5 peptide sequences 
used for antiserum generation do not show any sequence homology to other CHD 
proteins, an extract of Mi2ß-overexpressing HEK293 cells (transfected with pcDNA3-
hMi2beta-Flag) was tested in western blot probed with the CHD5 antisera to exclude 
any cross reactivity to Mi-2ß. Regarding the electrophoretic mobility, Flag-tagged Mi2ß 
is expected to run slightly above Flag-tagged CHD5. A faint band at this level was 
observed for S-peptide antiserum (see Fig. 4.7, lane 2). Anyhow, this band appears 
similarly in extract from Mi2ß-overexpressing cells as well as from untransfected 
HEK293 cells without a difference in intensity (Fig. 4.7, compare lanes 2 and 3). 
Additionally – as already mentioned – S-peptide does not show any sequence 
homology to Mi2ß. Hence, cross reactivity with Mi2ß cannot be excluded but is still 
very unlikely.  
For K-peptide antiserum and α-CHD5 (M-182) there was no hint for a cross reactivity 
with Mi2ß because no further band could be detected (see Fig. 4.7, lanes 4-9).  
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Fig. 4.7: Cross reactivity of CHD5 antibodies with CHD4
To exclude a cross reactivity of CHD5 antisera with CHD4, HEK293 cells were transiently
transfected with CHD5-Flag (lane 1, 4 and 7) in comparison with Mi2ß-Flag (lanes 2, 5 and 8).
Untransfected HEK293 cells were used as control (lanes 3, 6 and 9). Mi2ß is expected to run slightly
higher than CHD5. A faint band appeared at that level in lane 2 and 3. Thus, a cross reactivity
cannot be excluded for α-CHD5-S. No band was observed above CHD5 in lanes 5 and 8 (α-CHD5-K
and M-182), making a cross reactivity for α-CHD5-K and M-182 unlikely.
1       2        3 4       5       6 7         8        9
170 kDa
72 kDa
α-CHD5-S α-CHD5 (M-182)α-CHD5-K
CHD5
 
Using the crude antisera in Western blot, the imbalance between weak specific bands 
and strong background signals can impede their application. Therefore, a 
concentration of the antibody might be quite helpful. 
For concentration of antibodies the crude antisera were purified by affinity 
chromatography with Protein G-Sepharose columns.  
Protein G is a part of the cellular wall of Group C/G Streptococci which is characterized 
by its strong pH dependent affinity for the Fc region of immunoglobulin G making it 
suitable for IgG purification. The dramatic decrease of this affinity by lowering the pH 
is the basis for the purification. But it has to be mentioned that the natural spectrum of 
antibodies occurring in rabbits as well as antibodies against the carrier substance are 
not removed, so it is unlikely that any cross reactivity of the antibodies decreases.
218
 As 
a minor effect non-IgG proteins like albumin are also removed.  
The success of the concentration was demonstrated by SDS-PAGE loading samples 
from every different step of the purification (as example see antiserum K purification, 
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 Harlow E and Lane D, Using Antibodies: A laboratory Manual; New York (1999), p.74-76. 
Internet source: www.nunc.de. 
4 .  R e s u l t s  |  7 2  
 
Fig. 4.8). The heavy and the light chain appear nearly exclusively in the third to eighth 
elution fraction as expected.  
After concentration α-CHD5-R did not detect recombinant CHD5 in western blot any 
longer (data not shown). Probably, this might be due to the changes in pH during the 
elution. Thus, its further application was limited and M-182 was the preferred 
antibody when material from mice was analysed.   
For antisera K and S the concentration facilitated its use and no decrease in affinity 
was observed.  
72
55
43
34
25
Fig. 4.8: Concentration of crude CHD5-K antiserum by Protein G affinity chromatography
Samples from each step of the purification process were loaded on a 12.5 % SDS-PAGE.
Lane 1: input, lane 2: flow-through, lane 3: washing step, lane 4-11: fractions 1-8, lane 12: wash step with 
binding buffer, lane 13: wash step with elution buffer, lane 14: wash step 2 with binding buffer. 
 = antibody heavy chain   * = albumine     ♦ = antibody light chain
14
72
55
43
34
25
14
1    2    3     4    5    6    7 8     9   10  11  12  13  14
**


♦ ♦
 
The different antisera as well as M-182 antibody were tested for their ability to 
immunoprecipitate CHD5. Unfortunately, all three antisera (K, S and R) were not able 
to immunoprecipitate recombinant CHD5 as well as endogenous CHD5 from mouse 
brain extract although very high concentrations of antibody were tested (up to a 
dilution of 1:2; see Fig. 4.9 for immune serum S as example).  
Only M-182 successfully immunoprecipitated recombinant CHD5 as well as 
endogenous CHD5 from mouse whole cell extracts (Fig. 4.10).  
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Fig. 4.9: S-peptide antiserum does not immunoprecipitate CHD5
The S-peptide antiserum was tested for its ability to immunoprecipitate CHD5. The
S-antiserum was used in a dilution of 1:100 for IP, M-182 probed the following western
blot. WCE from HEK293 cells transiently transfected with CHD5-Flag was used in lanes
1 and 6, WCE from HEK293 in lanes 2 and 7, from mouse brain in 3 and 8, from mouse
glioblastoma cell line Gl261 in 4 and 8 and from astrocytes in lane 5 and 10.
10 % Input IP
170 kDa
72 kDa
1     2     3      4     5 6     7    8    9   10
 
Fig. 4.10: M-182 does immunoprecipitate CHD5 from mouse brain extract
The M-182 antibody was tested for its ability to immunoprecipitate CHD5 from mouse
brain WCE (lanes 1 and 4). The mouse glioblastoma cell line Gl261 (lanes 2 and 5) and
PBS (lanes 3 and 6) were taken as negative controls. The antibody was used in a dilution
of 1:200 in IP and 1:300 in the following western blot.
CHD5
10 % input IP
1          2       3      4         5       6
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The different antisera as well as the M-182 antibody were tested in 
immunofluorescence for detection of overexpressed CHD5 in HEK293 cells.  
Our antisera turned out to be inapplicable for immunofluorescence. Antisera K and S 
produced a diffuse unspecific staining (pictures not shown). Immune-serum R gave a 
homogenous nuclear pattern in CHD5-overexpressing cells as well as in control HEK293 
cells in equal intensity (see Fig. 4.11). Therefore, it was considered as unspecific 
staining.  
CHD5 - antibody (M-182) gave no apparent background and some bright nuclear 
signals. Assuming a mean transfection efficacy these few signals were reasonable. No 
staining was observed in HEK293 control cells. Therefore, this immunofluorescence 
staining was thought to be specific (see Fig. 4.12). 
 
HEK293-CHD5+
HEK293-Mock
α-CHD5-R + Alexa488 DAPI merge
Fig. 4.11: Immuneserum R stains HEK293 cell nuclei unspecifically
The immuneserum R was tested for its use in immunofluorescence. Therefore, HEK293 cells were
transiently transfected with pcDNA3.1/V5-His-TOPO-hCHD5 or left untransfected and stained with
immuneserum R in a dilution of 1:10 or DAPI. As secondary antibody Alexa Fluor 488 goat α-rabbit
IgG was used. In both CHD5 overexpressing and not-expressing cells the nuclei are brightly
stained. Thus, it was considered to be unspecific.
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HEK-CHD5+
HEK-Mock
DAPI merge
Fig. 4.12: M-182 is capable of detecting recombinant CHD5 in immunofluorescense
The CHD5 antibody M-182 was tested for its use in immunofluorescence. Therefore, HEK293 cells
were transiently transfected with pcDNA3.1/V5-His-TOPO-hCHD5 or left untransfected and stained
with M-182 in a dilution of 1:50 or DAPI. As secondary antibody Alexa Fluor 488 goat α-rabbit IgG
was used. In CHD5 overexpressing cells some nuclei are brightly stained, whereas no apparent
background was visible HEK293-Mock cells. Thus, the staining was considered to be specific.
α-CHD5 (M-182) + Alexa488 
 
In synopsis, all antisera generated in this study are able to specifically react with 
recombinant CHD5 protein in western blot. However, antisera S and K failed to detect 
endogenous CHD5 in mouse brain extract, even after concentration on a Protein G 
column. That seems to be comprehensible considering the mismatch of peptide 
sequences with mouse CHD5 protein sequence (see Fig. 4.2). Antiserum R was able to 
detect endogenous CHD5 in mouse brain extract but lost its activity during the 
concentration process on the Protein G column. Without purification it gave a strong 
background in western blot hindering its further application. In addition, the antisera 
turned out to be inapplicable in IP and IF experiments. It is possible that the 
performance of these antisera could be improved after affinity purification on a 
column containing immobilized peptides. However, in the interest of time, I continued 
my investigations using the M-182 CHD5 antibody. This CHD5 antibody efficiently 
detected both recombinant and endogenous CHD5, was able to immunoprecipitate 
CHD5 and allowed detection of CHD5 by immunofluorescence.   
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4.1.2 CHD5 overexpression does not induce senescence in SAOS-2 cells  
CHD5 was found to interfere with the p16-pRb-pathway for promotion of cellular 
senescence in MEFs.
219
   
The molecular mechanism of how CHD5 can influence senescence is not understood. 
In order to gain mechanistic insight into the effects of CHD5 on Rb-induced senescence 
I decided to use the so-called ‘flat cell assay’
220
. This is an established experimental 
system to study senescence in SAOS-2 cells.  
The human osteosarcoma cell line SAOS-2 lacks functional pRb. Instead of the full-
length nuclear localized Rb a mutant 90 kDa fragment is produced which is localized to 
the cytoplasm.
221
 A transfection of the wild-type Rb gene or its large pocket domain 
(Aa 379-928) together with a plasmid encoding a selection marker leads to an arrest in 
the G1-phase of the cell cycle, driving the cells into senescence.
222
 These cells undergo 
dramatic morphological changes which result in the formation of large, flat cells with 
cessation of cell division. Flat cells are still alive (the dye Trypan blue is excluded) and 
metabolically active. They can be easily identified and quantified under the light 
microscope; thereby the proportion of senescent cells can be determined. 
Co-expression of proteins in addition to pRb can be used to study the effect of these 
proteins in pRb-mediated senescence.
223
  
Firstly, it was necessary to determine whether CHD5 interferes with pRb-mediated 
senescence in this experimental system.  
 
Here, four different transfections in SAOS-2 cells were performed as follows:       
1. with pcDNA3.1/V5-His-TOPO/LacZ as Mock control 
2. with pCMV-hRb(379-928) as positive control known to induce senescence in SAOS-2 
cells  
                                                           
219
 Bagchi A et al, CHD5 is a Tumorsuppressor at Human 1p36. Cell (2007). 
220
 Hinds PW et al, Regulation of retinoblastoma protein functions by ectopic expression of human 
cyclins. Cell (1992). 
221
 Shew JY et al, C-terminal truncation of the retinoblastoma gene product leads to functional 
inactivation. Proc Natl Acad Sci USA (1990). 
222
 Welch PJ and Wang JY, Disruption of retinoblastoma protein function by coexpression of its C pocket 
fragment. Genes Dev (1995). 
223
 Hinds PW et al, Regulation of retinoblastoma protein functions by ectopic expression of human 
cyclins. Cell (1992). 
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3. with pcDNA3.1/V5-His-TOPO-hCHD5 to test if CHD5 overexpression alone has an 
influence on cellular senescence within this system and  
4. with pcDNA3.1/V5-His-TOPO-hCHD5 and pCMV-hRb(379-928) together to test 
whether CHD5 modulates pRb-induced senescence or even co-induces it in presence of 
pRb (large pocket domain).  
To each transfection pBABE was added, a plasmid containing a puromycin resistence. 
After transfection, cells were selected with puromycin for 4 days and stained with 
crystal violet for a better visualization of the flat cell morphology. Depending on the 
cell density at least 100 to 300 cells were counted using a light microscope.  
LacZ overexpression resulted in 4 % of flat cells as a kind of baseline senescence. 
pRb(large pocket domain) transfection led to an average of 68 % of flat cells indicating 
that this assay worked in my hands as published (see above for references).  
CHD5 overexpression alone produced 5 % flat cells which was comparable to the 
baseline senescence in the LacZ control. So this overexpression alone did not drive 
SAOS-2 cells into senescence. This result allowed then to assess whether Chd5 
modulates pRb-induced senescence when co-expressed.   
Upon co-tranfection of pRB and CHD5 72 % of cells developed a flat cell morphology. In 
comparison with the pRb overexpression the number of flat cells rose by 4 % in 
average. Taking into account that this assay is based on counting a limited number of 
cells, 4 % of difference in average does not indicate significance.  
It has to be mentioned that overexpression of proteins was not controlled by western 
blot because the selection process resulted in a reduced number of cells complicating 
protein extract preparation. Efficient transfection procedures were assumed by the 
visible effect of pRb transfections leading to flat cell formation.  
In conclusion, this demonstrates that CHD5 does not affect pRb-mediated senescence 
in this experimental system (see Fig. 4.13). 
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Experimental procedure:
LacZ (Mock)                           
RB(379-928)                           
CHD5                                      
CHD5+RB(379-928)                SAOS-2 cells
4 days
puromycin
flat cell formation?
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Fig. 4.13: CHD5 overexpression does not influence flat cell formation in SAOS-2 cells
A Scheme of experimental procedure: SAOS-2 cells were transfected either with an expression vector coding for
LacZ (as Mock control), CHD5, Rb (large pocket domain) or RB and CHD5. All transfections included the
puromycin resistence plasmid pBabe. Cells were selected with puromycin for 4 days, and the resulting flat (G1
arrested) cells were counted.
B Lighmicroscopy at 100-fold magnification after crystal violet staining of transfected cells
C Percentage of flat cells was calculated after crystal violet staining.
 
 
4.1.3 Overexpressed CHD5 does not directly interact with endogenous p53 
It has been proposed that CHD5 regulates the p53 level via the p19
ARF
 pathway.
224
 
However, an alternative and so far unexplored possibility is a direct interaction 
between CHD5 or a CHD5-containing complex and p53. A similar model was suggested 
for a MTA2-containing NuRD complex regulating the p53-mediated transactivation by 
modulating the p53 acetylation status.
225
  
The classical approach to overexpress candidate interaction partners and perform co-
immunoprecipitations failed because neither CHD5 nor any other protein besides ARF 
could be co-expressed together with wild-type p53 in HEK293 cells, even though 
expression of the individual proteins was successful (data not shown). The explanation 
for this effect remains unclear. 
Since HEK293 cells express robust levels of functionally inactive p53, we tested if it 
interacted with Flag-tagged CHD5. Therefore, HEK293 cells were transiently 
transfected with expression vectors for LacZ as a negative control, Flag-tagged CHD5 or 
                                                           
224
 Bagchi A et al, CHD5 is a Tumorsuppressor at Human 1p36. Cell (2007). 
225
 Luo J et al, Deacetylation of p53 modulates its effects on cell growth and apoptosis. Nature (2000). 
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wild-type p53. Whole cell extracts were subjected to immunoprecipitation using α-Flag 
M2 beads and α-p53-DO1, respectively. The precipitates were analysed in western blot 
by staining with α-Flag and α-p53 (FL-393). CHD5-Flag was successfully expressed (Fig. 
4.14, compare lanes 1 and 2) and efficiently precipitated with Flag antibody (Fig. 4.14, 
lane 5). In addition, endogenous and overexpressed p53 were successfully 
immunoprecipitated by DO-1 antibody (Fig. 4.14, lanes 7, 8 and 10).    
However, no co-immunoprecipitation of Flag-tagged CHD5 with endogenous p53 could 
be achieved, suggesting there is no direct interaction between overexpressed CHD5 
and endogenous p53 or that the interaction is not strong enough for a robust co-
immunoprecipitation.  
 
 
4.1.4 CHD5 expression profile in tissues and cell lines 
So far, little is known about the biological function of CHD5. To gain further insight into 
that, a detailed expression analysis of CHD5 in various tissues and cell lines on 
transcript and protein level was carried out in order to establish conditions and a cell 
system in which CHD5 is inducible or even expressed at robust levels for further 
functional assays.  
10 % input Flag-IP p53-IP (α-p53-DO1)
α-Flag (mouse)
CHD5 
α-p53 (FL-393)
p53 
Fig. 4.14: Co-immunoprecipitation of CHD5 and p53
HEK293 cells were transiently transfected with expression vectors for LacZ (lanes 1, 4 and 7), CHD5 (lanes
2, 5, 8 and 9) and wt-p53 (lanes 3, 6, 10 and 11). IP from WCE was performed with α-Flag M2 beads or
α-p53-DO1, western blot analysis of inputs and precipitates with α-Flag antibodies and α-p53 (FL-393).
Lanes 9 and 11: control with addition of beads without Do-1.
* unspecific bands, unlikely to be the DO1 heavy chain because DO1 and FL-393 are generated in
different species.
* *
* * * *
1     2    3     4    5    6     7     8    9   10    11 
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Recently, it was published that CHD5 is predominantly expressed in tissues from neural 
origin (brain and adrenal gland). A testicular expression was predicted by SAGE but a 
further validation on transcript and protein level was not carried out so far.
226
 
 
CHD5 expression analysis in primary tissue samples from rat and mouse 
A variety of tissue samples from rat and mouse were analyzed for CHD5 expression on 
RNA and protein level.  
CHD5 was highly expressed in rat brain and testes on transcript level in RT-qPCR (see 
Fig. 4.15 B), indicating that CHD5 expression is restricted to brain and testes within the 
panel of analyzed tissues. In muscle, liver, heart and lung CHD5 was only detectable at 
levels of background transcription. Background transcription was defined by very high 
threshold cycles (close to water control Cts) and a multi-peaked melting curve in some 
cases indicating that non-specific PCR products have contributed to the threshold 
cycle. 
Also on protein level CHD5 could be robustly detected in WCEs from rat brain and 
testes of an adult male rat. Neither muscle nor liver showed CHD5 expression (see Fig. 
4.15 A). Equal amounts of protein were carefully loaded but the loading control           
ß-tubulin showed redundantly major differences between the different tissues (see 
Fig. 4.15 A, 4.16 A). I assume that this reflects most likely the different expression 
levels of ß-tubulin in various tissues so that it was an inappropriate loading control. An 
alternative loading control was not tried; considering the high molecular weight of 
CHD5 (223 kDa), other typical loading controls like ß-actin are inapplicable because of 
their small size. Instead, protein amounts on the western blot membrane were 
randomly controlled by Ponceau staining. However, a statement on CHD5 expression 
based on these western blots remains critically but since the RNA and protein data 
completely coincide I would assume that the western blot reflects realistic expression 
levels even in liver and muscle.  
Extracts from lung and heart gave a non-acceptable smeary background (data not 
shown). Therefore these extracts were excluded from reasonable protein analysis. 
 
                                                           
226
 Thompson PM et al, CHD5, a new member of the chromodomain gene family, is preferentially 
expressed in the nervous system. Oncogene  (2003).  
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Next, protein extracts from different tissues of an adult male mouse were tested for 
CHD5 expression in western blot to exclude a species specific expression pattern. Like 
in rat CHD5 expression was found to be restricted to brain and testes; lung, spleen, 
liver, kidney and gut were CHD5-negative (see Fig.4.16). Again, differences in the 
loading controls limit that conclusion.  
Fig. 4.15: CHD5 expression in different rat tissues
A In order to detect CHD5 protein in various tissues WCEs from different rat tissues (80
µg each) were subjected to western blot (7.5 % SDS-PAGE), ß-tubulin was used as
loading control.
B For verification of western blot results RNA was extracted from different rat tissues
and used for mRNA quantification in RT-qPCR; the error bars represent the standard
deviation between three different RNA isolations.
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Fig. 4.16 CHD5 expression in different mouse tissues
WCEs from different mouse tissues were prepared and analyzed in western blot for
CHD5 expression, ß-tubulin was used as a loading control
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CHD5 expression analysis in cell lines 
In order to find a CHD5 expressing cell system for further functional studies 14 mostly 
neural-related cell lines were screened for CHD5 expression on transcript and protein 
level. 
The neuroblastoma cell lines SH-SY-5Y, SH-EP, SMS-KCN and IMR-32 were tested for 
CHD5 expression in western blot and RT-qPCR. In none of the cell lines CHD5 protein 
could be detected (see Fig. 4.17 A). On transcript level all cell lines showed expression 
levels comparable with those from HEK293 cells which were taken as negative controls 
because of their high threshold cycle in RT-qPCR and the absent protein expression 
(see 4.17 B). Thus, all tested neuroblastoma cell lines were assumed to be CHD5-
negative.  
There are several explanations for this absence of CHD5 expression. One is a 
homozygous deletion of the short arm of chromosome 1 (1p) where CHD5 is located. 
Second, a biallelic hypermethylation of the CHD5 promoter leads to the silencing of the 
gene (see introduction). Furthermore, both explanations can be combined if one allele 
is deleted and the promoter of the second is hypermethylated (loss of heterozygosity, 
LOH). Another possibility to silence the second allele is a mutation resulting in a 
truncated or functionally inactive protein.  
For two of the tested cell lines cytogenetic data regarding chromosome 1 are available: 
A deletion of one 1p allele is known in IMR-32 cells;
227
 SH-EP cells have a completely 
intact chromosome 1.
228
 
The hypothesis that the CHD5 expression of the intact allele is repressed by promoter 
hypermethylation in IMR-32 cells was further evaluated by treatment of these cells 
with the DNMT inhibitor 5-azacytidine. In case of a hypermethylated promoter such a 
demethylating treatment is supposed to restore CHD5 expression.  
However, 5-azacytidine treatment did not restore CHD5 protein expression in IMR-32 
cells (see Fig. 4.17 A, lane 8). 
 
 
                                                           
227
 Schleiermacher G et al, Combined 24-color karyotyping and comparative genomic hybridization 
analysis indicates predominant rearrangements of early replicating chromosome regions in 
neuroblastoma. Cancer Genet Cytogenet  (2003). 
228
 Carr J et al, High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single 
nucleotide polymorphism arrays. Cancer Genet Cytogenet (2007). 
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CHD5
(M-182)
CHD5 (K) 
A B
Fig. 4.17: CHD5 is not expressed in neuroblastoma cell lines
A 80 µg of WCE from different neuroblastoma cell lines was loaded on SDS-PAGE and further
subjected to western blot using two different antibodies against CHD5; ß-tubulin was used as a
loading control; recombinant CHD5 (lane 1) and WCE from transiently CHD5-transfected
HEK293 cells (lane 2) were used as positive controls, from HEK293 cells (lane 3) as negative
control. Neuroblastoma cell line extracts: SH-SY-5Y (lane 4), SMS-KCN (lane 5), SH-EP (lane 6),
IMR-32 (lane 7) and IMR-32 treated with 10 µM 5-azacytidine for 3 days (lane 8).
B RNA from different neuroblastoma cell lines was extracted and analysed by RT-qPCR,
confirming the western blot results. Expression levels were calculated according to the
2-∆∆Ct method; RPS14 was used as housekeeping gene and ∆Ct(HEK293) was set as calibrator.
Error bars represent the standard deviation between three different RNA isolations.
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Like neuroblastoma cell lines, the lymphocytic MOLT-4 cell line (data not shown), the 
glioblastoma cell lines U251, U373, U87, T98G (all from human origin, see Fig. 4.18) 
and Gl261 (from mouse, see Fig. 4.19 B and 4.20 B) do not express CHD5 at more than 
background levels. The glioblastoma cell line A172 showed an approximately forty fold 
higher expression of CHD5 than HEK293 cells in RT-qPCR although no protein was 
detectable in western blot (see Fig. 4.18, A and B). Transcript levels in HEK293 cells 
transiently transfected with CHD5 were in comparison around sixty fold higher than in 
A172 cells (see Fig. 4.18 C). This order of magnitude was similar to the difference 
between testicular and muscular expression in rat where muscle was not assumed to 
express functional CHD5. In order to further verify the absent CHD5 expression in A172 
cells, a large amount of nuclear extract was prepared and subjected to western blot. 
No signal was observed for A172 assuming an absent expression (see Fig. 4.20, A). 
Although all these data from cell lines were highly reproducible in different 
experiments, the results were additionally verified by the use of a second primer pair 
for CHD5 which amplifies a region closed to the 3’ end of the mRNA and a repetition of 
the cDNA synthesis with random primers. Using these primers confirmed the data 
from earlier experiments showing absent CHD5 expression (data not shown). 
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Fig. 4.18: CHD5 is not expressed in glioblastoma cell lines  
A 80 µg of WCE from different glioblastoma cell lines was loaded on SDS-PAGE and 
further subjected to western blot using two different antibodies against CHD5; ß-tubulin 
was used as a loading control; WCE from transiently CHD5 transfected HEK293 cells 
(lane 1) was used as positive control, WCE from HEK293 cells (lane 2) and Hela cells 
(lane 3) as negative controls. Glioblastoma cell line extracts:  A172 (lane 4), U251 (lane 5), 
U373 (lane 6), U87 (lane 7) and T98G (lane 8). 
B RNA from different neuroblastoma cell lines was extracted and analysed by RT-qPCR, 
confirming the western blot results. Expression levels were calculated according to the  
2
-∆∆Ct 
method; RPS14 was used as housekeeping gene and ∆Ct(HEK293) was set as 
calibrator. Error bars represent the standard deviation between three different RNA 
isolations. 
C Comparison of CHD5 RNA levels in transiently transfected HEK293 cells and A172 
cells. 
 
An explanation for the absence of CHD5 in glioblastoma cell lines besides a role as 
tumor suppressor might be the astrocytic origin of this tumor.  
There are 1.4 astrocytes per neuron in the human cortex but only 0.4 in mouse and rat 
cortex.
229
 Although it is likely that the robust western blot signal from brain is at least 
partially caused by such an abundant cell type like the astrocyte, a restriction to 
neurons or oligodendrocytes could not be excluded. Such a restriction might be 
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 Nedergaard M et al, New roles for astrocytes: Redefining the functional architecture of the brain. 
Trends Neurosci (2003). 
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supported by the data of The Allen Mouse Brain Atlas,
230
 a large collection of in situ 
hybridization data from mouse brain, suggesting a preferential expression of CHD5 in 
specific areas of the brain like the hippocampus. Therefore, a mouse cell line derived 
from hippocampus neurons, Ht 22, was tested in western blot, but no CHD5 protein 
could be detected (see Fig. 4.19 A). 
 
In order to exclude a repression of CHD5 during proliferation or immortalization, 
especially in cell culture, primary cells were tested. Primary astrocyte cultures are 
broadly used for a variety of approaches and are not difficult to keep in culture. 
Therefore, such a culture was established (see Methods, Primary astrocyte culture) 
and tested in early and late passages for CHD5 expression. No significant CHD5 
expression could be detected (see Fig. 4.19). Because no obvious difference between 
the early and late passage could be observed in different experiments, the shown RT-
qPCR data represent an average of both. 
 
A late passage (P19) from an ARF-deficient strain of a MEF culture was tested in 
western blot with no evidence for CHD5 expression (see Fig. 4.20 B). 
 
A nuclear extract from murine neural stem cells was also tested in western blot for 
CHD5 expression and gave a signal in western blot as the only material besides tissue 
extracts (see Fig. 4.20 A). Because a huge amount of nuclear extract (100µg) were 
used, an equal amount of NE from the glioblastoma cell line A172 was loaded in 
comparison without any evidence of CHD5 expression in  this cell line as already shown 
in Fig. 4.18. 
 
In summary, analysis of primary rat and mouse tissues revealed robust levels of CHD5 
only in brain and testes. None of the tested cell lines showed significant CHD5 
expression. The only cell system in which CHD5 is expressed at detectable levels are 
murine neural stem cells and HEK293 cells transiently transfected with an expression 
vector for Flag-tagged CHD5. The absence of CHD5 expression in cells of neural origin 
like Ht22 or astrocytes requires further investigation.  
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CHD5
ß-tubulin
Fig. 4.19: CHD5 expression in cultured astrocytes
A 60 µg of whole cell extracts from mouse brain, an astrocyte culture and Ht22 cells (a cell
line from mouse hippocampal neurons) in western blot probed with the α-CHD5 antibody
M-182
B RT-qPCR amplifying CHD5 in cDNA from mouse brain, astrocytes and the mouse
glioblastoma cell line Gl261. ß-actin was used as housekeeping gene, CHD5 mRNA levels
were normalized to mouse brain.
A B
0
100
200
300
400
500
600
700
800
900
1000
adult mouse brain cultured Astrocytes Gl261
re
la
ti
v
e
 C
H
D
5
 e
x
p
re
s
s
io
n
 (
A
U
)
 
CHD5
ß-tubulin
CHD5
ß-tubulin
A B
Fig. 4.20 CHD5 expression in primary cells from mice
A 100µg Nuclear extract from neuronal stem cells were analysed in western blot, mouse
brain WCE was used as a positive control, NE from A172 as negative control.
B WCE from a MEF culture, Gl261 as negative control.
 
 
4.1.5 Both isoforms of CHD5 are expressed in mouse brain and testes 
According to the NCBI database
231
 CHD5 is predicted to exist in two isoforms in Mus 
musculus. So far, the existence of more than one isoform is not suggested for any 
other organism besides the mouse.  
The second isoform lacks an in-frame exon (no 24) compared to isoform 1 resulting in 
a smaller protein. The corresponding area in the protein is localized close to the          
                                                           
231
 Internet source: www.ncbi.nlm.nih.gov/gene. 
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C-terminus (see Fig. 4.21 B). Remarkably, the corresponding part of this exon 24 is also 
absent in CHD4, although both proteins show a high overall similarity. 
 
Here, it was tested, whether both isoforms are expressed on RNA level in mouse brain 
and testes. Therefore, primers were designed that bridge specifically the 
corresponding exon borders (exon 23 to 24 for isoform 1, exon 23 to 25 for isoform 2); 
thus they were supposed to amplify exclusively one isoform (see Fig. 4.21 A).  
RNA from both tissues was extracted, reversely transcribed, analyzed in RT-PCR and 
separated on a 1.5% agarose gel. A water control was included in RT-PCR. 
To assure overall RT-PCR reliability ß-actin as a typical housekeeping gene was included 
and gave bright signals in brain and testes and no apparent band in water control (see 
Fig. 4.21 C; lanes 3, 6 and 9). 
A band between 100 and 200 base pairs was visualized for both isoform specific 
primers in brain and testes (see Fig. 4.21 C; lanes 1, 2, 4 and 5) that were absent in the 
water control (see Fig. 4.21 C; lanes 7 and 8). Considering the expected size of the 
amplicons (131 bp each) these bands were assumed to represent isoform 1 and 
isoform 2, respectively. At around 100 bp a second band was frequently observed (see 
Fig, 4.21 C; lanes 1, 2, 4, 7, 8 and 9). Most likely these unspecific bands represent 
primer dimers.  
In summary, transcripts of both CHD5 isoforms are detectable in brain and testes. No 
additional statement on their relative distribution can be made because RT-PCR is a 
semi-quantitative approach. To further test whether both isoforms are expressed on 
protein level a generation of isoform-specific antibodies would be necessary. Especially 
in the context of a CHD5-containing NuRD-like complex that might be interesting. 
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4.1.6 CHD5 expression is not upregulated upon differentiation of Pc12 cells 
The absence of CHD5 expression in tumor cell lines and its involvement in proliferation 
control as reported by Bagchi et al
232
 might suggest that CHD5 expression is restricted 
to non-proliferating cells e.g. terminally differentiated cells. 
The rat pheochromocytoma cell line Pc12 is a broadly used model to study neural 
differentiation in cell culture because they can be easily differentiated in presence of 
recombinant NGF for several days.
233
  
In order to test the hypothesis that CHD5 expression is upregulated during 
differentiation in a potentially CHD5 expressing cell line (because of its neural origin) 
we used Pc12 cells in differentiation.  
                                                           
232
 Bagchi A et al, CHD5 is a Tumorsuppressor at Human 1p36. Cell (2007). 
233
 Brynczka C et al, NGF-mediated transcriptional targets of p53 in Pc12 neuronal differentiation. BMC 
Genomics (2007). 
isoform1 isoform1 isoform1isoform 2 isoform2 isoform2ß-actin ß-actin ß- actin
200 bp
100 bp
brain testes H2O
Isoform2: Isoform 1:
*
A
NH 3 COOH
2 PHD zinc fingers 2 chromodomains Helicase / ATPase domain 
B
C
* * ** *
1            2            3           4            5           6           7          8           9
Fig. 4.21: Isoform expression in mouse tissue 
A Scheme of exon structure and position of isoform-specific primers 
B Position of the alternative exon in CHD5 protein 
C cDNA from mouse brain and testes was analyzed with isoform-specific primers by 
RT-PCR, followed by 1.5 % agarose gel.                                                                                                                 
 * primer dimers 
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Therefore, Pc12 cells were treated with 10 ng mNGF for 1, 4 and 7 days under low-
serum conditions (1 % FBS). During the first day, Pc12 cells started to loose their round 
shape and outgrowth of neurites could be observed under the light microscope. On 
day 7 the cell bodies were star-shaped and surrounded by a dense network of neurites 
(see Fig. 4.22 A). This morphology is characteristic for nerve cells and indicated the 
success of the differentiation process.  
Protein samples were taken on day 1, 4 and 7 after mNGF treatment and from 
undifferentiated Pc12 cells (day 0) for comparison. RNA was extracted on day 0 and 
day 7 after mNGF treatment.  
CHD5 was not detectable in western blot neither before differentiation nor after it (see 
Fig. 4.22 B). In addition, CHD5 mRNA was only expressed at very low levels compared 
to its robust expression in rat brain. No significant difference in transcript levels could 
be observed during differentiation.  
In summary, even though Pc12 cells are from neural origin and a CHD5 expression 
seemed reasonable, neither significant CHD5 transcripts in RT-qPCR nor protein in 
western blot could be detected. There was no upregulation of CHD5 during 
differentiation as assumed.    
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Fig. 4.22: CHD5 expression upon Pc12 differentiation
A Morphologic changes upon differentiation of Pc12 cells in light microscopy, 100x magnification.
B Pc12 cells were differentiated by addition of mNGF for 7 days, WCE was extracted on day 0 (lane 5), 
1 (lane 2), 4 (lane 3) and 7 (lane 4) and analysed in western blot for CHD5 expression. WCE from rat 
brain was used as positive control for CHD5 (lane 1), ß-tubulin was used as loading control.
C RNA was isolated from undifferentiated (t=0) and differentiated (t=7d) Pc12 cells, CHD5 mRNA was 
subjected to RT-qPCR and normalized to rat brain.
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4.2.1 NF-κB is activated upon TNFα stimulation in HEK293 cells 
In the absence of NF-κB pathway activation the most abundant NF-κB heterodimer 
p50/p65 is kept in the cytoplasm by interaction with IκB molecules. Upon activation 
the heterodimer is released, translocated into the nucleus and directed to its target 
genes. 
To confirm NF-κB nuclear re-localization in the cell line used for these studies, HEK293 
cells were incubated with TNFα at a concentration of 20 ng/ml for one hour. The NF-κB 
subunits p50 and p65 were visualized by immunocytochemistry. In untreated HEK293 
cells p50/p65 staining was preferentially cytoplasmic. Upon stimulation the staining 
pattern switched to a predominantly nuclear staining (see fig. 4.23). Both observations 
are consistent with an activation of the NF-κB pathway by TNFα in HEK293 cells. 
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Fig. 4.23: NF-κB is translocated to the nucleus upon TNFα stimulation in HEK293  
For visualization of NF-κB translocation HEK293 cells were stimulated with TNFα at a concentration of 
20 ng/ml for one hour (B, D) or left untreated (A, C). Immunofluorescence staining was performed 
with α-p65 (A, B) and α-p50 (C, D). Nuclei were visualized by DAPI staining. As secondary antibody 
Alexa Fluor 488 α-rabbit was used.  
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4.2.2 Activation of NF-κB upon TNFα and PTO stimulation in a luciferase 
reporter system 
To assess the general impact of different chromatin remodelers on NF-κB - induced 
transcriptional activation, we first used 293-mTLR9-luc cells.  
These HEK293 cells stably express the murine Toll-like-receptor 9 (TLR-9) and a 6-fold 
NF-κB luciferase reporter plasmid. These cells respond to different agents stimulating 
TLR-9 with a nuclear translocation of NF-κB
234
 (see figure 4.24 A).  
To establish the use of this cell system in our laboratory, Luciferase activity was 
determined at different points in time after treatment with TNFα or the TLR-9 agonist 
PTO. After TNFα stimulation, a 1.25 fold increase in luciferase activity was detectable 
after 2 hours. Luciferase activity steadily increased at later points in time and reached 
a maximum of 25 fold after 18 hours (see fig. 4.24 B). After PTO stimulation, luciferase 
activity rose by six fold after 2 hours and increased to a maximum of 118 fold after 18 
hours (see Fig. 4.24 C). These results confirm that NF-κB activity can be activated in 
these HEK293 cells by different stimuli. 
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Fig 4.24: Activation of 293-mTLR9-luc by 
various stimuli
A Scheme of 293-mTLR9-luc cells 
B  Time-course of NF-κB activation after 
stimulation with 20 ng/ml TNFα, measured as 
fold activation of luciferase activity. 
Experiments were performed in technical 
duplicats.
C Time-course of NF-κB activation after 
stimulation of TLR9 with 1 µM PTO, measured 
as fold activation of luciferase activity.
 
                                                           
234
 Bauer S et al, Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif 
recognition. Proc Natl Acad Sci USA (2001). 
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4.2.3 Induction of different target genes upon TNFα stimulation in HEK293 cells 
Having established that the NF-κB pathway is in principle intact in HEK293 cells, I 
investigated the activation of endogenous NF-κB target genes. The classical NF-κB 
target genes CXCL2 (C-X-C motif ligand 2; also called MIP-2α, GRO-ß), CCL2 (C-C motif 
ligand 2, also named MCP-1), CXCL10 (C-X-C motif ligand 10), IκB, TNFα, Il-8 
(interleukin 8), IRF-1 (Interferon regulatory factor 1) and IL-6 (interleukin 6) were 
chosen. 
To determine gene activity during early and late phases of the NF-κB response, RNA 
levels were quantified by RT-qPCR one and four hours after TNFα treatment. With the 
exception of IL-6, all tested genes were activated by at least 10 fold at one or both 
points in time following TNFα stimulation (see Fig. 4.25). The analysed genes showed 
kinetic differences with respect to expression levels during early and late points in 
time. CXCL2, CCL2, IκB, TNFα, IRF-1 and IL-8 were strongly induced after one hour of 
TNFα stimulation. By 4 hours gene activity had decreased to values between 20 % 
(CXCL2) and 60 % (CCL2) of the activity after one hour. Thus, this group of genes 
exhibits strongest expression during the early phase of the NF-κB response.  
By contrast, CXCL10 showed a seventy fold induction after one hour and further 
increased to nearly 200 fold by 4 hours (see fig. 4.25). This demonstrates that CXCL10 
is most strongly expressed during later stages of NF-κB response.  
Il-6 showed a maximum induction by three fold after one hour (see Fig. 4.25). This was 
regarded as very mild upregulation. Thus, Il-6 was not included in further studies.  
 
The induction of endogenous target genes was much more pronounced than most of 
the activation levels achieved in the 293-mTLR9-luc system. RT-qPCR is a very sensitive 
method to detect even small changes in gene activation that could be missed in a 
Luciferase assay. Taking into account that chromatin remodeling is just one influencing 
factor on gene activation and knockdown efficacy is always below 100 %, I did not 
expect tremendous effects in the further studies. Thus, to avoid less pronounced 
effects to be hidden I focused on the endogenous target gene activation for further 
studies and did not include experiments with 293-mTLR9-luc cells. 
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Fig.4.25 : Activation profiles of different NF-κB target genes upon TNFα stimulation.
HEK293 cells were stimulated with recombinant TNFα (20 ng/ml). RNA was isolated after 1
and 4 hours. NF-κB target genes were normalized to RSP14 as housekeeping gene. Error
bars represent the standard error.
0
5
10
15
20
25
1 h 4 h
fo
ld
a
c
ti
v
a
ti
o
n
IRF-1
0
20
40
60
80
100
1 h 4 h
fo
ld
 a
c
ti
v
a
ti
o
n
IL-8
0
50
100
150
200
250
1 h 4 h
fo
ld
 a
c
ti
v
a
ti
o
n
CXCL10
0
0,5
1
1,5
2
2,5
3
3,5
1 h 4 h
fo
ld
a
c
ti
v
a
ti
o
n
Il-6
 
 
 
 
 
 
4 .  R e s u l t s  |  9 4  
 
4.2.4 siRNA-mediated knockdown of Mi-2ß, CHD3 and BRG1/Brm in HEK293 cells 
To study the role of chromatin remodeling factors during the activation of NF-κB target 
genes, I established siRNA-mediated knockdowns of CHD3, CHD4 and BRG1/Brm in 
HEK293 cells. A time-course was performed for every siRNA to determine the most 
efficient knockdown.  
Two siRNAs against CHD4 were tested (siCHD4#1 and siCHD4#2), either alone or in 
combination. Both were capable of reducing the level of CHD4 protein after 2 and 3 
days (see Fig. 4.26, compare lanes 1-3 with 4-5 and 6-8 with 9-10, respectively). The 
strongest effect was observed for siCHD4#1 after 4 days (Fig. 4.26, lane 11). The use of 
both siRNAs together did neither augment the knockdown efficiency nor resulted in a 
diminished knockdown. On RNA level both siRNAs alone and in combination achieved 
a reduction of transcripts to less than 30 % at all tested points in time. Treatment with 
siCHD4#1 resulted in the strongest suppression of transcripts after 3 days (see            
Fig. 4.27).  
 
 
1       2      3       4     5 11    12    13   14
α-Mi2
α-Tubulin
Figure 4.26: Efficiency of Mi2ß protein knockdown in HEK293 cells after 2, 3 and 4 days.
In order to determine the most efficient Mi2ß knockdown a time-course was performed. 50 µg
of WCEs were used for western blotting comparing two different siRNA against CHD4 alone or
together with a non-targeting siRNA (siNon-target) or a Mock control.
6      7      8      9     10
2 days 3 days 4 days
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Fig. 4.27: Efficiency of Mi2ß knockdown on transcript level.
HEK293 cells were incubated with 2 different siRNAs against CHD4 (siCHD4#1, siCHD4#2) for
two to four days. Both siRNAs were tested alone and in combination. RNA was extracted,
reversely transcribed and subjected to RT-qPCR. CHD4 mRNA levels were normalized to RPS14
as housekeeping gene. Error bars indicate the standard error.
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BRG1 and Brm are supposed to be partially redundant and compensatory. The used 
siRNA disrupting BRG1 expression (siBRG1/Brm) also targets Brm although it is 
expressed to a much lesser extent in HEK293 cells. Whether Brm is functionally 
relevant in HEK293 cells at this low expression level is unclear. Thus, this study will 
focus on BRG1. BRG1 protein was reduced by siBRG1/Brm after 2, 3 and 4 days but the 
highest reduction was observed after 4 days (see Fig. 4.28). On RNA level BRG1 was 
strongest repressed after 2 days but transcripts remained below 40 % on day 3 and 4 
(see Fig. 4.29). Brm RNA levels were kept below 50 % (see Fig. 4.30).  
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Fig. 4.28: Efficiency of BRG1/Brm knockdown in HEK293 cells after 2, 3 and 4 days.
In order to determine the most efficient BRG1/Brm knockdown a time-course was performed.
50µg of WCEs were used for western blotting comparing a BRG1/Brm knockdowns with siNon-
target (non-targeting siRNA) and Mock control.
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Fig. 4.29: Efficiency of BRG1 knockdown on transcript level.
HEK293 cells were treated with a siRNA against BRG1/Brm for two to four days. RNA was extracted,
reversely transcribed and subjected to RT-qPCR. BRG1 mRNA levels were normalized to RPS14 as
housekeeping gene. Error bars represent the standard error.
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Fig. 4.30: Efficiency of Brm knockdown after 2-4 days
HEK293 cells were treated with siRNA against BRG1/Brm for two to four days. RNA was extracted,
reversely transcribed and subjected to RT-qPCR. Brm mRNA levels were normalized to RPS14 as
housekeeping gene. Error bars represent the standard error.
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Because CHD4 and BRG1 proteins showed the highest reduction after 4 days, this point 
in time was chosen for further experiment. At this stage transcript levels were still 
below 40 % assuming a sufficient knockdown.  
A combination of siCHD4#1 and siCHD4#2 was of no advantage regarding the 
knockdown efficiency (see above).  
 
Because the use of siNon-target resulted also in a reduction of CHD4 and BRG1/Brm 
transcripts (see Fig. 4.27, 4.29), a siRNA against CHD3 (siCHD3) was additionally used 
as a second ‘non-targeting’ control because CHD3 expression is not detectable on 
protein level in HEK293 cells (Gundula Streubel, personal communication). CHD3 RNA 
level was reduced by > 50 % after 4 days of knockdown (see Fig. 4.31).  
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Fig. 4.31: Efficiency of CHD3 knockdown after 4 days
HEK293 cells were treated with a siRNA against CHD3 (siCHD3) for four days. RNA was
isolated, reversely transcribed and subjected to RT-qPCR. CHD3 mRNA levels were
normalized to RPS14 as housekeeping gene. Error bars represent the standard error.
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To test whether CHD3 knockdown had any influence on CHD4, WCEs from CHD3 
knockdown and Mock were compared in western blot (see Fig. 4.32). The Mi2 antibody 
used for that blot (H-242) is a rabbit polyclonal antibody raised against amino acids 
1671-1912 of human CHD4 but also recognizes CHD3.
235
 A significant difference in Mi2 
protein levels between the siCHD3 treated sample and the Mock control could not be 
observed (Fig. 4.32, compare lanes 1 and 5).  Thus, siCHD3 was assumed to be a 
suitable second non-targeting control for further experiments. 
α-Mi-2
α-Tubulin
Fig. 4.32: CHD3 knockdown does not significantly influence Mi-2 protein level
To ensure that CHD3 siRNA does not reduce CHD4 protein levels, 50 µg of protein was used
for western blot comparing Mi-2 levels after a four-day CHD3 or CHD4 knockdown with the
Mock control and non-targeting siRNA treated samples.
1        2        3         4       5
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 Internet source: www.scbt.com/datasheet-11378-mi2-h-242-antibody.html. 
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4.2.5 Knockdown of CHD4 and BRG1 impairs induction of NF-κB target genes  
In order to assess the impact of CHD4 and BRG1 for the induction of different TNFα-
induced NF-κB target genes, a siRNA-mediated knockdown of both proteins was 
performed in HEK293 cells. Cells were stimulated with TNFα for one or four hours, RNA 
was extracted, reversely transcribed and subjected to RT-qPCR. A siRNA against CHD3 
(siCHD3) was taken as a second unspecific control (as described in 4.2.4).  
BRG1 knockdown resulted in a reduced induction of all tested NF-κB target genes by 
app. 50 % after one hour of TNFα stimulation (see Fig. 4.33 and 4.34). Surprisingly, 
CHD4 knockdown affected similarly the induction of the tested genes. With the 
exception of IRF-1 and Il-8, no difference in target gene induction impairment of 
greater than 10 % was observed between siCHD4#1 and siCHD4#2. These differences 
might reflect different knockdown efficiencies or siRNA-specific off-target effects.  
Interestingly, the induction after four hours was not impaired for either siRNA (Fig. 
4.33, 4.34). Thus, the observed effects are assumed to be dependent on the kinetics of 
the activation. 
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Fig. 4.33: Induction of TNFα induced NF-κB target genes is impaired by
knockdown of CHD4 and BRG1 (1)
CHD4 and BRG1 protein levels were reduced by siRNA-mediated knockdown for 4 days in 
HEK293 cells. NF- κB was activated by stimulation with TNFα (20ng/ml). RNA was extracted
after one and four hours, reversely transcribed and subjected to RT-qPCR. Induction of
target genes was calculated as n-fold activation normalized to Mock. Error bars indicate the
standard deviation between 3 independent experiments.
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Fig. 4.34: Induction of TNFα induced NF-κB target genes is impaired by
knockdown of BRG1 and CHD4 (2)
Summary of impaired NF- κB target gene induction after CHD4 or BRG1 knockdown. The
target gene activation after TNFα treatment for 1 hour is presented as % induction of Mock.
Error bars represent the standard deviation between three independent experiments.
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To rule out an unspecific effect of CHD4 or BRG1 knockdown on transcription in 
general, the expression of the housekeeping gene ß-actin was measured. No alteration 
of ß-actin by knockdown or TNFα stimulation could be observed (see Fig. 4.35). Thus, 
the observed effects are specific for the tested target genes.  
Fig. 4.35: CHD4 and BRG1 knockdown does not influence ß-actin expression
To test whether CHD4 and BRG1 knockdowns influence the expression of the housekeeping
gene ß-actin, its expression level was determined by RT-qPCR. ß-actin was neither induced
by TNFα stimulation nor significantly altered by any knockdown. Error bars indicate the
standard deviation between three independent experiments.
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Treatment with siCHD3 or non-targeting siRNA had in most cases no significant effect 
on gene expression compared to untreated cells (Mock). However, the expression of 
two genes was significantly affected in control siRNAs experiments: Firstly, siCHD3 
treatment resulted in a strong increase of Il-8 (150 fold versus 90 fold in Mock) one 
hour after TNFα addition (see Fig. 4.33).  Secondly, treatment with non-targeting siRNA 
led to stronger increase in CXCL10 expression compared to Mock (290 fold versus 200 
fold) after 4 hours of TNFα incubation (see Fig. 4.33). Since these deviations were 
limited to single genes, it is conceivable that they represent gene-specific off-target 
effects of the control siRNAs.  
4.2.6 Mechanism of impairment 
In HEK293 cells, a knockdown of BRG1 and CHD4 significantly impaired the induction of 
NF-κB target genes after TNFα stimulation. In order to assess the mechanism of this 
impairment, ChIP experiments were performed to determine whether the studied 
chromatin remodelers are directly associated with the target genes. CXCL2 was chosen 
for these experiments because the observed effects on this gene were strong and 
robust. CXCL2 is an inducible chemokine involved in attraction of neutrophils to sites of 
infection.
236
 Five primer pairs were designed for CXCL2, amplifying the promoter 
region, a part of exon 2, intron 3, exon 4 and a region 0.4 kb downstream of the gene 
(Fig. 4.36). As a second non-specific control besides the downstream region of CXCL2, 
the ß-actin promoter was chosen, because it was already shown that TNFα stimulation 
neither induces its transcription nor that any of the tested chromatin remodeler 
knockdowns impair it.  
0.4 kb downstream
Fig. 4.36: Localization of ChIP primers within the CXCL2 gene
Scheme of ChIP primer positions. κB site (predicted NF-κB binding site) is indicated by the red 
arrow.
κB site
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 Ramirez-Carrozzi VR et al, Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome 
remodeling complexes during an inflammatory response. Genes Dev (2006). 
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To assess any background binding, a sample with the exclusive addition of beads 
without antibody was run resulting in acceptable low signals (less than 0.003 % input, 
see Fig. 4.37). 
Recruitment of NF-κB was tested by ChIP experiments using an antibody against the 
NF-κB subunit p50. A predicted binding site of NF-κB (κB site) is located at the 
beginning of exon one (chromosome 4: 74964991-74964980; “CGGGAATTTCCC”,
237
 
only few base pairs apart from the reverse promoter primer, see Fig. 4.36).  The p50 
ChIP revealed a strong recruitment to the CXCL2 promoter after 40 minutes (0.04 % 
input) and a further increase after 60 minutes (0.06 % input) of TNFα stimulation. 
Recruitment of p50 to the other tested regions of the gene and the ß-actin promoter 
was only slightly increased (less than 0.03 % input).  
Histone H3 ChIPs showed a strong decrease of binding within the promoter region 
after 40 minutes (from 0.2 % to 0.1 % input) and even less (0.05 % input) after 60 
minutes (see Fig. 4.37). At exon 2 a similar decrease was notable after 60 minutes, 
indicating a more open state of the chromatin. A decrease of H3 binding was also 
present at the ß-actin promoter (ranging from 0.01% to 0.05 % input). Because the 
overall binding of H3 at this gene was also much lower (presumably due to its 
housekeeper role), any relevance of the latter observation remained elusive.  
The depletion of histone H3 within the promoter region of CXCL2 suggested that 
chromatin remodeling took place. Thus, a recruitment of CHD4 and BRG1 especially to 
the promoter was conceivable and ChIP experiments for both were carried out. 
Mi2 ChIPs produced a weak constitutive signal but no increased binding after TNFα 
stimulation was observed (see Fig. 4.37). One explanation for this result could be a 
constitutive low binding of Mi-2 to CXCL2. However, the Mi2-antibody has not been 
used in our laboratory for ChIP experiments so far. Thus, it remained unclear whether 
CHD4 is not recruited to the CXCL2 gene or the Mi2-antibody does not work in ChIP 
experiments. Such a failure to detect recruitment of CHD4 to NF-κB-bound CXCL2 
promoter by ChIP could be due to the inability of the CHD4 antibody to precipitate 
CHD4 in the context of cross-linked chromatin. Thus, it would be useful to test another 
Mi-2 antibody in these experiments.  
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BRG1 ChIPs produced unspecific signals for all amplified regions. Thus, I assumed that 
the used antibody was not suitable for ChIP experiments (data not shown).  
However, although the depletion of histone H3 suggested the involvement of 
chromatin remodelers and the knockdown experiments revealed a role for CHD4 and 
BRG1 in the TNFα-induced NF-κB activation, a direct recruitment of both remodelers to 
the model target gene, CXCL2, could not be confirmed. It might be necessary to try 
different CHD4 and BRG1 antibodies and other target genes for this ChIP experiment in 
future. 
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Fig. 4.37: p50, H3 and CHD4 ChIP experiments of the CXCL2 gene
ChIP experiments were performed in HEK293 cells after TNFα stimulation for 40 and 60
minutes using antibodies against the NF-kB subunit p50, Histon H3 and Mi2. As a negative
control a sample with the exclusive addition of beads without antibody was used. Error
bars represent the standard error.
00,1 untreated 40 min 60 min
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As a second approach to evaluate whether CHD4 and BRG1 might be recruited by     
NF-κB to target genes, a co-immunoprecipitation using an antibody against the NF-κB 
subunit p65 was performed. HEK293 cells were stimulated with TNFα for one, two and 
four hours, nuclear extracts were prepared, subjected to p65-IP and analyzed in 
western blots for CHD4 and BRG1 co-immunoprecipitation. The fraction of p65 in 
nuclear extracts increased after TNFα stimulation, again indicating the nuclear re-
localization of NF-κB (see Fig. 4.38, lanes 1-4). The p65 co-immunoprecipitation 
worked well (see Fig. 4.38, lanes 5, 7, 9 and 11) without unspecific binding to the beads 
(see Fig. 4.38, lanes 6, 8 and 10). Neither CHD4 nor BRG1 co-immunoprecipitated with 
p65 before or after TNFα stimulation. This suggests that no abundant and/or robust 
NF-κB-CHD4 and NF- κB-BRG1 complexes form after NF-κB activation by TNFα at the 
tested points in time but still cannot exclude such an interaction.  
 
10% input p65 IP
Mi-2
BRG1
p65
1      2     3     4      5     6     7     8     9    10   11
 
 
Fig. 4.38: Co-immunoprecipitation of RelA with Mi-2 and BRG1 upon TNFα stimulation
400 µg of nuclear extract were subjected to p65-IP. The following western blot was stained
with antibodies against Mi2, BRG1 and p65. No interaction of RelA with Mi-2 and BRG1 upon 
TNFα stimulation (20 ng/ml) in HEK293 cells was observed.
 
5 .  D i s c u s s i o n  |  1 0 6  
 
 
5. Discussion 
5.1. Discussion objective 1 
5.1.1 Establishment of polyclonal antisera against CHD5 
One major goal of this work was the characterization of polyclonal CHD5 antibodies 
and the evaluation of their use as a tool to investigate CHD5. Three polyclonal peptide 
antisera were successfully generated by Ina Wanandi. All of them specifically reacted 
with recombinant hCHD5 protein in Western Blot. In addition, antiserum R was able to 
detect endogenous CHD5 from mouse brain lysates. None of them could be 
successfully used in immunoprecipitation and immunofluorescence. For further studies 
all of them can be used in Western Blot in order to detect CHD5 from human origin, 
antiserum R additionally for murine CHD5. They are not suitable for 
immunoprecipitations or for immunofluorescence stainings. For these applications and 
for detection of rodent CHD5 in Western Blot the CHD5 antibody M-182 was shown to 
be better applicable in this study. Thus, for further experiments I mostly used this      
M-182 antibody. 
Concurrently with this study, several CHD5 antibodies became available. Three of them 
detected a band at 250 kDa (α-CHD5 RabMAb from Epitomics
238
; rabbit polyclonal      
α-CHD5 from Abcam
239
; Y-1 as published by Yoshimura S et al
240
). This was somewhat 
surprising because we detected the recombinant CHD5 protein at 220 kDa, consistent 
with the estimated molecular mass of CHD5, with our antisera and additionally with 
the CHD5 antibody M-182. Furthermore, in this study, endogenous CHD5 from mouse 
brain lysates was shown to have the same electrophoretic mobility as the recombinant 
CHD5 protein. But most likely, this discrepancy is due to the use of different molecular 
markers as these can differ dramatically and allows no further conclusion. 
The rabbit α-CHD5 monoclonal antibody from Epitomics was predicted to cross-react 
with hCHD3 by the manufacturer. The manufacturer suggested a detection of CHD5 
with their antibodies in protein extracts from adrenal gland and the neuroblastoma 
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 www.epitomics.com/products/product_info/10413/CHD5-antibody-5212-1.html. 
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 www.abcam.com/Chromodomain-helicase-DNA-binding-protein-5-antibody-ab66516.html. 
240
 Yoshimura S et al, A rat monoclonal antibody against the chromatin remodeling factor CHD5. 
Hybridoma (Larchmt). (2010).  
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cell line SH-SY-5Y. According to this study and Potts et al
241
  both were shown not to 
express CHD5 protein.  Thus, these results argue that this antibody probably detect 
CHD3 instead of CHD5. 
The rabbit α-CHD5 polyclonal antibody from Abcam (ab66516) was evaluated by the 
manufacturer on liver tissue lysates and protein extracts from HeLa cells. Also 
Yoshimura et al
242
 established their monoclonal CHD5 antibody Y-1 on protein extracts 
from HeLa cells labelling the detected band as CHD5.  I detected CHD5 in RNA and 
protein extracts neither from rat liver nor from HeLa cell protein extracts. The absent 
expression in HeLa cells is consistent with data from Potts et al.
243
 Altogether, I doubt 
whether these antibodies indeed detect CHD5. 
Two other commercial antibodies were described to detect a protein at 90 kDa (goat 
α-CHD5 antibody from Everest Biotech
244
; goat α-CHD5 from ProSci
245
). This distinct 
difference in molecular weight could be in principle explained by the existence of 
another isoform of CHD5 or degradation of CHD5 protein in the extracts tested. So far, 
besides the second isoform of CHD5 in mice, which differs only insignificantly from the 
predicted molecular weight of the first one, no other splicing variant is predicted to my 
knowledge that could explain this low electrophoretic mobility. 
Although the use of different molecular markers decreases the comparability between 
different laboratories, as mentioned above, I would rigorously assess whether the 
proteins at 90 kDa and 250 kDa detected by the commercial antibodies indeed 
specifically react with CHD5. Possibly, the bands at 90 kDa and 250 kDa could be 
caused by cross-reactivity to CHD3 or CHD4. For further studies, I preferred to use the 
CHD5 antibody M-182. 
5.1.2 CHD5 overexpression does not induce senescence in SAOS-2 cells  
CHD5 was found to interfere with the p16-pRb-pathway for promotion of cellular 
senescence in MEFs
246
 but the molecular mechanism remained unclear. In order to 
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gain mechanistic insight into the effects of CHD5 on Rb-induced senescence I decided 
to use the so-called ‘flat cell assay’
247
 in SAOS-2 cells. Rb-induced senescence was 
successfully induced by transfection of its large pocket domain. CHD5 overexpression 
itself did not induce senescence in that cell system. It appeared conceivable that CHD5 
modulates senescence exclusively in the presence of pRb. Thus, we studied the 
formation of flat cells upon co-expression of pRb and CHD5. This co-expression did not 
further augment or diminish the pRb-induced senescence. I did not control whether 
co-expression was successful because the selection process during transfection 
complicated protein extraction. A successful transfection was assumed by the 
reproducible induction of senescence in Rb-transfected cells and expression of both 
proteins was driven by the same promoter (CMV). Thus, an inefficient co-transfection 
was unlikely, but could explain nevertheless any absent effect. A better method than 
Western Blot to control the successful co-transfection would be an 
immunofluorescence staining of CHD5 and pRb. 
Furthermore, it is possible that CHD5 and pRb directly interact during the induction of 
senescence via a Rb-domain outside its large pocket domain. In this study, only the 
large pocket domain of Rb was transfected, thus, a possible interaction could be 
disturbed. Here, it could be worthwhile to repeat these experiments with transfection 
of the entire Rb.  
However, CHD5 does not seem to influence senescence in this experimental system. 
Another system to study the influence of CHD5 on senescence could be a cell line with 
inducible CHD5 expression.  
5.1.3 Overexpressed CHD5 does not directly interact with endogenous p53 
It has been proposed that CHD5 regulates the p53 level via the p19
ARF
 pathway.
248
  
Alternatively, CHD5 or a CHD5-containing complex could directly interact with p53. A 
similar model was suggested for a MTA2-containing NuRD complex regulating the p53-
mediated transactivation by modulating the p53 acetylation status.
249
  Since CHD5 was 
shown to be part of a NuRD-like complex
250
, it may be found to function similarly.  
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Thus, we tested the possible interaction of endogenous (functionally inactive) p53 and 
overexpressed Flag-tagged CHD5 in HEK293 cells. This approach was chosen because 
the classical method to show a co-immunoprecipitation of two overexpressed proteins 
failed since a simultaneous overexpression of both candidate interaction partners did 
not succeed. No co-immunoprecipitation of Flag-tagged CHD5 with endogenous p53 
could be achieved, suggesting there is no direct interaction between overexpressed 
CHD5 and endogenous p53. Another possibility would be that the interaction is not 
strong enough for a robust co-immunoprecipitation. Furthermore, a possible 
interaction might be restricted to a cellular stress response. To test this hypothesis, the 
experiment could be repeated during cellular stress as induced via TNFα, heat-shock or 
cytotoxic treatment.  
 
5.1.4 CHD5 expression profile in tissues and cell lines 
So far, CHD5 expression was thought to be restricted to cells of neural origin as in the 
central nervous system and adrenal gland.
251
 To gain further insight, I performed a 
detailed expression analysis of CHD5 in primary tissues and several cell lines.  
In rat muscle, liver, heart and lung CHD5 was only detectable at levels of background 
transcription. This is in agreement with previous reports.
252
 CHD5 protein was also 
absent. It is still possible that its expression is below our detection threshold and that it 
may have some important functions even at these low levels. Moreover, there may be 
specific cell types within these tissues that express CHD5. For example, an expression 
in peripheral muscle nerve cells appears plausible because of their neural origin. This 
would have been missed when analyzing tissue lysates in Western Blot and RT-qPCR. 
Thus, it might be indicated to also perform immunofluorescence stainings on primary 
tissue sections. The CHD5 antibody M-182 is suitable for that application as tested on 
tissue sections of mouse brain (data not shown).  
As a second explanation, CHD5 expression could be restricted to specific 
developmental stages what would have also been missed. This assumption led to our 
                                                           
251
 Thompson PM et al, CHD5, a new member of the chromodomain gene family, is preferentially 
expressed in the nervous system; Oncogene (2003). 
252
 Potts RC et al, CHD5, a Brain-Specific Paralog of Mi2 Chromatin Remodeling Enzymes, Regulates 
Expression of Neuronal Genes. PLoS One (2011).  
Thompson PM et al, CHD5, a new member of the chromodomain gene family, is preferentially expressed 
in the nervous system; Oncogene (2003). 
5 .  D i s c u s s i o n  |  1 1 0  
 
experiments with Pc12 cells undergoing differentiation, but there are many other cell 
types and developmental processes which could also be assessed.  
 
I tested four neuroblastoma cell lines for CHD5 expression. None of the four tested 
neuroblastoma cell lines expressed CHD5. Many neuroblastoma cell lines have been 
tested for CHD5 expression on transcript level so far and none was shown to harbor 
significant levels.
253
 To my knowledge, this study was the first to analyze the cell lines 
SH-EP and SMS-KCN; the absence of CHD5 in IMR-32 and SH-SY-5Y are consistent with 
previous studies.
254
 Furthermore, the absence of CHD5 in neuroblastoma cell lines is in 
agreement with the suggested role for CHD5 as tumor suppressor in 
neuroblastomas.
255
 
As previously mentioned, several possibilities exist for the lack of CHD5 expression. 
The first possibility is a homozygous deletion of the short arm of chromosome 1 (1p) 
including the CHD5 locus. This possibility is excluded at least for SH-EP cells because 
they were shown to have an intact short arm of chromosome 1.
256
 Another possible 
explanation could be a loss of heterozygosity (LOH). A LOH is defined as inactivation of 
one allele by deletion and silencing of the second allele by promoter hypermethylation 
or an inactivating mutation. A deletion of one 1p allele is known for IMR-32.
257
 
Although the CHD5 promoter was shown to be unmethylated in this cell line
258
 I tested 
this hypothesis further by treating IMR-32 cells with the demethylating agent               
5-azacytidine because the methylation status can differ even between different 
passages of a cell line (Frank Lyko, personal communication). However, 5-azacytidine 
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could not restore CHD5 expression at the protein level, thus it might not explain the 
absence of CHD5 in IMR-32 cells or the restored expression was still below our 
detection limit.  
Nevertheless, a recent analysis of tissue samples from 188 neuroblastoma patients 
demonstrated no examples of somatically acquired CHD5 mutations, indicating that 
homozygous genomic inactivation is rare. Furthermore, a methylation of the CHD5 
promoter was commonly found in the high-risk tumors, generally associated with both 
1p deletion and MYCN amplification.
259
 Because re-expression of CHD5 during 
induction therapy was found to be associated with a better clinical outcome
260
, a 
possible CHD5 restoration induced by demethylating agents provides a promising new 
therapeutic strategy for the treatment of high-risk neuroblastomas.  
 
Regarding CHD5 expression in brain I was interested which cell types in brain express 
CHD5. Assuming that it has to be an abundant cell type, I established successfully a 
primary astrocyte culture. Lysates from these cultures were negative for CHD5 in RT-
qPCR and Western Blot, which is in agreement with recently published data.
261
 
Moreover, the staining pattern of a CHD5 in-situ-hybridization on mouse brain tissue 
sections from The Allen Institute Mouse Brain Atlas appeared more like a neuronal 
expression pattern.
262
 Furthermore, a prominent staining of the hippocampus region, a 
part of the brain with an important function for memory, was remarkable. This region, 
or, more precisely, the subgranular zone of the hippocampal dentate gyrus, was shown 
to function as a stem cell niche in adult mammals.
263
 Therefore, I tested protein lysates 
from Ht22 cells, a cell line derived from hippocampal neurons, and from murine neural 
stem cells for CHD5 expression. The Ht22 cells turned out to be negative although I 
expected that CHD5 should be expressed in these cells. Considering the possibility that 
CHD5 is involved in negative regulation of cellular proliferation, its expression might be 
lost in cell culture, thus enabling cells to proliferate with less restriction in culture. 
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Immunofluorescence stainings of tissue sections from the hippocampus would be 
required to further support the data from The Allen Institute Mouse Brain Atlas 
showing abundant CHD5 expression in this region of the brain. 
Surprisingly, the murine neural stem cells turned out to express CHD5. Given that 
neural stem cells in the adult brain account for only a small number of cells and 100 µg 
of nuclear extract were required to produce a signal in Western Blot that was less 
intense than that from rodent brain lysates, neural stem cells cannot be the main 
CHD5-expressing cell type in brain. It may be inferred that the bulk of CHD5 is 
expressed in neurons as it was recently shown by Garcia et al.
264
 In addition, it needs 
to be determined whether CHD5 expression is maintained in long-term neural stem 
cell cultures. Considering its anti-proliferative properties,
265
 a loss of expression 
appears plausible in principle. 
However, this is the first evidence that neural stem cells express CHD5. More, they are 
the first known naturally CHD5-expressing cell type that can be kept in cell culture for 
further functional and biochemical experiments. 
 
Nevertheless, for a comprehensive CHD5 expression profile of brain cells it may be 
indicated to perform a cell sort of brain cells, for example via antibody-coupled 
magnetic beads, followed by an analysis of protein lysates in Western Blot. In addition, 
immunofluorescence staining of mouse brain sections with adequate co-staining for 
characterization of the different cell types could be carried out.  
 
Interestingly, CHD5 knockdown was found to reduce gene sets commonly found to be 
upregulated in Alzheimer's disease. Thus, suggesting that CHD5 might be required for 
the expression of these Alzheimer promoting genes. At the same time, CHD5 was 
demonstrated to constitute a NuRD-like complex interacting with HDAC2 in neurons.
266
 
An inhibition of class I HDACs by sodium valproate and other HDAC inhibitors was 
demonstrated to improve the memory deficits in a mouse model of Alzheimer's 
disease.
267
 That could be at least partially related to the interaction of HDAC2 and 
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CHD5. Although I would assume CHD5 interacting with HDAC2 is mainly involved in 
repression of genes, a promotion of Alzheimer-promoting genes via an indirect 
mechanism appears possible. Thus, the inhibition of class I HDAC inhibitors could be an 
interesting therapeutic approach for the future treatment of Alzheimer’s disease.  
 
In this study, four human glioblastoma cell lines as well as the mouse glioblastoma cell 
line Gl261 were tested for CHD5 expression. None of them were found to express 
CHD5. Glioblastoma cell lines are brain-derived and, more precisely, they are of 
astrocytic origin. Thus, considering the absence of CHD5 in astrocytes, that may have 
been predicted and does not allow any conclusion on functional consequences. 
Interestingly, the CHD5 promoter was shown to be hypermethylated in three of our 
tested cell lines (T98G, A172 and U87),
268
 suggesting a plausible mechanism of CHD5 
silencing possibly during fate-commitment to the astrocytic lineage. For further insight 
into this topic a methylation analysis of the CHD5 promoter in astrocytes might be of 
interest. Moreover, neural stem cells could be differentiated into astrocytes in culture 
while monitoring the methylation status of the CHD5 promoter in parallel to its 
expression level.  
Regarding the common deletion of 1p in gliomas, CHD5 was claimed to be a candidate 
tumor suppressor gene. More, Ichimura et al
269
 found CHD5 mostly included in the 
deleted area of 1p36 in gliomas. Bagchi et al
270
 found CHD5 RNA to be absent in a 
subset of glioma samples with deleted CHD5 compared to normal brain. Interestingly, 
in glioma samples without CHD5 deletion they found CHD5 expression present but to a 
lesser extent than in normal brain. I remain in doubt whether the detection of CHD5 in 
this subset really provides evidence for CHD5 expression. Gliomas usually infiltrate the 
brain by active migration through the extracellular spaces of neurons (see 
introduction). This complicates any microdissection of the tumor from the surrounding 
brain structures for proper analysis. Furthermore, in glioma samples without CHD5 
deletion the indicated standard deviation was many times greater than in the other 
samples supporting my suspicion that these samples were contaminated to a varying 
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degree. I would suggest exploring CHD5 expression again in these subsets of gliomas 
by immunofluorescence staining, thus avoiding contamination with surrounding 
neurons.  
To postulate CHD5 as a possible tumor suppressor in gliomas based on its absent 
expression is a bold hypothesis. For that to be concluded, extensive functional studies 
are required. Even if the glioma origin would be assumed to be a cell type with stem-
cell-like properties, CHD5 presence could be even favorable for tumorigenesis, as we 
demonstrated CHD5 expression in murine neural stem cells. Furthermore, it was 
shown that CHD5 promotes the expression of a subset of genes commonly 
upregulated in neural stem cells
271
 suggesting a promotion of stem-cell maintenance, 
rather than the opposite. However, this remains at the level of speculation until 
detailed functional data are available. I would not exclude that CHD5 might play a role 
as tumor suppressor in gliomas and especially glioblastomas but the rationale behind 
this assumption decreases with the absence of CHD5 expression in astrocytes.  
 
5.1.5 CHD5 expression in testes 
Surprisingly, CHD5 protein was robustly expressed in mouse and rat testes. Although 
its testicular expression was predicted by SAGE, it was reported to be absent
272 
or 
indeterminate
273
 in previous studies. CHD5 expression on transcript level was strongly 
consistent with protein expression. Given the paucity of neural-related tissue within 
the testes it is very unlikely that the robust CHD5 expression is caused by that. CHD5 
could be ubiquitously expressed in testes or restricted to any abundant cell type as 
cells from different stages of spermatogenesis, Sertoli or Leydig cells. Considering the 
massive expression of CHD5 in testes it may be assumed that it is expressed in cells of 
spermatogenesis. This is further supported by the finding that CHD5 is not yet 
expressed in testes of 3 week old mice, reflecting its possible involvement in 
spermatogenesis (J. Bergs, personal communication). 
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I did not test CHD5 expression in tissue lysates of ovaries. This would be an important 
issue to assess in the future because the ovaries host the female germ cells like testes 
the male germ cells. Thus, an expression in ovaries is feasible. 
 
In this context, the possible role of CHD5 as a tumor suppressor may again attract 
some attention. In order to explore this possibility of whether CHD5 may play a role as 
tumor suppressor in germ cell tumors (GCTs), I analyzed published cytogenetic data for 
chromosomal aberrations involving 1p, especially deletions of 1p36 including the CHD5 
locus.  
In most publications, cytogenetic analysis is focused on loci proximal to the CHD5 locus 
which is located subtelomerically. Thus, a detailed analysis from literature whether the 
CHD5 locus is included in common regions of deletion was complicated. In many 
publications, microsatellite markers for a region closed to the CHD5 locus were used 
and an absence of the markers made a simultaneous deletion of the CHD5 locus likely, 
but a final conclusion cannot be drawn. Furthermore, the majority of cytogenetic 
analyses in germ cell tumors were performed before 2003 when CHD5 was first 
described.
274
 Thus, an explicit search for the CHD5 locus remains to be done. 
Nevertheless, the available data is summarized below:  
Chromosomal aberrations including the short arm of chromosome 1 are frequently 
observed in germ cell tumors (GCTs) but they appear less specific than in other 
neoplasms.
275
 
Zahn S et al
276
 showed that deletion of 1p36 is a common event in pediatric GCTs but 
constitutes a rare aberration in adults. Several other authors detected cases of 
pediatric GCTs with deletions of 1p36, presumably including the CHD5 locus in most of 
them.
277
  
                                                           
274
 Thompson PM et al, CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous 
system; Oncogene (2003). 
275
 Saikevych IA et al, Cytogenetic study of a testicular tumor in a translocation (13;14) carrier. Cancer Genet Cytogenet. 
(1987).  
276
 Zahn S et al, Imbalances of Chromosome Arm 1p in Pediatric and Adult Germ Cell Tumors Are Caused by True Allelic 
Loss: A Combined Comparative Genomic Hybridization and Microsatellite Analysis. Genes Chromosomes Cancer (2006).  
277
 Stock C et al, Cytogenetic aspects of pediatric germ cell tumors. Klin Padiatr. (1995).   
Stock C et al, Detection of numerical and structural chromosome abnormalities in pediatric germ cell tumors by means of 
interphase cytogenetics. Genes Chromosomes Cancer (1994).  
Bussey KJ et al, Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-
related differences--a Children's Cancer Group study. Genes Chromosomes Cancer (1999).  Schneider DT el at, Genetic 
analysis of mediastinal nonseminomatous  germ cell tumors in children and adolescents. Genes Chromosomes Cancer 
(2002).   
Schneider DT et al, Genetic analysis of childhood germ cell tumors with comparative genomic hybridization. Klin Padiatr. 
(2001).  
5 .  D i s c u s s i o n  |  1 1 6  
 
Especially a large majority of pediatric yolk sac tumors harbor 1p36 deletions.
278
 Since 
no larger studies on the significance of 1p36 deletions were completed so far, and all 
published data consists more or less of case collections, a precise estimation of its 
incidence cannot be carried out although it seems to be a common event. The same is 
true for a possible prognostic impact. Interestingly, yolk sac tumors are, like 
neuroblastomas, a disease of younger children.
279
   
 
In adults, several cases of GCTs are described in which 1p/1p36 is involved in non-
random chromosomal rearrangements and deletions.
280
 Although it was my intention 
to analyze thoroughly the involvement of the CHD5 locus in the published cases, that 
was very difficult because markers specific for that locus were only infrequently used. 
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Nevertheless, several of the published cytogenetic data make an inclusion of CHD5 in 
the deleted region likely.  In contrast, Mathew S et al
281
 found the 1p22 region in 
particular involved in 1p deletions. 
In synopsis of the described cases in adults, a preference of 1p36 deletions for specific 
histological subtypes of GCTs appears unlikely, although some authors found such 
predominance as Rodriguez et al
282
 for teratomas. But one histological hallmark of 
GCTs, especially in non-seminomas, is the coexistence of various histological subtypes 
within one tumor.
283
 In principle, a chromosomal aberration could be restricted to one 
of the specific histological components.  
As for the pediatric tumors, as discussed above, the significance of the cytogenetic 
findings is limited by the lack of large systematic data collections. In addition, given the 
amazing histological variety of GCTs, a separated analysis of the different histological 
components within one tumor might be required.  
Summarizing, it has to be mentioned that pediatric yolk sac tumors appears to be the 
sole tumor entity within GCTs displaying commonly 1p36 deletions including most 
likely the CHD5 locus. 
 
Furthermore, I was interested whether CHD5 expression is altered in any genome-wide 
study of GCTs. No alteration of CHD5 expression in genome-wide studies was 
mentioned.
284
 That does not exclude any alteration of CHD5 expression because the 
studies focused mainly on upregulated genes and, in addition, it is always possible that 
altered genes are missed in microarrays due to normalization or technical issues.  
 
The hypothesis that CHD5 works as tumor suppressor in testicular cancer/GCTs might 
simplify the comprehensive view of a chromatin remodeler. Many of these enzymes, 
such as CHD4 and BRG1, display ambivalent roles during tumorigenesis (see 
introduction). Although CHD5 was shown to interact with HDAC2 in a NuRD-like 
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complex
285
, thus it is possibly involved in repression of genes, such a complex has not 
been shown in testes so far. A function of CHD5 as monomer is equally likely as a 
NuRD-like or another multi-protein complex containing CHD5. In addition to the 
already demonstrated involvement in anti-proliferation and senescence,
286
 CHD5 could 
be involved in stem cell maintenance or fine-tuning of differentiation as suggested by 
its expression in neural stem cells. Regarding GCTs, it should be considered that 
polyploidy is a frequently observed phenomenon.
287
 As a sharp contrast to the tumor 
suppressor hypothesis, a polyploidy could lead to a functional important increase of 
CHD5 dosage as well.  
 
5.1.6 Both isoforms of CHD5 are expressed in mouse brain and testes 
According to the NCBI database, CHD5 is predicted to have two isoforms in Mus 
musculus. So far, the existence of more than one isoform is not suggested for any 
other organism besides the mouse. Thus, I was interested whether both isoforms are 
expressed in mouse brain and testes. Therefore, an isoform-specific RT-PCR was 
designed. This RT-PCR revealed the expression of both isoforms in brain and testes. No 
quantitative statement could be made because RT-PCR is a semi-quantitative 
approach. For that, a RT-qPCR approach could be designed. Furthermore, it would be 
interesting whether both isoforms are translated into protein or if their expression is 
regulated at a post-transcriptional level. To asses this question a generation of 
isoform-specific antibodies would be required.  
CHD5 was shown to exist in a NuRD-like complex in mouse brain.
288
 That raises the 
question whether both isoforms can constitute such a complex. Alternatively, the 
formation of a NuRD-like complex could be restricted to one isoform. Especially a 
restriction to isoform 2 appears plausible to me because it has a higher similarity to 
Mi-2.  To test this hypothesis, the generation of an isoform-specific antibody would be 
also necessary. 
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5.1.7 CHD5 expression is not upregulated upon differentiation of Pc12 cells 
An explanation for the absence of CHD5 expression in tumor cell lines and its 
suggested function as a tumorsuppressor supported the hypothesis that CHD5 
expression might be restricted to non-proliferating cells such as terminally 
differentiated cells. Thus, I used the rat pheochromocytoma cell line Pc12 and 
differentiated them in presence of NGF. The differentiation was successful as indicated 
by the active outgrowth of neurites and further changes in cell morphology. Western 
Blot analysis of protein samples taken at different points in time during differentiation 
revealed absent CHD5 expression. In conclusion, CHD5 was not induced upon 
differentiation in this cell system.  
Although it was only a reasonable hypothesis, there are several explanations for CHD5 
absence in Pc12 cells. Firstly, pheochromocytoma is a tumour originating in the 
chromaffin cells from the adrenal medulla.
289
 CHD5 transcripts were shown to be 
present in the adrenal gland.
290
 Given that the adrenal medulla is a part of the 
sympathetic nervous system, CHD5 expression could be predominantly expected 
there. This assumption was recently confirmed.
291
 However, the opposite - a 
restriction of CHD5 expression to the adrenal cortex - would explain its absence in 
Pc12 cells but is now invalid.  
Secondly, the restriction of CHD5 expression to the adrenal medulla and its function as 
tumor suppressor could explain the absence in the corresponding tumour e.g. by 
deletion. A deletion of 1p is described for Pc12 cells.
292
 This could possibly provide an 
explanation for absence of CHD5. 
Nevertheless, Pc12 cells undergoing differentiation may not be a suitable cell system 
to study CHD5 function. 
5.1.8 Outlook 
For continuation of the CHD5 project, I would initially attempt to distinguish which 
cells types express CHD5 in testes. I consider immunofluorescence staining as the most 
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appropriate method for this and at least the CHD5 antibody M-182 is suitable for this 
application. Secondly, I would like to test (especially testicular) GCTs for CHD5 
expression. If any of the tumor samples display CHD5 expression, I would consider 
studying a larger panel of testicular GCTs with regard to histological subtype and 
outcome.  
After synopsis of the published cytogenetic data regarding 1p36 deletions in pediatric 
yolk sac tumors, I consider an independent study of CHD5 expression in this tumor 
entity as a very promising approach. The presumably common inclusion of the CHD5 
locus in deletions observed in this tumor entity as well as the parallel with 
neuroblastomas makes a biological and hopefully diagnostic impact of CHD5 more 
likely. 
5.2. Discussion objective 2 
5.2.1 Induction of genes in response to TNFα requires BRG1 and CHD4  
In this study, a RNAi strategy was used to explore the functional roles of the chromatin 
remodelers CHD4 and BRG1 during TNFα-induced NF-κB target gene induction. The 
results revealed that both, BRG1 and CHD4, were required for efficient NF-κB target 
gene activation at early as opposed to later points in time. These results were 
somewhat surprising because both remodelers have been repeatedly shown to work 
antagonistically
293
 but not synergistically. Furthermore, although some studies suggest 
an activating role, CHD4/NuRD is thought to be one of the classical repressor 
complexes.
294
 These findings raised many interesting questions. Are both remodelers 
involved in chromatin remodeling at the target genes themselves during early gene 
induction? Do they have unknown functions? Do they act on different target structures 
or on the same ones? Do they influence target gene induction via a direct or an 
indirect mechanism? Do they work in their most abundant and best characterized 
complexes (NuRD, BAF/PBAF), within novel complexes or as monomers?  
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Although several experiments were performed during this thesis in order to find the 
mechanism of action, it remained unknown. An impaired induction of inflammatory 
target genes upon TNFα stimulation can be caused at all stages of the pathway as a 
direct or indirect mechanism. In the following part, I will discuss the possible 
mechanisms of how CHD4 and BRG1 could act in the experimental scenario regarding 
the questions raised above. The direct mechanisms are discussed first followed by the 
indirect mechanisms. 
5.2.2 The requirement of BRG1 and CHD4 during the TNFα-induced                
NF-κB response is exclusive to the induction of early response genes  
Inflammatory response genes are often classified as primary, late primary and 
secondary response genes according to induction kinetics, transcription factors 
involved and dependency on de novo synthesis of these transcriptions factors. Primary 
response genes are induced during the first two hours of stimulation. Furthermore, 
they are regulated by transcription factors that are constitutively expressed and 
activated by signal-dependent post-translational modifications. The prime example of 
such a transcription factor is NF-κB. Secondary response genes rely on de novo 
synthesis of transcription factors. They are usually induced within a time frame of two 
to eight hours.
295
 
With the exception of CXCL10, all target genes tested in this study exhibited their 
greatest induction one hour after TNFα stimulation. Although a dependence on de 
novo protein synthesis for their induction has not been explored, it was assumed that 
they are independent due to the short time period between stimulus and maximum 
expression. Thus, they are classified as primary response genes. This is in agreement to 
literature where they were clearly independent on de novo protein synthesis.
296
  
Regarding the induction kinetics, CXCL10 could be classified as primary as well as 
secondary response gene in this study because it was upregulated seventy fold after 
one hour of TNFα stimulation but rose further to 200-fold expression after four hours. 
                                                           
295
 Medzhitov R and Horng T, Transcriptional control of the inflammatory response. Nat Rev Immunol. 
(2009). 
296
 Ramirez-Carrozzi VR et al, A unifying model for the selective regulation of inducible transcription by 
CpG islands and nucleosome remodeling. Cell (2009). 
5 .  D i s c u s s i o n  |  1 2 2  
 
In literature, CXCL10 is classified as primary response gene
297
 but there are no data 
available comparing its activation after 2 and 4 hours. In principle it appears plausible 
that it is activated with 2 peaks, the first without requirement of de novo protein 
synthesis and the second induced by newly synthesized transcription factors. 
Recently, Ramirez-Carrozzi et al
298
 explored the role of CHD4 and BRG1 in relation to 
the induction of inflammatory genes after LPS stimulation in macrophages. They found 
BRG1 was required for the induction of late primary and secondary response genes but 
not for early primary response genes. On the other hand, the limitation of this 
activation was dependent on CHD4. Thus, disruption of CHD4 resulted in a prolonged 
inflammatory response. 
In contrast, I found that CHD4 and BRG1 are both required for induction of early 
primary response genes after one hour of TNFα stimulation. These genes were still 
upregulated after four hours and at this time a disruption of BRG1 and CHD4, 
respectively, did not temper their expression. This suggests that chromatin remodelers 
are mainly involved in the very early induction period of inflammatory genes in this 
specific context. The key mediator of this early response is NF-κB.
299
 A robust 
interaction of RelA (as one of the most abundant NF-κB subunits) with both 
remodelers could not be observed in this study by co-immunoprecipitation 
experiments (see Fig. 4.38). But that does not exclude either a direct interaction with 
other subunits or the fact that chromatin remodeling by BRG1 and CHD4, respectively, 
is a prerequisite for NF-κB binding to its target genes. A key experiment to test 
whether NF-κB binding to target genes is dependent on activity of both remodelers 
would be a p50/p65 ChIP experiment upon knockdown of BRG1 and CHD4, 
respectively. 
Different transcription factors and pathways are activated upon TNFα stimulation (see 
Fig. 2.5).  After four hours another component of the TNFα pathway in addition to      
NF-κB might be actively involved in the induction of our target genes and would 
possibly not require CHD4 and BRG1 for chromatin remodeling. Alternatively, the 
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target genes already have an open chromatin after 4 hours and there is no further 
need for chromatin remodeling. Thus, after four hours the expression of the tested 
target genes may not be diminished by knockdown of BRG1 and CHD4. A kinetic for 
RelA and p50 binding to the promoters of the studied genes could be helpful in 
determining whether the NF-κB recruitment increases or decreases after one hour. In 
the next step, a knockdown of both major NF-κB subunits could determine whether 
the transcription after four hours is dependent on them.  
The different classes of response genes were further characterized in a genome-wide 
approach by Ramirez-Carrozzi et al
300
. They found that primary response genes 
harboured promoter CpG islands which facilitated induction from constitutively active 
chromatin without requiring SWI/SNF remodeling complexes. TNFα was found to 
preferentially induce this class of genes in macrophages. Thus, it was suggested that 
TNFα-induced genes are activated independently from SWI/SNF remodelers. 
Interestingly, four of the seven tested genes in our study (CXCL2, TNFα, IκB and IRF-1) 
belong to the class of genes that have a CpG island in their promoter and are predicted 
to be SWI/SNF independent according to Ramirez-Carrozzi et al
301
. Two of the 
remaining studied genes, CCL2 and CXCL10, respectively, were described to be 
SWI/SNF-dependent without a CpG island in their promoter region.
302
 The gene which 
was tested last, IL-8, was not included in their study and its promoter status is a 
contentious issue. However, there is no CpG island predicted by UCSC genome browser 
and the promoter was described as not containing a typical CpG island.
 303
    
Although the concept postulating that CpG islands containing promoters are SWI/SNF-
independent in macrophages appears entirely convincing to me, we found a totally 
different situation. In HEK293 cells, all tested TNFα-induced genes, irrespective of their 
CpG island status, were SWI/SNF dependent at early points in time. Furthermore, they 
were additionally CHD4-dependent. Thus, a requirement for chromatin remodelers in 
the inflammatory response to diverse stimuli might not obey an overarching principle 
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according to the suggested theory regarding gene structure. This view might be limited 
by the use of different cell types because cell-type-specific differences in the 
classification of response genes are already known. For instance, IL-6 was shown to be 
a SWI/SNF-dependent secondary response gene in LPS-stimulated macrophages but a 
SWI/SNF-independent primary response gene in MEFs, most likely due to a different 
biological need in various cell types.
304
 I used exclusively HEK293 cells for which there 
are no data available regarding the different classes of response genes. This might limit 
any conclusion from the published data in comparison with this work. In addition, we 
tested a limited amount of target genes; a genome-wide approach would allow a 
broader analysis of gene characteristics.  
5.2.3 The role of CHD4 in transcriptional activation upon TNFα stimulation 
In mammals, the bulk of CHD4 is thought to reside in the NuRD complex and no other   
stable Mi-2-containing complex has been discovered so far. Additionally, only vague 
hints exist that there could be a functional role for CHD4 outside the NuRD complex.
305
  
Recently, it was shown that dMi-2 is also part of the newly identified complex dMec. 
This complex constitutes the major Mi-2 containing complex in Drosophila. 
Furthermore, it was shown not to rely on histone deacetylation to effect 
transcriptional repression. 
306
  
In this study, due to time limitation I could not test whether CHD4 or the entire NuRD 
complex is required for gene activation. To evaluate the hypothesis that the entire 
NuRD complex is needed, it would be reasonable to perform sequential knockdown 
experiments for all NuRD subunits.  
In both known Mi-2-containing complexes, NuRD and dMec, CHD4 was strongly linked 
to transcriptional repression.
307
 Therefore, a requirement for gene activation, as 
shown here, is quite surprising and suggests a role in active transcription. Only few 
studies have hitherto implicated CHD4 in transcriptional activation. For example, 
during T-cell development, Mi-2 associates with the CD4 enhancer resulting in 
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recruitment of the E-box binding protein HEB and the histone acetyltransferase p300 
to the CD4 enhancer. This causes histone H3-hyperacetylation of the regulatory region 
and enables CD4 transcription. With both factors, CHD4 was shown to interact in a 
HDAC independent manner suggesting this activity to be independent from NuRD.
308
  
Furthermore, CHD4 was implicated to be involved in rRNA activation in the 
nucleolus.
309
 Recently, an activating role of dMi-2 in Drosophila heat shock gene 
induction was demonstrated. dMi-2 was recruited to Drosophila heat shock genes in a 
PAR–dependent manner. There, it associated with nascent heat shock gene transcripts 
and its catalytic activity was required for efficient transcription and co-transcriptional 
RNA processing.
310
 Whether a further role of Mi-2 exists in splicing is far from clear but 
it might recruit splicing machinery to RNA via binding to nascent transcripts.
311
  
In summary, at least in some circumstances CHD4 appeared to be involved in 
transcriptional activation.  
Several mechanisms are conceivable as to how CHD4 could act in transcriptional 
activation of TNFα-induced genes.  
One possible mechanism could be a recruitment of CHD4 to the target genes followed 
by binding to nascent RNA and involvement in co-transcriptional RNA processing 
similar to the observed scenario upon heat shock gene activation in Drosophila. 
Interestingly, PARP-1 was demonstrated as interacting with NF-κB upon LPS 
stimulation in mammalian cells
312
 and TNFα-induced transcriptional activation of a 
subset of NF-κB target genes was shown to be defective in PARP-1-deficient mice.
313
 
Thus, PARP might also be a candidate to modulate CHD4 action in the context of TNFα 
pathway.  
Moreover, as described for the CD4 locus, CHD4 could associate with a histone 
acetyltransferase, thereby establishing activating histone marks. One might argue that 
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the observed high basal levels of active histone modifications like acetylation at 
primary response genes dispense with the requirement for additional histone 
modifications because the chromatin is already in an open conformation.
314
 However, 
the histone acetyltransferase p300 was shown to be required for early target gene 
induction upon TNFα stimulation,
315
 thus an additional requirement of activating 
histone modifications might be feasible. An approach to validate or exclude this 
hypothesis would be a co-immunoprecipitation of CHD4 and the most abundant 
acetyltransferases like p300. 
In order to explore any direct mechanism in this study, a recruitment of CHD4 to the 
CXCL2 gene upon TNFα stimulation was tested by ChIP experiments. Such recruitment 
could not be demonstrated in these experiments. That does not exclude any 
recruitment because I studied only one model gene. For a reliable result more target 
genes would have to be studied. Furthermore, the used antibody was not established 
in ChIP experiments in our laboratory beforehand. In addition, experiments were 
performed after 20 (data not shown), 40 and 60 minutes. If CHD4 had been recruited 
in the very initial phase of TNFα-pathway activation and released soon thereafter, 
detection could have been missed. Furthermore, if our ChIP results indeed represent a 
very low but steady binding of CHD4 to CXCL2, it might undergo activation by a post-
translational modification upon stimulation.  
As a second approach, an interaction of CHD4/BRG1 and the NF-κB subunit RelA upon 
TNFα stimulation was evaluated revealing no robust interaction between the 
chromatin remodelers and RelA. These results do not support the view that the 
remodelers are recruited to the target genes via interaction with DNA-bound 
transcription factors and are acting directly at the affected genes. But so far, a 
technical cause cannot be excluded as a reason for my results. Because the key to all 
possible direct mechanisms is almost exclusively the demonstration of a positive 
recruitment to the tested target genes, for further studies this question should be     
re-addressed with considerable effort.  
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In principle, any siRNA-mediated off-target effect can cause irregularities in gene 
expression. Considering the unaffected four-hour-response and housekeeping gene 
expression, these explanations become less likely. In addition, identical off-target 
effects for two siRNAs targeting different regions of the same transcript, as used in this 
study, seem implausible. Were there to be any remaining doubt, rescue experiments 
could be performed to ultimately exclude this kind of confounder. 
316
 
5.2.4 The role of BRG1 in transcriptional activation upon TNFα stimulation 
BRG1 was repeatedly shown to be required for target gene induction in different 
inflammatory responses as to renal ischemia
317
, LPS
318
, IFNα
319
, TGFß
320
 and IL-6.
321
 No 
doubt that BRG1 is of great significance to the fine-tuning of inflammatory responses 
to diverse stimuli. But depending on the specific context, the requirement for BRG1 
differs considerably regarding the kinetics and modes of action. Further studies might 
improve insight into its detailed function in the context of inflammatory responses. 
Since only one siRNA targeting BRG1/Brm was used in this study, off-target effects 
upon BRG1 knockdown leading to the observed reduction in early TNFα induced gene 
activation cannot be fully excluded. But considering the specificity for early gene 
induction and the unaffected expression of the housekeeping gene, off-target effects 
as confounders seem to be very unlikely. A possible control experiment besides rescue 
experiments could be a TNFα-induction of inflammatory genes in SW13 cells. These 
cells lack BRG1 and Brm expression.
322
 In case of dependence on BRG1, early target 
genes should be induced less strongly. Furthermore, a re-expression of BRG1 should 
enable or multiply the inflammatory response.  
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A direct recruitment of BRG1 to the CXCL2 gene upon stimulation could not be shown 
(data not shown) possibly due to the lack of a highly specific BRG1 antibody 
established for ChIP experiments in our laboratory.  
Although many indirect effects are in principal conceivable for the impaired TNFα 
response, the direct recruitment of BRG1 to target genes, or a requirement for 
constitutively bound BRG1 followed by subsequent involvement in opening chromatin 
remodeling, has been shown in several cases and therefore seems possible.
323
 
Moreover, BRG1 binding to a subset of target promoters in response to TGFß was 
shown to be required for recruitment of RNA polymerase II,
324
 indicating its direct 
involvement in transcriptional activation. 
In this study, the associations of histone H3 with the promoter of our model gene, 
CXCL2, decreased upon activation. This finding led to the conclusion that some 
chromatin remodeling definitively took place (see Fig. 4.37). An H3 ChIP experiment 
under BRG1 knockdown conditions could further specify whether the removal of H3 is 
BRG1-dependent. 
BRG1 exists in different complexes. Due to time limitation I did not test whether BRG1 
is required for NF-κB target gene induction with an entire complex or as a monomer. 
To explore the involvement of the most abundant BRG1-containing complexes, a 
knockdown of BAF250 (representative for BAF complex) and BAF180 (representative 
for PBAF) might enable us to answer this question.  
Interestingly, the arginine methyltransferase CARM1 was shown to interact with the 
histone acetyltransferase p300 and RelA in HEK293 cells after 30 minutes of TNFα 
stimulation. Induction of CXCL2, CCL2 and CXCL10 was dependent on CARM1 and 
p300.
325
 Remarkably, in a subsequent study CCL2 and CXCL10 were found to be 
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CARM1-independent after three hours of stimulation.
326
 These kinetic properties and 
the target genes are reminiscent of this study. 
Moreover, BRG1 was shown to interact with CARM1 within the NUMAC (nucleosomal 
methylation activator complex). In this context, CARM1 stimulates the ATPase activity 
of BRG1 and enhances ER-dependent transcription.
327
 Together, these observations 
lead me to speculate that a NUMAC-like chromatin remodeler ‘super-complex’ 
interacts with RelA upon TNFα stimulation. A co-immunoprecipitation of BRG1 and 
CARM1 would provide further information but this will not be the question I address 
first when continuing this study. 
5.2.5 Are CHD4 and BRG1 recruited to the same target structures? 
Since BRG1 and CHD4 were both shown to positively regulate the induction of early 
response genes upon TNFα stimulation, the question arises whether they are involved 
in the same steps of transcriptional activation. Furthermore, there is already some 
evidence to show that both proteins interact or work in a type of ‘super complex’ of 
chromatin remodelers.
328
 However, I did not observe any direct interaction between 
both upon TNFα stimulation (data not shown). Nevertheless, an interaction between 
CHD4 and BRG1 via linker proteins is still possible. So far, I am not able to answer this 
question.  
5.2.6 Summary: Possible direct mechanisms of BRG1/CHD4 involvement 
Although any suggestion of a mechanistic model for the involvement of BRG1 and 
CHD4 in the TNFα response is speculative at this stage, I will generate two models 
combining a possible function of both chromatin remodelers:  
1) CHD4 as a monomer could be targeted to the responding genes upon TNFα 
stimulation by an unknown mechanism (perhaps by PARP). There, it assembles with a 
histone acetyltransferase, initiating a hyperacetylation of histones. The bromodomains 
of BRG1 recognize the acetylated histone tails, thereby mediating a recruitment of the 
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BAF/PBAF complex to the target genes. Finally, the BAF/PBAF complex decreases the 
nucleosome occupancy of the target gene’s promoter, thus improving the access of 
NF-κB and the transcription machinery to the target gene. 
2) BRG1 could be recruited to the promoter regions of the target genes upon TNFα 
stimulation. There, it could provide better access for transcription factors and the 
transcriptional machinery by a decrease of nucleosome occupancy at the promoter 
region. CHD4 could be recruited to the open-reading frame, bind to the nascent RNA 
and participate in co-transcriptional RNA processing. 
5.2.7 Mechanisms which impair key events of the TNFα pathway  
As mentioned above, any dysfunction of the TNFα signaling by disruption of the 
chromatin remodeler expression could be caused by alterations at any single stage of 
the pathway. Now, to exemplify this, I will highlight some key events that could 
possibly be affected by more indirect mechanisms.  
Release of cytoplasmic NF-κB from its inhibitor IκB and nuclear translocation 
This part of NF-κB activation could be impaired by indirect mechanisms targeting the 
proteasomal degradation of IκB.  
IκB was not upregulated in unstimulated HEK293 cells when CHD4 and BRG1 
expression was disrupted by RNAi (data not shown). Thus, an excess of IκB inhibiting 
the nuclear translocation of NF-κB appears unlikely.  But there are still many ways in 
which this part of the signaling could be hampered. The key experiment to investigate 
whether this part of NF-κB signaling is intact would be to test if the p50/RelA 
heterodimer enters the nucleus under knockdown of BRG1 and CHD4, respectively. For 
instance, this could be performed by immunofluorescence staining. Any indirect effect 
that impairs the nuclear re-localization of NF-κB would lead to a sustained cytoplasmic 
staining. 
Regulation of NF-κB in the nucleus 
In contrast to the well-studied regulation of NF-κB in the cytoplasm, its nuclear 
regulation is less well understood. NF-κB activity could possibly be fine-tuned via post-
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translational modifications as is shown in some cases.
329
 Although CHD4 and BRG1 are 
mainly involved in chromatin remodeling, in principle their complexes could also 
modify non-DNA-associated proteins as shown for HDAC1/NuRD and p53,
330
 thereby 
adjusting NF-κB activity. Exploring this possibility is the most challenging. 
Binding of NF-κB to DNA 
Although it might be feasible that κB-sites are less accessible when their DNA is tightly 
wrapped around histones, it was shown that the incorporation of κB-sites in positioned 
nucleosomes only slightly decreases the ability of NF-κB to bind to these sites.
331
 But 
given the paucity of existing experimental data on this topic, it cannot be excluded that 
an open chromatin structure or nucleosome remodeling are obligatory for NF-κB 
recruitment to DNA.
332
 I have observed that histone H3 is removed from the promoter 
region of CXCL2 upon TNFα stimulation. It remains unclear whether this is a 
prerequisite for NF-κB binding to its κB-site at the CXCL2 promoter. It might be worth 
performing a p50/p65 ChIP experiment upon knockdown of CHD4 and BRG1 
respectively, although any other chromatin remodeling enzyme could in principle be 
involved in this specific step as well. 
5.2.8 Perspectives 
The surprising finding that CHD4 and BRG1 are both required for the efficient early 
target gene induction after TNFα stimulation has raised the many extremely 
interesting questions which have been discussed above. Of further interest might be to 
gain more insight into the precise regulation of transcription in inflammatory 
responses. 
Since BRG1 is a known tumor suppressor often deleted in cancer and TNFα is a 
common mediator in tumor-related inflammation (see Introduction), this raises the 
additional question of whether there is any functional consequence for the impaired 
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early gene induction in response to TNFα. Might this uncouple a cancer cell from a 
subset of inhibiting signals generated in the microenvironment?  
Another interesting question might be in the context of tumors depending on 
constitutive active NF-κB signaling like Hodgkin lymphoma or some subtypes of diffuse 
large B cell lymphoma.
333
 Suggesting that not all NF-κB target genes have permanently 
open chromatin, it might be of interest whether there is a dependence on chromatin 
remodelers also in this context. Thus, an inhibition of chromatin remodelers or other 
subunits of their complexes might provide a new therapeutic approach in these tumor 
entities.  
  
In conclusion, the findings of this study provide an interesting view on the involvement 
of ATP-dependent chromatin remodelers in inflammatory gene activation which could 
in future contribute to a better understanding of transcriptional control in 
inflammation. 
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6.2. List of abbreviations and acronyms 
 
aa amino acid 
ac acetyl 
ACF ATP-utilizing chromatin assembly and remodeling factor 
ADP adenosindiphosphate 
ATP adenosintriphosphate 
BAF BRG1-associated factors 
BAP Brahma-associated proteins 
BLAST basic local alignment search tool 
bp base pair 
BRG1 Brahma-associated gene 1 
BRK Brahma and Kismet domain 
BRM brahma 
BSA bovine serum albumine 
C- carboxy- 
C/EBP CCAAT/Enhancer-Binding Protein-β 
CCL2 C-C motif ligand 2 
cDNA complementary DNA 
CHD chromodomain-helicase-DNA binding 
CHD5 chromodomain, helicase, DNA binding protein 5 
ChIP chromatin immunoprecipitation 
CHRAC chromatin assembly complex 
CK2 casein kinase 2 
CpG cytosine-phospatidyl-guanosine 
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Ct cycle threshold 
CT computed tomography 
CXCL2 C-X-C motif ligand 2 
Da dalton 
DAPI 4',6-diamidino-2-phenylindole 
dATP desoxyadenosintriphosphate 
dCTP desoxycytosinosintriphosphate 
dGTP desoxyguanidintriphosphate 
DIV days in vitro 
dMec drosophila MEP-1-containing complex 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO dimethyl suloxide 
DNA desoxyribonucleic acid 
DNMT DNA methyltransferase 
dNTP desoxyribonucleotidetriphosphate 
DSB double strand break 
dsRNA double stranded RNA 
DTT dithiotreithol 
dTTP desoxythyminidintriphosphate 
EDTA ethylenediaminetetraacetic acid 
ER estrogen receptor 
FBS fetal Bovine Serum 
FCS fetal calf serum 
for forward 
g gram 
G1 gap phase 1 
GCT Germ cell tumor 
GR glucocorticoid receptor 
H histone 
HAT histone acetyltransferase 
HBSS Hank's Buffered Salt Solution 
HDAC histone deacetylase 
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HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid N-(2- 
HMG high mobility group 
HP1 heterochromatin protein 1 
HPLC high performance liquid chromatography 
HRP horseradish peroxidase 
IF immunofluorescence 
IFNα Interferon alpha 
Ig immunoglobuline 
IκB inhibitor of NF-κB 
IL Interleukin 
IMDM Iscove's Modified Dulbecco's Medium 
INO80 inositol requiring 80 
INSS International Neuroblastoma Staging System 
IP immunoprecipitation 
IRF-1 Interferon regulatory factor 1 
ISWI imitation switch 
KAP-1 krüppel-associated box domain–associated protein -1 
kDA kilodalton 
LB Luria-Bertani 
LKB1 liver kinase B1 
LPS lipopolysaccharide 
LSD1 lysine-specific demethylase 1 
M molar 
mA miiliampere 
MBP methyl-CpG-binding protein 
MDa mega dalton 
me methyl 
MEF mouse embryonic fibroblast 
MEF mouse embryonic fibroblast 
min minute 
mNGF murine Nerve growth factor 
MRI magnetic resonance imaging 
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mRNA messenger RNA 
MTA metastasis associated protein 
N- amino- 
NAD nicotinamide adenine dinucleotide 
NE nuclear extract 
NF-κB nuclear factor kappa B 
nm nanometer 
NoRC nucleolar remodeling complex 
NuRD nucleosome remodeling and histone deacetylation 
NURF nucleosome remodeling factor 
PAA polyacrylamide 
PAGE polyacrylamide gel electrophoresis 
PAR poly(ADP-ribose) 
PARP poly(ADP-ribose) polymerase 
PBAF polybromo-associated BAF 
PBAP polybromo-associated BAP 
PBS phosphate buffered saline 
Pc polycomb 
PCR polymerase chain reaction 
PEI polyethyleneimine 
PHD plant homeo domain 
PMSF phenylmethane sulfonyl fluoride 
PPAR peroxisome proliferator-activated receptor 
PS penicilline/ streptomycine 
P-TEFb positive transcription elongation factor b 
PVDF polyvinylidine difluoride 
QPCR quantitative PCR 
rDNA ribosomal DNA 
rev reverse 
RNA ribonucleic acid 
RNAi RNA interference 
RpAp retinoblastoma associated protein 
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RPD3 reduced potassium dependency 3 
rpm revoltations per minute 
RPMI Roswell Park Memorial Institute 
RSC remodels the structure of chromatin 
RT room temperature 
SAGE serial analysis of gene expression 
SANT ySWI3, yADA2, hNCoR, hTFIIIB 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sec second 
shRNA short hairpin RNA 
SLIDE SANT-like ISWI domain 
Snf2 sucrose non-fermenting protein 2 homolog 
ssRNA single stranded RNA 
suc sucrose 
SUMO small ubiquitin-like modifier 
SWI/SNF switch/sucrose non-fermenting 
Swr1 Swi2/Snf2-related 1 
Temed N,N,N′,N′-Tetramethylethylenediamine 
TGFß Transforming growth factor beta 
TLR-9 Toll-like receptor 9 
TNFα Tumor necrosis factor alpha 
Tris tris(hydroxymethyl)aminomethane 
v/v volume per volume 
w/v weight per volume 
WCE whole cell extract 
wt wild-type 
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6.3 Curriculum vitae 
Dieser Abschnitt enthält persönliche Daten und ist deshalb nicht Bestandteil der Online-
Veröffentlichung. 
6.4 Verzeichnis der akademischen Lehrer 
Meine akademischen Lehrer waren die folgenden Damen und Herren Professoren, 
Doktoren und Dozenten 
In Marburg: 
Adamkiewicz, Aigner,  Aumüller, Bals, Barth, Bartsch, Basler, Bauer, Baum, Becker, 
Bender, Bien, Brehm, Burchardt, Cetin, Czubayko, Daut, Donner-Banzhoff, Duda, Eilers, 
Ellenrieder, Elsässer, Engenhart-Cabillic, Fuchs-Winkelmann, Gerdes, Görg, Gress, 
Grundmann, Grzeschik, Gudermann, Hasilik, Hertl, Höffken, Hofmann, Hoyer, 
Jerrentrup, Kalinowsky, Kann, Klenk, Klose, König, Koolman, Krause, Kroll, Kuhn, Lill, 
Löffler, Lohoff, Maisch, Maier, Mandrek, Martin, Meier, Meissner, Moll, Moosdorf, 
Müller, Mueller, Müller-Brüsselbach, Mutters, Neubauer, Neumüller, Nimsky, Oertel, 
Pagenstecher, Plant, Ramaswamy, Rausch, Renz, Richter, Roehm, Rosenow, 
Rothmund, Ruchholtz, Schäfer, Schmidt, Seitz, Steiniger, Suske, Vogelmeier, Voigt, 
Wagner, Weihe, Werner, Westermann, Wollmer, Wulf, Wündisch. 
 
In New York (Memorial Sloan-Kettering Cancer Center): 
Brentjens,  D’Andrea, Deng, Dickler, Lake, Maslek, Mody, Salvit, Theodoulou.  
 
In Sheffield: 
Chidambaram-Nathan, Reed, Skinner, Wyman.  
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